<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>299</serviceExecutionTime><Trial id="100041"><TitleDisplay>Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis</TitleDisplay><TitleOfficial>A Phase II Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">KRX-0502-204</Identifier><Identifier type="NCT">NCT01736397</Identifier></Identifiers><Indications><Indication id="3191">Iron deficiency anemia</Indication></Indications><BiomarkerNames><BiomarkerName id="794" role="Therapeutic effect marker" type="Genomic;Proteomic">Serotransferrin</BiomarkerName><BiomarkerName id="1051" role="Therapeutic effect marker" type="Genomic;Proteomic">Ferritin</BiomarkerName><BiomarkerName id="1236" role="Therapeutic effect marker" type="Biochemical">Hemoglobin</BiomarkerName><BiomarkerName id="2200" role="Therapeutic effect marker" type="Genomic;Proteomic">Fibroblast growth factor 23</BiomarkerName><BiomarkerName id="2382" role="Therapeutic effect marker" type="Biochemical">Phosphorus</BiomarkerName><BiomarkerName id="3083" role="Therapeutic effect marker" type="Biochemical">Phosphate</BiomarkerName><BiomarkerName id="7895" role="Therapeutic effect marker" type="Physiological">Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ferric citrate (oral, hyperphosphatemia), Panion &amp; BF/Akebia/Japan Tobacco/Torii/3SBio</Name><Drug id="54959">ferric citrate (oral, hyperphosphatemia), Panion &amp; BF/Akebia/Japan Tobacco/Torii/3SBio</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="54959">ferric citrate (oral, hyperphosphatemia), Panion &amp; BF/Akebia/Japan Tobacco/Torii/3SBio</Drug><IndicationsPioneer><Indication id="3191">Iron deficiency anemia</Indication></IndicationsPioneer><Companies><Company><Company id="27395">Keryx Biopharmaceuticals Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="54959" type="Drug"><TargetEntity id="419209" type="siDrug">Ferric citrate</TargetEntity><TargetEntity id="666413" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="27395" type="Company"><TargetEntity id="4295900456" type="organizationId">Keryx Biopharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="3191" type="ciIndication"><TargetEntity id="D50" type="ICD10"/><TargetEntity id="10022972" type="MEDDRA"/><TargetEntity id="D018798" type="MeSH"/><TargetEntity id="-533542915" type="omicsDisease"/><TargetEntity id="1249" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>20</NumberOfSites><CompaniesSponsor><Company id="27395">Keryx Biopharmaceuticals Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="2953">Anti-inflammatory</Class><Class id="472">Phosphate lowering agent</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>149</PatientCountEnrollment><PatientCountEvaluable>149</PatientCountEvaluable><DateStart>2012-11-30T00:00:00Z</DateStart><DateEnd type="actual">2013-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-11-19T13:33:20Z</DateChangeLast><DateAdded>2012-11-30T10:15:12Z</DateAdded><Contacts><Contact type="Scientific contact"><Name>Geoffrey Block, MD</Name></Contact><Contact type="Scientific contact"><Name>Glenn Chertow, MD</Name></Contact><Contact type="Scientific contact"><Name>Steven Fishbane, MD</Name></Contact><Contact type="Scientific contact"><Email>sshemesh@keryx.com</Email><Name>Shay Shemesh</Name></Contact><Contact type="Scientific contact"><Email>cconnelly@keryx.com</Email><Name>Carolyn Connelly</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Stage III to V chronic kidney disease&lt;/li&gt;&lt;li&gt;Serum phosphorus 4.0 to 6.0 mg/dl prior to randomization&lt;/li&gt;&lt;li&gt;Ferritin&amp;lt;/= 300 ng/ml &lt;/li&gt;&lt;li&gt;Transferrin Saturation (TSAT)&amp;lt;/= 30% &lt;/li&gt;&lt;li&gt;Hemoglobin 9.5 to 11.5 g/dl&lt;/li&gt;&lt;li&gt;Must consume a minimum of two meals/day&lt;/li&gt;&lt;li&gt;eGFR&amp;lt; 60 ml/min/1.73 m2&lt;/li&gt;&lt;li&gt;Patients with estimated glomerular filtration rates&amp;lt; 60 ml/min/1.73 m2&lt;/li&gt;&lt;li&gt;Use of intravenous iron or erythropoiesis- stimulationg agents was prohibited&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Parathyroidectomy within 24 weeks of study&lt;/li&gt;&lt;li&gt;Gastrointestinal bleed or inflammatory bowel disease within 12 weeks of study&lt;/li&gt;&lt;li&gt;Requirement for dialysis or kidney injury within 8 weeks of study&lt;/li&gt;&lt;li&gt;Absolute requirement for oral iron, intravenous iron, erythropoiesis-stimulating agent, blood             transfusions, and Sensipar during the study&lt;/li&gt;&lt;li&gt;Absolute requirement for calcium-, magnesium-, or aluminum-containing drugs with             meals&lt;/li&gt;&lt;li&gt;Absolute requirement for vitamin C, niacin, or nicotinamide outside of multivitamins&lt;/li&gt;&lt;li&gt;History of hemochromatosis&lt;/li&gt;&lt;li&gt;Allergy to iron products&lt;/li&gt;&lt;li&gt;History of malignancy in last five years&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in Transferrin Saturation (TSAT) From Baseline to End of Treatment: The difference in TSAT between the value at the end of treatment (week 12) minus the baseline measurement</Description><Timeframe>12 Weeks</Timeframe></Measure><Measure><Description>Change in Serum Phosphorus Levels From Baseline to End of Treatment: the difference in serum phosphorus between the value at the end of treatment (week 12) minus the baseline measurement</Description><Timeframe>12 Weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in Hemoglobin Levels From Baseline to End of Treatment: the difference in hemoglobin levels between the value at the end of treatment (week 12) minus the baseline measurement</Description><Timeframe>12 Weeks</Timeframe></Measure><Measure><Description>Change in Ferritin Levels From Baseline to End of Treatment: the difference in ferritin levels between the value at the end of treatment (week 12) minus the baseline measurement</Description><Timeframe>12 Weeks</Timeframe></Measure><Measure><Description>Changes in FGF-23, urinary phosphate excretion and estimated glomerular filtration rate</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In November 2013, results were published.  &lt;ulink linkType="Drug" linkID="54959"&gt;KRX-0502&lt;/ulink&gt; (ferric citrate) was safe and well-tolerated. There were 19 and 32% discontinuation rates in &lt;ulink linkType="Drug" linkID="54959"&gt;KRX-0502&lt;/ulink&gt; (ferric citrate) and placebo groups, respectively, including treatment failures. No study related discontinuations were observed due to hypophosphatemia. There were serious adverse events observed  in 8% &lt;ulink linkType="Drug" linkID="54959"&gt;KRX-0502&lt;/ulink&gt; (ferric citrate)(n = 6) versus 14% placebo (n = 10) patients. Two deaths were recorded  (both in the placebo group). No statistically significant differences in serum calcium levels and liver enzymes as measured by alanine transaminase (ALT) and aspartate transaminase (AST) was observed   [&lt;ulink linkType="Reference" linkID="1496525"&gt;1496525&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results were published in May 2014. In between treatment arms, the incidence and severity of adverse effects showed  similarity. There was no patient who developed sustained hypophosphatemia [&lt;ulink linkType="Reference" linkID="1588840"&gt;1588840&lt;/ulink&gt;]. Similar results were published in May 2015 [&lt;ulink linkType="Reference" linkID="1689574"&gt;1689574&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, pooled results from a phase II and III studies (NCT01736397 and NCT02268994) were published. The aim of this analysis was to evaluate safety and efficacy. A total of 75.3 (n = 143/190) and 61.7% (n = 116/188) of ferric citrate- and placebo-treated patients reported Treatment-emergent adverse events (AEs), respectively; most frequent AEs were gastrointestinal events (49.5 and 52%, respectively). Discolored feces (21.6 versus 0%), diarrhea (20.5 versus 12.2%), constipation (18.4 versus 10.1%) and nausea (9.5 versus 4.3%) were the specific events seen in &amp;gt; 5% of ferric citrate- versus placebo-treated patients, respectively. Serious AE was experienced by a total of 10.5 and 11.2% of ferric citrate- and placebo-treated patients, respectively. A total of two patients in each group died [&lt;ulink linkType="Reference" linkID="2038406"&gt;2038406&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2018, results of pooled analysis from two studies (NCT01736397 and NCT02268994) were published. In ferric citrate and placebo group, adverse events potentially related to HF were observed  more frequently in patients with HF (23 and 17%) versus those without HF (12 and 11%) [&lt;ulink linkType="Reference" linkID="2096081"&gt;2096081&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to determine if &lt;ulink linkType="Drug" linkID="54959"&gt;KRX-0502&lt;/ulink&gt; (ferric citrate) was a safe and      effective treatment for the management of serum phosphorus levels and iron deficiency in      anemic chronic kidney disease (CKD) stage 3 to 5 patients not on dialysis.  Total length of treatment would be       approximately 12 weeks.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In November 2013, results were published.  &lt;ulink linkType="Drug" linkID="54959"&gt;KRX-0502&lt;/ulink&gt;   met both co-primary and all key secondary endpoints with highly statistically significant results. The co-primary efficacy endpoints: the mean change in serum phosphorus (4.7 to 4.4 versus 4.5 to 3.9 mg/dl [p &amp;lt; 0.001]) and TSAT (21 to 20 versus 22 to 32% [p &amp;lt; 0.001]) from baseline to the end of the 12-week treatment period   was observed in placebo (n = 69) versus &lt;ulink linkType="Drug" linkID="54959"&gt;KRX-0502 &lt;/ulink&gt;(ferric citrate) (n = 72) groups, respectively. The key secondary endpoints: the mean change in ferritin (110 to 106 versus 116 to 189 ng/ml [p &amp;lt; 0.001]),  hemoglobin (10.6 to 10.4 versus 10.5 to 11 g/dl [p &amp;lt; 0.001]), from baseline to the end of the 12-week treatment period was observed in placebo (n = 69) versus &lt;ulink linkType="Drug" linkID="54959"&gt;KRX-0502&lt;/ulink&gt;  (ferric citrate) (n = 72) groups, respectively. The mean change in intact FGF-23 (263 to 293 versus 319 to 200 pg/ml [p = 0.017]) and C-Terminal FGF-23  (511 to 579 versus 468 to 316 pg/ml [p &amp;lt; 0.001]) from baseline to the end of the 12-week treatment period  was observed in placebo (n = 60) versus &lt;ulink linkType="Drug" linkID="54959"&gt;KRX-0502&lt;/ulink&gt; (ferric citrate) (n = 63) groups, respectively. Treatment failures were observed in patients having hemoglobin &amp;lt; 9.0 g/dl (9 versus 1) and serum phosphorus &gt;/= 6.0 mg/dl (2 versus 0) in  placebo versus &lt;ulink linkType="Drug" linkID="54959"&gt;KRX-0502&lt;/ulink&gt; (ferric citrate) treated groups respectively [&lt;ulink linkType="Reference" linkID="1496525"&gt;1496525&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results were published in May 2014.    There was a significant increase in TSAT from 22 +/- 7 to 32 +/- 14% and reduced serum phosphate from 4.5 +/-  0.6  to 3.9 +/- 0.6 mg/dl, each p &amp;lt; 0.001 versus placebo in whom transferrin saturation remained stable at 21 +/- 8 to 20 +/-8% and serum phosphate declined by 0.3 mg/dl (4.7 +/-0.6 to 4.4 +/-0.8 mg/dl) in KRX-0502 treatment. Treatment with Ferric citrate led to an increase  in the hemoglobin from 10.5 +/- 0.8  to 11.0 +/- 1.0 g/dl (p &amp;lt; 0.001 versus placebo), with a reduction urinary phosphate 39% (p &amp;lt; 0.001 versus placebo) and intact FGF-23 from 319 +/- 577 to 200 +/- 386 RU/ml (p = 0.017 versus placebo) [&lt;ulink linkType="Reference" linkID="1588840"&gt;1588840&lt;/ulink&gt;]. Similar results were published in May 2015 [&lt;ulink linkType="Reference" linkID="1689574"&gt;1689574&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Further results in May 2015 showed that, serum intact FGF-23 levels reduced from a median of 159 to 105 pg/ml (p = 0.02 versus placebo) [&lt;ulink linkType="Reference" linkID="1689574"&gt;1689574&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, pooled results from a phase II and III studies (NCT01736397 and &lt;ulink linkType="Protocol" linkID="214239"&gt;NCT02268994&lt;/ulink&gt;) were published. The aim of this analysis was to evaluate safety and efficacy. Treatment with ferric citrate reported a consistent rise in hemoglobin and modest decline in serum phosphate, with few excursions below the normal range [&lt;ulink linkType="Reference" linkID="2038406"&gt;2038406&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2018, results of pooled analysis from two studies (NCT01736397 and NCT02268994) to determine the usefulness of oral ferric citrate in patients with iron-deficiency anemia and chronic kidney disease with or without heart failure were published.  HF was noted in 22% (n = 81) of patients. No significant difference was observed in the proportion of patients with hemoglobin response to ferric citrate treatment in patients with and without HF (43 versus 49%; respectively; p = 0.47); changes from baseline in hemoglobin, iron parameters, and serum phosphate were found to be similar [&lt;ulink linkType="Reference" linkID="2096081"&gt;2096081&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This would be randomized, double-blind, placebo-controlled, three-period, multicenter clinical      trial. Following a screening and qualification period and a 2-week washout period (for      those patients entering the study on a phosphate binder), eligible patients would be      randomized in a 1 : 1 ratio to receive either &lt;ulink linkType="Drug" linkID="54959"&gt;KRX-0502&lt;/ulink&gt; (ferric citrate) or placebo for up to      approximately 12 weeks. Patients would receive &lt;ulink linkType="Drug" linkID="54959"&gt;KRX-0502&lt;/ulink&gt;  with or within 1 h of meals or snacks. The starting dose of ferric citrate was 3 tablets/day and titrated by the patient's serum phosphorus results at each treatment visit.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized 1  :  1 to receive either &lt;ulink linkType="Drug" linkID="54959"&gt;KRX-0502&lt;/ulink&gt; (ferric citrate; three 1-g [elemental iron 210 mg] tablets/day with food, up to 12 tablets/day) or placebo for 12 weeks. Doses were titrated to lower serum phosphate concentrations to a target range (0.97 to 1.13 mmol/l) [&lt;ulink linkType="Reference" linkID="1496525"&gt;1496525&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1588840"&gt;1588840&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1689574"&gt;1689574&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2038406"&gt;2038406&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2096081"&gt;2096081&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="245503">ferric citrate (oral, hyperphosphatemia), Panion &amp; BF/Akebia/Japan Tobacco/Torii/3SBio</Intervention><Treatments><Treatment><Dose>1 gram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Address1>Asheville</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Address1>Bethesda</Address1><Address2>Maryland</Address2><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts/></Site><Site><Address1>Denver</Address1><Address2>Colorado</Address2><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Address1>Detroit</Address1><Address2>Michigan</Address2><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Address1>Edgewater</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Address1>Evergreen Park</Address1><Address2>Illinois</Address2><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Address1>Great Neck</Address1><Address2>New York</Address2><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Address1>Houston</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Address1>La Mesa</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Address1>Meridian</Address1><Address2>Idaho</Address2><CountrySubDivision code="ID">Idaho</CountrySubDivision><Contacts/></Site><Site><Address1>Miami</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Address1>Mineola</Address1><Address2>New York</Address2><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Address1>Orangeburg</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts/></Site><Site><Address1>Pontiac</Address1><Address2>Michigan</Address2><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Address1>Reno</Address1><Address2>Nevada</Address2><CountrySubDivision code="NV">Nevada</CountrySubDivision><Contacts/></Site><Site><Address1>Sacramento</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Address1>San Antonio</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Address1>Springfield</Address1><Address2>Massachusetts</Address2><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Address1>Tempe</Address1><Address2>Arizona</Address2><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Address1>Wilmington</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>End stage renal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7703">Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD)</PatientSegment><SubSegments><SubSegment id="7700">Subjects with stage 3 chronic kidney disease</SubSegment><SubSegment id="7701">Subjects with stage 4 chronic kidney disease</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7716">Subjects with Anemia of Chronic Kidney Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Anemia</Disease><PatientSegments><PatientSegment><PatientSegment id="19884">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="7510">Subjects with non-dialysis dependent renal disease</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01736397</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Anemia" id="17205"><Endpoint>Assessment of iron status</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17206">Assessment of serum ferritin</SubEndpoint><SubEndpoint disease="Anemia" id="17218">Assessment of transferrin saturation</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Anemia" id="17273"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22549"><Endpoint>Assessment of Serum Electrolytes</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22552">Assessment of phosphate</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22562"><Endpoint>Assessment of iron status</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Anemia" id="17219"><Endpoint>Hematological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17220">Assessment of hemoglobin status</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="17273"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17275">Assessment of biochemical parameters</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="17353"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17357">Assessment of serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="17356"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22544"><Endpoint>Hematological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22545">Assessment of hemoglobin levels</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22595"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Anemia" id="14360"><Criterion>Subjects with Anemia of Renal Disease</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14361">Subjects with non-dialysis dependent renal disease</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="14412"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Inclusion><Inclusion disease="Anemia" id="14431"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Anemia" id="14493"><Criterion>Subjects with Normal/Acceptable Hemoglobin Count</Criterion></Inclusion><Inclusion disease="End stage renal disease" id="17629"><Criterion>Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD)</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17642">Subjects with stage 3 chronic kidney disease</SubCriterion><SubCriterion disease="End stage renal disease" id="17644">Subjects with stage 4 chronic kidney disease</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="33342"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14433">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Anemia" id="11802"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Anemia" id="11815"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11823">Subjects with premalignant/malignant condition</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11819"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Anemia" id="11821"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Anemia" id="11848"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11853">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11855"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Anemia" id="13183"><Criterion>Subjects with Iron Overload</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17521"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17528"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17531"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17533"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17536"><Criterion>Subjects with History of/Scheduled for Renal Replacement Therapy</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17537">Subjects with protocol specified dialysis related criteria</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17541"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17546">Subjects with history of/scheduled for erythropoietin/iron supplements</SubCriterion><SubCriterion disease="End stage renal disease" id="17548">Subjects with history of/scheduled for nutritional supplements/dietary therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17551"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17553"><Criterion>Subjects with Contraindications to Study Procedure</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-11-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2013-08-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>9.06 Months</EnrollmentPeriod><EnrollmentRate>16.45 Patients/Month</EnrollmentRate><DateFirstReceived>2012-11-16T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-11-30T10:15:12Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2013-11-09T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="updated"><Date>2013-12-31T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="146416"><TitleDisplay>Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer</TitleDisplay><TitleOfficial>Phase I/II, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single-Agent in Patients With Recurrent Small-Cell Lung Cancer</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01901653</Identifier><Identifier type="Organisational Study">SCRX16-001</Identifier></Identifiers><Indications><Indication id="1261">Small-cell lung cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="1289" role="Therapeutic effect marker" type="Structural (imaging)">Tumor mass</BiomarkerName><BiomarkerName id="2054" role="Toxic effect marker" type="Cellular">Blood platelets</BiomarkerName><BiomarkerName id="7033" role="Toxic effect marker" type="Genomic;Proteomic">Lipase</BiomarkerName><BiomarkerName id="8157" role="Therapeutic effect marker" type="Genomic">delta-like protein 3</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>SC16LD6.5</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1063564" type="Company"><TargetEntity id="5034758203" type="organizationId">Stem CentRx Inc</TargetEntity></SourceEntity><SourceEntity id="1261" type="ciIndication"><TargetEntity id="10041056" type="MEDDRA"/><TargetEntity id="D055752" type="MeSH"/><TargetEntity id="70573" type="ORPHANET"/><TargetEntity id="-1257831198" type="omicsDisease"/><TargetEntity id="614" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>8</NumberOfSites><CompaniesSponsor><Company id="1063564">Stemcentrx Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>82</PatientCountEnrollment><PatientCountEvaluable>82</PatientCountEvaluable><DateStart>2013-07-31T00:00:00Z</DateStart><DateEnd type="actual">2016-11-28T00:00:00Z</DateEnd><DateChangeLast>2018-11-06T04:19:28Z</DateChangeLast><DateAdded>2013-07-18T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>SCRI Innovations</Affiliation><Name>Donald Strickland, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Provision of informed consent&lt;/li&gt;&lt;li&gt;Male or female &gt;/= 18 years of age&lt;/li&gt;&lt;li&gt;Histological or cytological confirmed diagnosis of small cell lung cancer, either limited or extensive disease at initial presentation is allowed (including large cell neuroendocrine carcinoma of the lung)&lt;/li&gt;&lt;li&gt;Evidence of progressive disease during or following one or two prior chemotherapy regimens:&lt;ul&gt;&lt;li&gt;At least one prior regimen must have contained a platinum salt&lt;/li&gt;&lt;li&gt;'Adjuvant therapy' will constitute a prior treatment regimen&lt;/li&gt;&lt;li&gt;No more than 2 prior regimens are allowed&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Measurable disease (only for the phase II portion)&lt;/li&gt;&lt;li&gt;Eastern cooperative oncology group (ECOG) performance status 0 to 1&lt;/li&gt;&lt;li&gt;A minimum life expectancy of 12 weeks&lt;/li&gt;&lt;li&gt;Adequate bone marrow, hepatic and renal function as evidenced by:&lt;ul&gt;&lt;li&gt;Absolute neutrophil count (ANC) &gt;/= 1.5 x 10(9)/l&lt;/li&gt;&lt;li&gt;Platelet count &gt;/= 100 x 10(9)/l&lt;/li&gt;&lt;li&gt;Hemoglobin &gt;/= 9.0 g/dl&lt;/li&gt;&lt;li&gt;Serum bilirubin&amp;lt; 1.5 x ULN&lt;/li&gt;&lt;li&gt;Aspartate aminotransferase (AST)/Alanine transferase (ALT) (SGOT/SGPT)&amp;lt; 2.5 x ULN for the reference laboratory or &amp;lt; 5 x ULN in the presence of liver metastases&lt;/li&gt;&lt;li&gt;Serum creatinine&amp;lt; 1.5 x ULN&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;No 'active' central nervous system (CNS) metastases. Prior CNS metastases are allowed, provided adequate palliative therapy has been administered and CNS disease control has been established prior to study entry. A brain MRI scan,&amp;lt;/= 28 days from day 1, is required&lt;/li&gt;&lt;li&gt;Female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures and who have a negative serum pregnancy test within 1 week prior to initial study treatment&lt;/li&gt;&lt;li&gt;Male patients willing to use adequate contraceptive&lt;/li&gt;&lt;li&gt;At least 21 days must have elapsed prior to day 1 cycle 1, from chemotherapy, radiotherapy, immunotherapy or following major surgery and any surgical incision should be completely healed. At least 14 days must have elapsed prior to day 1 cycle 1 for 'limited palliative radiotherapy', defined as a course of therapy encompassing&amp;lt; 25% total bone marrow volume and not exceeding 30 Gy&lt;/li&gt;&lt;li&gt;At least 14 days must have elapsed for chemotherapy regimens, biological, and targeted therapy given continuously or on a weekly basis with limited potential for delayed toxicity&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who are pregnant or breastfeeding&lt;/li&gt;&lt;li&gt;Active involvement of the Central Nervous System (CNS)&lt;/li&gt;&lt;li&gt;Uncontrolled infection or systemic disease&lt;/li&gt;&lt;li&gt;Clinically significant cardiac disease not well controlled with medication (eg, congestive heart failure, symptomatic coronary artery disease eg, angina, and cardiac arrhythmias) or myocardial infarction within the last 12 months&lt;/li&gt;&lt;li&gt;Chemotherapy regimens within the last 21 days (or within 6 weeks for prior nitrosourea or mitomycin C).  Chemotherapy regimens, biological, and targeted therapy given continuously or on a weekly basis with limited potential for delayed toxicity within the last 14 days&lt;/li&gt;&lt;li&gt;No concurrent systemic chemotherapy or anticancer biological therapy is allowed. Patients on hormonal treatment for breast cancer or prostate cancer may continue on treatment and enter into study&lt;/li&gt;&lt;li&gt;Known hypersensitivity to any components of SC16LD6.5 study drug product&lt;/li&gt;&lt;li&gt;Patients with known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both), a history of solid organ or bone marrow transplantation would generally be considered to have met exclusion criteria, however exceptions may be considered on a case-by-case basis by the medical monitor&lt;/li&gt;&lt;li&gt;Psychiatric disorder or social or geographic situation that would preclude study participation&lt;/li&gt;&lt;li&gt;QT interval measurement corrected by Fridericia's formula (QTcF) interval of&amp;gt; 450 ms (males) or &amp;gt; 470 ms (females)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Maximum tolerated dose (MTD) of rovalpituzumab tesirin: MTD was determined by testing increasing doses from 0.05 mg/kg up to 0.8 mg/kg on Day 1 of every 21-day or 42-day cycle, Phase 1a cohorts 1 to 8. MTD will be defined as the dose level immediately below the dose level at which ≥ 2 of the first 3 subjects per cohort (or ≥ 2 of 6 subjects) during the first cycle experience a study drug related dose limiting toxicity (DLT)</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 assessed objective response rate</Description><Timeframe>18 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Clinical benefit rate (CBR): Clinical Benefit is defined as a subject with best Overall Response of Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) prior to receiving any subsequent anticancer therapy; as defined by RECIST version 1.1. CBR is defined as the proportion of subjects with Clinical Benefit based on assessment of overall response. CBR will be presented as a number and percentage with 95% confidence bounds. Any subjects not exhibiting a response (CR or PR or SD) are considered non-responders.Outcome is based on data reported by Investigator (INV); available and evaluable radiographic scans were collected retrospectively for review by an Independent Review Committee (IRC)</Description><Timeframe>From first dose of Rovalpituzumab tesirine to last event timepoint, up through study completion (on avergae approximately 4 months)</Timeframe></Measure><Measure><Description>Safety</Description></Measure><Measure><Description>Objective Response Rate (ORR): overall response was assessed at each visit post-baseline based on a subject's lesion measurements or assessments (complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD], or not evaluable as defined by RECIST v1.1, plus an additional category of early death). The best overall response was then determined. A subject was defined as having an objective response if they had a best overall response of CR or PR prior to receiving any subsequent anticancer therapy; confirmed response is confirmation of CR or PR at least 4 weeks from the initial determination per RECIST v1.1. Subjects with a post-baseline assessment were included in the calculations for objective response rate (ORR). Outcome is based on data reported by Investigator (INV); available and evaluable radiographic scans were collected retrospectively for review by an Independent Review Committee (IRC)</Description><Timeframe>From first dose of rovalpituzumab tesirine to last event, up through study completion (on average approximately 4 months)</Timeframe></Measure><Measure><Description>Duration of Response (DOR): duration of response (DOR) was defined as the number of months from the initial CR or PR to the time of disease progression or death, whichever occurred first. Outcome is based on data reported by Investigator (INV); available and evaluable radiographic scans were collected retrospectively for review by an Independent Review Committee (IRC)</Description><Timeframe>From first dose of Rovalpituzumab tesirine to last event timepoint, up through study completion (on average approximately 4 months, but up to 6.51 months)</Timeframe></Measure><Measure><Description>Progression-free Survival (PFS): progression-free survival (PFS) was defined as the number of months from the first day of study drug administration to disease recurrence or progression, or death on study. Outcome is based on data reported by Investigator (INV); available and evaluable radiographic scans were collected retrospectively for review by an Independent Review Committee (IRC)</Description><Timeframe>From first dose of rovalpituzumab tesirine to last event timepoint, up through study completion (approximately 4 months on average, but up to 14.46 months)</Timeframe></Measure><Measure><Description>Maximum Serum Concentration (Cmax) of rovalpituzumab tesirine Antibody Drug Conjugate (ADC): the maximum serum concentration (Cmax; measured in microg/ml) is the highest concentration that a drug achieves in the blood after administration in a dosing cycle</Description><Timeframe>From Day 1 of first dose to End of Dose Cycle</Timeframe></Measure><Measure><Description>Area Under the Serum Concentration-time Curve (AUC) of Rovalpituzumab Tesirine ADC: the area under the serum concentration-time curve (AUC; measured in microgd/ml) is a method of measurement to determine the total exposure of a drug in blood serum</Description><Timeframe>From Day 1 of first dose to End of Dose Cycle</Timeframe></Measure><Measure><Description>Overall survival: overall survival (OS) was defined as the time from the first day of study treatment to death. Subjects who were alive were censored at the date of last known alive</Description><Timeframe>From first dose of Rovalpituzumab tesirine to last event, up through study completion (on average approximately 5 to 7 months, but up to 14.6 months)</Timeframe></Measure><Measure><Description>Pharmacokinetics of SC16LD6.5: standard PK variables, including Cmax, AUC, Vd, CL, and T1/2, will be assessed for SC16LD6.5, and D6.5</Description><Timeframe>18 months</Timeframe></Measure><Measure><Description>RECIST version 1.1 assessed progression free survival</Description><Timeframe>18 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In June 2016, results were presented. DLTs were observed in two of two patients with 0.8 mg/kg dosage. Overall, a total of 38 and 88% of patients reported grade 3+ and all grade TEAEs, respectively. Fatigue (4 and 35%), pleural effusion (8 and 31%), peripheral edema (3 and 27%), nausea (0 and 19%), hypoalbuminemia (0 and 18%), thrombocytopenia (11 and 16%), maculo-papular rash (3 and 16%) and loss of  appetite (0 and 16%) were the highest related treatment-emergent adverse events (grade 3+ and all grades, respectively) reported in &gt;/=15% of SCLC patients. Thrombocytopenia (platelet count decreased), serosal effusions (pleural or pericardial effusion, ascites or capillary leak syndrome, peripheral edema and/or hypoalbuminemia) and skin reaction (blister, dermatitis acneiform, dry skin erythema, erythema multiforme, palmar-plantar erthrodysesthesia syndrome, photosensitivity reaction, pruritus, pruritus generalized, rash, rash erythematous, rash maculo-papular, skin exfoliation and skin irritation) were the highest related TEAEs groups. Thrombocytopenia (11%), pleural effusion (8%), fatigue (4%), edema peripheral, and rash maculo-papular (3% each) were the &gt;/= grade 3 severe toxicities. SC16LD6.5  showed manageable safety profile [&lt;ulink linkType="Reference" linkID="1769255"&gt;1769255&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1766693"&gt;1766693&lt;/ulink&gt;]. In December 2016, similar results were presented [&lt;ulink linkType="Reference" linkID="1882893"&gt;1882893&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1882693"&gt;1882693&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, results were presented. SC16LD6.5 was found to be well-tolerated [&lt;ulink linkType="Reference" linkID="1769469"&gt;1769469&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2017, results were published. At a dose of 0.8 mg/kg q3w of SC16LD6.5, dose-limiting toxic effects occurred including grade 4 thrombocytopenia (in two of two patients at that dose level) and grade 4 liver function test abnormalities (in one patient). Thrombocytopenia, pleural effusion and increased lipase were the most frequent grade 3 or worse treatment-related adverse events observed in 11, 8, and 7% of patients with small-cell lung cancer (n = 74), respectively. Drug-related serious adverse events occurred in 38% of patients. The maximum tolerated dose of rovalpituzumab tesirine was 0.4 mg/kg every 3 weeks [&lt;ulink linkType="Reference" linkID="1920923"&gt;1920923&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this first-in-human, open-label, dose-escalation, single-group, phase I/II  study was to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of &lt;ulink linkType="Drug" linkID="86549"&gt;SC16LD6.5&lt;/ulink&gt; (rovalpituzumab tesirine) at different      dose levels in patients with small-cell lung cancer (SCLC) whose cancer has progressed or recurred      following standard chemotherapy. Once a safe and tolerable dose was determined, the      anti-cancer activity of SC16LD6.5 would be assessed by measuring the extent of tumor      shrinkage [&lt;ulink linkType="Reference" linkID="1882893"&gt;1882893&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1882693"&gt;1882693&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2015, the enrollment was completed [&lt;ulink linkType="Reference" linkID="1692694"&gt;1692694&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;As of December 2016, cohorts  treated with either 0.2 or 0.3 mg/kg iv administered q3w or q6w were expanded [&lt;ulink linkType="Reference" linkID="1882893"&gt;1882893&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In April 2016, results were presented. SC16LD6.5 demonstrated overall response rates of 44% in the patients identified with high expression of DLL3 [&lt;ulink linkType="Reference" linkID="1756798"&gt;1756798&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, results were presented. Responses were observed at 0.2 to 0.4 mg/kg doses. Recommended phase II dose was 0.3 mg/kg, q6w x2. In all patients and in patients with &gt;/= 50% of cells expressing DLL3, objective response rate (ORR) was 18 and 39%, respectively, and clinical benefit rate (CBR) was 68 and 89%, respectively, per investigator; and the ORR was 16 and 31%, respectively, and CBR was 64 and 85%, respectively, per central review validated confirmed responses. Confirmed responses were comparable in second and third line treatments. In second-line treatment, ORR was 13 and 29% and CBR was 72 and 86% and in third line treatment, ORR was 25 and 50% and CBR was 64 and 92% in all patients and patients with &gt;/= 50% of cells expressing DLL3, respectively. The median overall survival (OS) was 5.8 and 4.6 months and OS at one year was observed in 32 and 18% of patients in patients with &gt;/= 50% of cells expressing DLL3 and in all patients, respectively. Overall, confirmed response rate and overall survival improved when compared with historical approved treatments. When compared with second-line treatment (&lt;ulink linkType="Drug" linkID="4577"&gt;topotecan&lt;/ulink&gt;), SC16LD6.5 treated patients reported improved confirmed response rate (17 and 5 versus 43 and 14% [sensitive and R/R, respectively]) and one-year overall survival (27 and 9 versus 38 and 19% [sensitive and R/R, respectively]). Similarly, when compared with third-line conventional therapy, SC16LD6.5 treated patients reported improved confirmed response rate (18 versus 50%) and one-year overall survival (12 versus 33%) [&lt;ulink linkType="Reference" linkID="1769255"&gt;1769255&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1766693"&gt;1766693&lt;/ulink&gt;]. In January 2017, similar results were published [&lt;ulink linkType="Reference" linkID="1920923"&gt;1920923&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, results were presented. SC16LD6.5 was found to be efficacious [&lt;ulink linkType="Reference" linkID="1769469"&gt;1769469&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2016, results were presented. The Responses were seen between 0.2 and 0.4 mg/kg. The MTD was established as 0.4 mg/kg, and SC16LD6.5 half-life was 12 days. The recommended phase II dose was 0.3 mg/kg q6wx2. Confirmed response rates, measured by DLL3 status, for 0.2 to 0.4 mg/kg doses were 18% overall (total n = 60) and 38% for high DLL3 patients (total n = 26). The same subset of patients expressed higher overall survival compared to the whole patient population (29 versus 15%). Median progression-free survival (PFS) and median duration of response were 4.3 and 2.8 months and 5.8 and 4.6 months for the high DLL3 and overall population respectively   [&lt;ulink linkType="Reference" linkID="1882893"&gt;1882893&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1882693"&gt;1882693&lt;/ulink&gt;]. In January 2017, similar results were published [&lt;ulink linkType="Reference" linkID="1920923"&gt;1920923&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive rovalpituzumab tesirine   as a single agent, at increasing dose levels as permitted based on real-time assessment of safety and tolerability, intravenously over 30 min. Doses would be repeated on Day 1 of each 21-day or 42-day cycle until either unacceptable toxicity or evidence of disease progression occurs.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received SC16LD6.5 (0.1, 0.2, 0.4 and 0.8 mg/kg q3w or 0.3 and 0.4 mg/kg q6w). Patients in expansion cohort received 0.2 mg/kg q3w or 0.3 mg/kg q6w [&lt;ulink linkType="Reference" linkID="1756798"&gt;1756798&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1769255"&gt;1769255&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1766693"&gt;1766693&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1920923"&gt;1920923&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients (n = 74) received SC16LD6.5 0.05 (n = 3), 0.1 (n = 1), 0.2 (n = 25), 0.4 (n = 3) and 0.8 (n = 2) mg/kg q3w [&lt;ulink linkType="Reference" linkID="1882893"&gt;1882893&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1882693"&gt;1882693&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>SC16LD6.5</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>19.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3020">Skin rash</Indication><CountPatientsAffectedPercentage>16.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3038">Appetite loss</Indication><CountPatientsAffectedPercentage>16.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3098">Hypoalbuminemia</Indication><CountPatientsAffectedPercentage>18.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="324">Thrombocytopenia</Indication><CountPatientsAffectedPercentage>16.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="402">Edema</Indication><CountPatientsAffectedPercentage>27.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsAffectedPercentage>35.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="334317">SC16LD6.5</Intervention><Treatments><Treatment><Dose>0.05 milligram/kg</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>0.1 milligram/kg</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>0.2 milligram/kg</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>0.3 milligram/kg</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>0.4 milligram/kg</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>0.8 milligram/kg</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Blue Ridge Cancer Care</Name><Address1>Roanoke</Address1><Address2>Virginia</Address2><Address3>24014</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts/></Site><Site><Name>Duke University Medical Center</Name><Address1>Durham</Address1><Address2>North Carolina</Address2><Address3>27710</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Florida Cancer Specialists</Name><Address1>Sarasota</Address1><Address2>Florida</Address2><Address3>34232</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Memorial Sloan Kettering Cancer Center</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10065</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Tennessee Oncology</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3>37203</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site><Site><Name>University of Alabama at Birmingham</Name><Address1>Birmingham</Address1><Address2>Alabama</Address2><Address3>35294</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts/></Site><Site><Name>University of Chicago Medical Center</Name><Address1>Chicago</Address1><Address2>Illinois</Address2><Address3>60637</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>University of Texas MD Anderson Cancer Center</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lung tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3618">Subjects with Small Cell (Oat Cell) Lung Cancer (SCLC)</PatientSegment><SubSegments><SubSegment id="3620">Subjects with extensive disease small cell lung cancer (ED-SCLC)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3647">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01901653</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lung tumor" id="8504"><Endpoint>Assessment of Objective Response</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8505">Assessment of objective response rate(ORR)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Lung tumor" id="8663"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8670">Assessment of maximum tolerated dose (MTD)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lung tumor" id="8481"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lung tumor" id="8489"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lung tumor" id="8663"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lung tumor" id="3907"><Criterion>Subjects with Small Cell (Oat Cell) Lung Cancer (SCLC)</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3909">Subjects with extensive disease small cell lung cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3913"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3968"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3971">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3975"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3976">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Lung tumor" id="3977">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3988"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3989">Subjects with history of anti-cancer chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3997"><Criterion>Subjects with Treatment Resistant Disease</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3948">Subjects with chemotherapy resistant/refractory disease</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="4073"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4098">Subjects recovered from all prior therapies and/or their toxic/adverse effects</SubCriterion><SubCriterion disease="Lung tumor" id="22381">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="22380"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion></Inclusion><Inclusion disease="Lung tumor" id="33317"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4024">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34001"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4032">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34147"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4106">Men with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34925"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4074">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lung tumor" id="5121"><Criterion>Subjects with Evidence of Metastasis</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5125">Subjects with central nervous system metastases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="5132"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5269"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5270">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Lung tumor" id="5277">Subjects with history of/scheduled for biological therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="5344"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5347">Subjects with abnormal laboratory values</SubCriterion><SubCriterion disease="Lung tumor" id="5365">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="20281"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5128">Subjects with central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="20282"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-11-28T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2015-08-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>25.03 Months</EnrollmentPeriod><EnrollmentRate>3.28 Patients/Month</EnrollmentRate><DateFirstReceived>2013-07-11T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-07-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-03-17T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-05-07T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="Added"><Date>2016-06-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2016-06-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2016-06-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2016-06-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2016-06-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2016-06-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2016-07-25T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="updated"><Date>2017-05-04T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="157131"><TitleDisplay>Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL</TitleDisplay><TitleOfficial>A Double-blind, Randomized, Placebo-controlled, Phase II Study to Evaluate ProCervix Efficacy to Clear HPV 16 and HPV 18 Infection in Women With Normal Cytology or ASCUS/LSIL</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01957878</Identifier><Identifier type="Organisational Study">PC10VAC02</Identifier><Identifier type="Other">2013-003358-25</Identifier><Identifier type="Trial Acronym">RHEIA-VAC</Identifier></Identifiers><Indications><Indication id="396">Papillomavirus infection</Indication></Indications><BiomarkerNames><BiomarkerName id="1689" role="Therapeutic effect marker" type="Genomic">Human papillomavirus DNA</BiomarkerName><BiomarkerName id="8279" role="Therapeutic effect marker" type="Proteomic">Anti-human papillomavirus type 16 antibodies</BiomarkerName><BiomarkerName id="11847" role="Therapeutic effect marker" type="Proteomic">Anti-human papillomavirus type 18 antibodies</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>ProCervix</Name><Drug id="53218">ProCervix</Drug></Intervention><Intervention type="InterventionPrimary"><Name>imiquimod</Name><Drug id="7067">imiquimod</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>imiquimod</Name><Drug id="7067">imiquimod</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="53218">ProCervix</Drug><IndicationsPioneer/><Companies><Company><Company id="1014134">Genticel</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="7067">imiquimod</Drug><IndicationsPioneer/><Companies><Company><Company id="1014134">Genticel</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="7067" type="Drug"><TargetEntity id="111924" type="siDrug">Imiquimod</TargetEntity></SourceEntity><SourceEntity id="53218" type="Drug"><TargetEntity id="703168" type="siDrug">GTL-001</TargetEntity></SourceEntity><SourceEntity id="1014134" type="Company"><TargetEntity id="5035524699" type="organizationId">GenKyoTex SA</TargetEntity></SourceEntity><SourceEntity id="396" type="ciIndication"><TargetEntity id="D030361" type="MeSH"/><TargetEntity id="-774172916" type="omicsDisease"/><TargetEntity id="865" type="siCondition"/></SourceEntity><SourceEntity id="7821" type="Action"><TargetEntity id="2313" type="Mechanism">Toll-Like Receptor 7 (TLR7) Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>45</NumberOfSites><CompaniesSponsor><Company id="1014134">Genticel</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1760">Adenylate cyclase modulator</Action><Action id="7821">TLR-7 agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="12372">Protein subunit vaccine</Class><Class id="12379">Therapeutic vaccine</Class><Class id="1379">Interferon modulator</Class><Class id="15189">Topical dermatological antiviral product</Class><Class id="1545">Anticancer</Class><Class id="1596">Immunomodulator</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="611">Dermatological formulation</Technology><Technology id="612">Emulsion dermatological</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="585">Oral formulation</Technology><Technology id="84">Protein fusion</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>239</PatientCountEnrollment><PatientCountEvaluable>233</PatientCountEvaluable><DateStart>2013-12-31T00:00:00Z</DateStart><DateEnd type="actual">2016-10-31T00:00:00Z</DateEnd><DateChangeLast>2017-07-10T16:12:08Z</DateChangeLast><DateAdded>2013-10-18T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Hospital Clinico San Carlos</Affiliation><Name>Jose Aragon</Name></Contact><Contact type="Public contact"><Affiliation>Hopital Jeanne de Flandre CHU de Lille</Affiliation><Name>Katty Ardaens</Name></Contact><Contact type="Public contact"><Affiliation>Hopital de Hautepierre</Affiliation><Name>JJ BALDAUF</Name></Contact><Contact type="Public contact"><Affiliation>CHU de Reims Institut Alix de Champagne</Affiliation><Name>Jean Bory</Name></Contact><Contact type="Public contact"><Affiliation>Institut Catala d Oncologia L. Hopitalet de Llobregat</Affiliation><Name>Xavier Castellsague</Name></Contact><Contact type="Public contact"><Affiliation>University of Antwerp</Affiliation><Name>Pierre Damme</Name></Contact><Contact type="Public contact"><Affiliation>CHU Dijon</Affiliation><Name>Serge Douvier</Name></Contact><Contact type="Public contact"><Affiliation>PPD; 27/35 Rue Victo Hugo 94853 Ivry Sur Seine France</Affiliation><Email>sylvie.fradet@ppdi.com</Email><Name>Sylvie Fradet</Name><Phone>33182880887</Phone></Contact><Contact type="Public contact"><Affiliation>Hospital Universitario "12 de Octubre</Affiliation><Name>Jesus Jimenez</Name></Contact><Contact type="Public contact"><Affiliation>GORH, CHU Estaing</Affiliation><Name>Anne Kaermmerlen</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patient is female between the ages of 25 and 50 years (inclusive)&lt;/li&gt;&lt;li&gt;Patient is pre-menopausal (referring to the time period preceding menopause, excluding perimenopause) and not on hormone replacement therapy (HRT)&lt;/li&gt;&lt;li&gt;Patient must have cervical HPV 16 and/or 18 infection confirmed by RT-PCR assay at baseline. Patient can be co-infected with other HPV serotypes&lt;/li&gt;&lt;li&gt;Patient has a cervical cytological evaluation with a normal, ASCUS or LSIL result at baseline&lt;/li&gt;&lt;li&gt;Patient has employed highly effective contraception the month prior to the first vaccination and will agree to employ highly effective contraception for at least 12 months after the first vaccination. Highly effective methods of birth control include those that result in a low failure rate (ie,&amp;lt; 1% per year) when used consistently and correctly such as implants, injectable, combined oral contraceptives, levonorgestrel-releasing intrauterine system, intra-uterine devices (IUDs), vasectomised partner and true sexual abstinence&lt;/li&gt;&lt;li&gt;Patient is in general good health based on medical history and physical examination&lt;/li&gt;&lt;li&gt;Patient is able to communicate effectively with study personnel and is considered reliable, willing, and cooperative in terms of compliance with the protocol requirements&lt;/li&gt;&lt;li&gt;Patient voluntarily gives written informed consent to participate in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patient has a current acute or chronic disease, other than infection with HPV, which would be expected to interfere with the planned evaluations of response&lt;/li&gt;&lt;li&gt;Patient has vaginal atrophy with or without topical hormonal therapies or systemic selective estrogen receptor modulators (SERMs)&lt;/li&gt;&lt;li&gt;Patient has prior exposure to HPV prophylactic vaccine or patient has participated in the past in another vaccination clinical trial related to infection with HPV&lt;/li&gt;&lt;li&gt;Current high grade lesions or history of untreated high grade cervical lesion (either CIN2 or CIN3)&lt;/li&gt;&lt;li&gt;Patient has current or a history of cancer of the cervix&lt;/li&gt;&lt;li&gt;Patient has clinically significant (CS) gynecological abnormalities that could interfere with study Patient, in the judgment of the investigator (eg, prolapse, myoma, fibroid, hysterectomy)&lt;/li&gt;&lt;li&gt;Patient has a laboratory abnormality grade &gt;/= 2, as defined using the Toxicity Grading Scale for aealthy adult and adolescent volunteers enrolled in preventative vaccine clinical trials&lt;/li&gt;&lt;li&gt;Patient has received any live viral vaccine within 3 months or any other non live vaccine within 2 weeks of first study product administration&lt;/li&gt;&lt;li&gt;Patient has primary or secondary systemic immunosuppression (defined as prolonged [&gt;/= 7 days] use of corticosteroids that is &gt;/= 20 mg of prednisone-equivalent per day or any other immunosuppressive drug)&lt;/li&gt;&lt;li&gt;Patient has a history of severe allergy (requiring hospital care) or or history of severe asthma requiring oral or parenteral drug management in the last year (treatments with inhaled corticosteroids, short-acting beta agonists [SABA], long-acting beta agonists [LABA] or theophylline are allowed)&lt;/li&gt;&lt;li&gt;Patient has a history of malignant cancer, except the following adequately treated cancers: basal cell carcinoma, or dermatological squamous cell carcinoma&lt;/li&gt;&lt;li&gt;Patient was administered with another investigational drug or vaccine within 30 days prior to the screening visit or is participating in any other study&lt;/li&gt;&lt;li&gt;Patient has a known hypersensitivity to&lt;ulink linkType="Drug" linkID="7067"&gt;imiquimod&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Patient has a history of severe reaction to any drug, included kanamcycin or vaccination&lt;/li&gt;&lt;li&gt;Patient has a medical condition with clinical and/or biological consequences judged by the Investigator incompatible with vaccination(s)&lt;/li&gt;&lt;li&gt;Patient has positive results for human immunodeficiency virus (HIV), hepatitis B virus (HBV) surface antigen (HBsAg), or hepatitis C virus (HCV)&lt;/li&gt;&lt;li&gt;Patient has a symptomatic vaginal or genital infection (for example, symptomatic candida infection). If appropriate in the judgment of the Investigator, subjects with symptomatic infection may be treated and reconsidered for enrolment after resolution of the symptomatic infection&lt;/li&gt;&lt;li&gt;Patient has a history of or currently active genital herpes disease&lt;/li&gt;&lt;li&gt;Patient is pregnant or is breastfeeding&lt;/li&gt;&lt;li&gt;Patient has a positive serum human chorionic gonadotrophin (HCG) result at enrollment&lt;/li&gt;&lt;li&gt;Preventative vaccine clinical trials for the following parameters:&lt;ul&gt;&lt;li&gt;Hemoglobin (Hb)&lt;/li&gt;&lt;li&gt;Hematocrit (Hct)&lt;/li&gt;&lt;li&gt;White blood cell count (WBC)&lt;/li&gt;&lt;li&gt;Lymphocytes&lt;/li&gt;&lt;li&gt;Neutrophils&lt;/li&gt;&lt;li&gt;Eosinophils&lt;/li&gt;&lt;li&gt;Platelet count (plt)&lt;/li&gt;&lt;li&gt;Urea nitrogen (BUN)&lt;/li&gt;&lt;li&gt;Creatinine&lt;/li&gt;&lt;li&gt;Alanine aminotransferase (ALT)&lt;/li&gt;&lt;li&gt;Aspartate aminotransferase (AST)&lt;/li&gt;&lt;li&gt;Alkaline phosphatase (ALP)&lt;/li&gt;&lt;li&gt;Total bilirubin (Tbili)&lt;/li&gt;&lt;li&gt;Prothrombin time (PT)&lt;/li&gt;&lt;li&gt;C-reactive protein (CRP)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Clearance of HPV 16 and HPV 18 infection using a type specific, sensitive and quantitative HPV PCR assay</Description><Timeframe>Month 12</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Clearance of HPV 16 and HPV 18 infection</Description><Timeframe>Months 6, 15, 18, and 24</Timeframe></Measure><Measure><Description>Occurrence, intensity, duration and relationship of any solicited local and general signs and symptoms during a 14-day follow-up period after each ProCervix or placebo dose</Description><Timeframe>14 days post each vaccination</Timeframe></Measure><Measure><Description>Confirmed clearance (non-detection of HPV 16 and/or HPV 18 DNA by RT-PCR on at least two consecutive visits) of HPV 16 and HPV 18 infection</Description><Timeframe>Months 12 and 15 of trial period</Timeframe></Measure><Measure><Description>Occurrence, intensity, duration and relationship of unsolicited local and general signs and symptoms occurring until month 12</Description><Timeframe>From vaccination to 12 months</Timeframe></Measure><Measure><Description>Occurrence and relationship of all SAE occurring throughout the study period</Description><Timeframe>Study period</Timeframe></Measure><Measure><Description>Sustained clearance (non-detection of HPV 16 and/or HPV 18 DNA by RT-PCR at month 6 or 12 and up to the end of the study) at month 12 up to the end of the study of HPV 16 and HPV 18 infection</Description><Timeframe>Months 12, 15, 18 and 24 of trial period</Timeframe></Measure><Measure><Description>Hematological and biochemical levels outside the normal laboratory ranges at each specified visit</Description><Timeframe>Study period</Timeframe></Measure><Measure><Description>Time to the first clearance of HPV 16 and HPV 18 infection</Description><Timeframe>Months 6, 12, 15, 18 and 24 of trial period</Timeframe></Measure><Measure><Description>Duration of the first clearance of HPV 16 and/or HPV 18 infection</Description><Timeframe>Months 6, 12, 15, 18 and 24 of trial period</Timeframe></Measure><Measure><Description>Proportion of incident HPV 16 or HPV 18 infections when absent at baseline</Description><Timeframe>Months 6, 12, 15, 18 and 24 of trial period</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In January 2016, results were presented. GTL-001 was generally safe and well-tolerated. The most common adverse events was transient local reactions at injection site. Unexpected safety signal was not observed [&lt;ulink linkType="Reference" linkID="1730506"&gt;1730506&lt;/ulink&gt;].  In June 2016, similar results were presented  [&lt;ulink linkType="Reference" linkID="1772646"&gt;1775633&lt;/ulink&gt;]. Similar results were presented in December 2016 [&lt;ulink linkType="Reference" linkID="1884997"&gt;1884997&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2016, results were presented. There were no safety concerns observed with ProCervix treatment as per Data Safety and Monitoring Board (DSMB) [&lt;ulink linkType="Reference" linkID="1778599"&gt;1778599&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this double-blind, randomized, placebo-controlled, parallel-group, phase II study was to evaluate the efficacy of &lt;ulink linkType="Drug" linkID="53218"&gt;ProCervix&lt;/ulink&gt; (GTL-001) or placebo (concomitantly administered with &lt;ulink linkType="Drug" linkID="7067"&gt;Aldara&lt;/ulink&gt; cream) in patients infected with Human Papillomavirus (HPV) 16 and/or HPV 18 with normal cytology (NILM), borderline (ASCUS) or with low -grade lesions (LSIL) [&lt;ulink linkType="Reference" linkID="1531108"&gt;1531108&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1629148"&gt;1629148&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1676086"&gt;1676086&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1727136"&gt;1727136&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1730506"&gt;1730506&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1772646"&gt;1772646&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1884997"&gt;1884997&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2014, patient enrollment reached the halfway mark in the RHEIA-VAC trial and enrollment was active at 39 centers in Belgium, Finland, France, Germany, the Netherlands, Spain and the UK. At that time, the Data and Safety Monitoring Board recommended to continue the trial as planned  [&lt;ulink linkType="Reference" linkID="1576653"&gt;1576653&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2014,  patient recruitment  (n = 239) was completed  [&lt;ulink linkType="Reference" linkID="1612244"&gt;1612244&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1629451"&gt;1629451&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1652668"&gt;1652668&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1670682"&gt;1670682&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1676086"&gt;1676086&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2015, about 50% of the recruited patients reached 12 months post-vaccination [&lt;ulink linkType="Reference" linkID="1676086"&gt;1676086&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Main objective of the study was to evaluate the efficacy of ProCervix adjuvanted with imiquimod, in comparison with placebo adjuvanted with imiquimod, to induce HPV 16 and 18 viral clearance at 12 months in HPV 16 and/or 18 infected women using a type specific, sensitive and quantitative HPV polymerase chain reaction (PCR) assay. &lt;/para&gt;&lt;para&gt;Secondary objectives of the trial were:&lt;br/&gt;To evaluate the efficacy of ProCervix adjuvanted with imiquimod, in comparison with placebo to induce HPV 16 and 18 sustained viral clearance. &lt;br/&gt;To evaluate the efficacy of ProCervix adjuvanted with imiquimod, in comparison with placebo, to induce HPV 16 and/or 18 viral clearance at 6, 12, 15, 18 and 24 months. &lt;br/&gt;To evaluate the safety and tolerability of ProCervix adjuvanted with imiquimod.&lt;/para&gt;&lt;para&gt;Exploratory objectives of the study were:&lt;br/&gt;To assess HPV 16 and/or HPV 18 viral clearance at one or more timepoints up to 12, 18 and 24 months in HPV 16 and/or 18 infected woman.&lt;br/&gt;To evaluate the cellular and humoral immunogenicity of ProCervix adjuvanted with imiquimod. &lt;br/&gt;To assess regression of cytological abnormalities and histological lesions at 12, 18 and 24 months in patients with HPV 16 and/or HPV 18-associated ASCUS/LSIL at enrolment. To assess the prevention of progression to CIN2+ in HPV 16 and/or 18 infected women 18 and 24 months after first immunization.&lt;/para&gt;&lt;para&gt;By December 2016, 218 patients completed the study (112 in the treated group and 106 in the placebo group) [&lt;ulink linkType="Reference" linkID="1884997"&gt;1884997&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;The results published in April 2015 revealed that ProCervix was potential in eradicating HPV16 infections, as well as able to protect from HPV18 infections, and vice-versa [&lt;ulink linkType="Reference" linkID="1652668"&gt;1652668&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2016, initial  results were presented. In the overall population, the 12-month primary endpoint was not met. At 12 months, an interim analysis following the last injection shows there was no statistical difference in viral clearance between treatment and placebo in the overall study population there was a clear separation in two predefined subgroups, namely patients with normal cytology and patients &amp;lt; 30 years old at baseline. Between the treated group compared to the placebo group in two prospectively defined sub-populations, there was a statistically significant separation. At 12 months, viral clearance (overall population) was  48.7 and 39.7% (p = 0.188) in patients treated with GTL-001 and placebo, respectively  whereas in patients with  normal cytology at baseline was 62.5 and 38.7%  in patients treated with GTL-001 and placebo, respectively (p = 0.018).  At baseline, patients &amp;lt; 30 years old viral clearance at 12 months was 58.6 and 32.1%  in patients treated with GTL-001 and placebo, respectively (p = 0.049)  [&lt;ulink linkType="Reference" linkID="1730506"&gt;1730506&lt;/ulink&gt;]. Similar results were presented in April 2016 [&lt;ulink linkType="Reference" linkID="1754151"&gt;1754151&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1884997"&gt;1884997&lt;/ulink&gt;]. In June 2016, similar results were presented [&lt;ulink linkType="Reference" linkID="1772646"&gt;1775633&lt;/ulink&gt;]. Similar results were presented in December 2016 [&lt;ulink linkType="Reference" linkID="1884997"&gt;1884997&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, post-hoc analysis results were presented.  Statistically significant viral clearance in a combined subgroup representing over 80% of GTL-001 target population was observed. During the sub-group analysis, the viral  clearance of GTL-001 and placebo at 12 months were found to be 54.8 and 35.3% (p = 0.067), respectively in undetermined cellular anomalies (ASCUS); in total NILM and ASCUS it was found to be 58.7 and 37.5% (p = 0.0029), respectively and  in low-grade lesions (LSIL) it was found to be 37.0 and 43.1% (p = 0.560), respectively [&lt;ulink linkType="Reference" linkID="1754151"&gt;1754151&lt;/ulink&gt;]. In June 2016, similar results were presented [&lt;ulink linkType="Reference" linkID="1772646"&gt;1772646&lt;/ulink&gt;]. Similar results were presented in December 2016 [&lt;ulink linkType="Reference" linkID="1884997"&gt;1884997&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016,  further interim results at 18 months were presented. No statistical difference in viral clearance between treatment or in the sub groups from the natural clearance in the placebo group observed [&lt;ulink linkType="Reference" linkID="1772646"&gt;1775633&lt;/ulink&gt;]. Similar results were presented in December 2016 [&lt;ulink linkType="Reference" linkID="1884997"&gt;1884997&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2016, final results were presented. Consistent statistical differences were not found  in any of the secondary endpoints   (confirmed and sustained clearance) at 24 months between ProCervix and placebo. The incidence of patients progressing to high-grade lesions was similar in both groups. In ProCervix group, a significant increase in anti-CyaA antibodies was observed, which persisted during the entire course of the study and it was not observed in placebo group [&lt;ulink linkType="Reference" linkID="1884997"&gt;1884997&lt;/ulink&gt;].&lt;br/&gt; &lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would consist of two treatment groups:&lt;br/&gt;Group 1: patients would receive &lt;ulink linkType="Drug" linkID="53218"&gt;ProCervix&lt;/ulink&gt; and adjuvanted by &lt;ulink linkType="Drug" linkID="7067"&gt;Aldara&lt;/ulink&gt;, (a cream containing 5% of imiquimod).&lt;br/&gt;Group 2: patients would receive placebo matching ProCervix and adjuvanted by &lt;ulink linkType="Drug" linkID="7067"&gt;Aldara&lt;/ulink&gt;, (a cream containing 5% of imiquimod).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received treatment with either &lt;ulink linkType="Drug" linkID="53218"&gt;ProCervix&lt;/ulink&gt;; or placebo matching ProCervix (concomitantly administered with &lt;ulink linkType="Drug" linkID="7067"/&gt;&lt;ulink linkType="Drug" linkID="7067"&gt;Aldara&lt;/ulink&gt;, a cream containing 5% of imiquimod) [&lt;ulink linkType="Reference" linkID="1676086"&gt;1676086&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients received ProCervix (n = 117) 600 microg or placebo (n = 116) inter-dermal injections 6 weeks apart, and in both cases two applications of imiquimod cream 5%, 15 min and 24 h after each injection of vaccine or placebo. At 18 and 24 months, all patients in the trial continue to be followed for safety and efficacy at 15, 18 and 24 months after their second injection [&lt;ulink linkType="Reference" linkID="1730506"&gt;1730506&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1754151"&gt;1754151&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1775633"&gt;1775633&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1884997"&gt;1884997&lt;/ulink&gt;].&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="357745">ProCervix</Intervention><Treatments><Treatment><Dose>600 microgram</Dose><Route>Intradermal</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Belgium"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Sylvie Fradet</Name></Contact></Contacts></Site><Site><Name>Centre for the Evaluation of Vaccination Vaccine &amp; Infectious Disease Institute (VAXINFECTIO) Faculty of Medicine University of Antwerp Belgium</Name><Address1>Antwerp</Address1><Contacts/></Site><Site><Name>Grand Hôpital de Charleroi Site Notre-Dame</Name><Address1>Charleroi</Address1><Contacts/></Site><Site><Name>Regionaal Ziekenhuis Heilig Hart Tienen Hospital</Name><Address1>Tienen</Address1><Address2>Vlaams Brabant</Address2><CountrySubDivision>Vlaams Brabant</CountrySubDivision><Contacts/></Site><Site><Name>University Hospitals Leuven</Name><Address1>Leuven</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Sylvie Fradet</Name></Contact></Contacts></Site><Site><Name>Charité - Universitätsmedizin Berlin Hospital</Name><Address1>Berlin</Address1><Contacts/></Site><Site><Name>Elisabeth Krankenhaus Essen GmbH - Clinic/Outpatient Facility</Name><Address1>Essen</Address1><Contacts/></Site><Site><Name>Klinikum Wolfsburg Hospital</Name><Address1>Wolfsburg</Address1><Contacts/></Site><Site><Name>Klinikum der Friedrich Schiller Universität Jena Hospital</Name><Address1>Jena</Address1><Contacts/></Site><Site><Name>LMU Klinikum der Universität- Hospital</Name><Address1>München</Address1><Contacts/></Site><Site><Name>Universitätsklinikum Erlangen Hospital</Name><Address1>Erlangen</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Spain"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Sylvie Fradet</Name></Contact></Contacts></Site><Site><Name>Clinica Ginecologica Ceoga, Clinic/Outpatient Facility</Name><Address1>Lugo</Address1><Contacts/></Site><Site><Name>Hospital Clinic Dept of Obstetrics and Gynecology C/ Villarroel Unidad de Ginecología Oncológica, Instituto Clínico de Ginecología y Obstetricia y Neonatología (ICGON), Hospital Clínic, Instituto de Investigaciones Biomédi</Name><Address1>Barcelona</Address1><Contacts/></Site><Site><Name>Hospital Clínico San Carlos</Name><Address1>Madrid</Address1><Contacts/></Site><Site><Name>Hospital La Paz de Madrid</Name><Address1>Madrid</Address1><Contacts/></Site><Site><Name>Hospital Regional Universitario Carlos Haya - Hospital Materno Infantil</Name><Address1>Malaga</Address1><Contacts/></Site><Site><Name>Hospital Sagrado Corazón de Sevilla</Name><Address1>Sevilla</Address1><Contacts/></Site><Site><Name>Hospital Universitari Vall D Hebron</Name><Address1>Barcelona</Address1><Contacts/></Site><Site><Name>Hospital Universitario "12 de Octubre"</Name><Address1>Madrid</Address1><Contacts/></Site><Site><Name>Hospital del Mar</Name><Address1>Barcelona</Address1><Contacts/></Site><Site><Name>Institut Catala d'Oncologia L'Hopitalet de Llobregat</Name><Address1>Barcelona</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Finland"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Sylvie Fradet</Name></Contact></Contacts></Site><Site><Name>Helsinki University Central Hospital</Name><Address1>Helsinki</Address1><Contacts/></Site><Site><Name>Kuopio University Hospital</Name><Address1>Kuopio</Address1><Contacts/></Site><Site><Name>Tampereen yliopistollinen sairaala Hospital</Name><Address1>Tampere</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>CHU Amiens Hopital Sud</Name><Address1>Amiens</Address1><Contacts/></Site><Site><Name>CHU Dijon</Name><Address1>Dijon</Address1><Contacts/></Site><Site><Name>CHU de Nîmes - Hopital Universitaire Caremeau</Name><Address1>Nîmes</Address1><Contacts/></Site><Site><Name>CHU de Reims Institut Alix de Champagne</Name><Address1>Reims</Address1><Contacts/></Site><Site><Name>Centre Hospitalier Lyon Sud</Name><Address1>Pierre Benite</Address1><Contacts/></Site><Site><Name>Centre d'Investigation Clinique de Vaccinologie Cochin Pasteur (CIC BT505)</Name><Address1>Paris</Address1><Contacts/></Site><Site><Name>GORH, CHU Estaing</Name><Address1>Clermont-Ferrand</Address1><Contacts/></Site><Site><Name>Hôpital Jeanne de Flandre CHU de Lille</Name><Address1>Lille</Address1><Contacts/></Site><Site><Name>Hôpital Saint Jacques</Name><Address1>Besançon</Address1><Contacts/></Site><Site><Name>Hôpital de Hautepierre</Name><Address1>Strasbourg</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="UK"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Sylvie Fradet</Name></Contact></Contacts></Site><Site><Name>Academic O&amp;G University of Manchester Research - St Mary's Hospital</Name><Address1>Manchester</Address1><Contacts/></Site><Site><Name>Dumfries and Galloway Royal Infirmary Hospital</Name><Address1>Dumfries</Address1><Contacts/></Site><Site><Name>Liverpool - GUM - Liverpool Centre for Sexual Health</Name><Address1>Liverpool</Address1><Contacts/></Site><Site><Name>St Mary's Hospital</Name><Address1>London</Address1><Contacts/></Site><Site><Name>The Centre for Immunology and Infection Hull York Medical School University of York</Name><Address1>York</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Netherlands"><Sites><Site><Name>Center Gynaecological Oncology Amsterdam AMC, NKI-AVL, VUmc</Name><Address1>Amsterdam</Address1><Contacts/></Site><Site><Name>St. Antonius Ziekenhuis Hospital</Name><Address1>Nieuwegein</Address1><Contacts/></Site><Site><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Sylvie Fradet</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Papillomavirus infection</Disease><PatientSegments><PatientSegment><PatientSegment id="10861">Subjects with High Risk Human Papillomavirus Infection</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Human Papillomavirus Vaccine</Disease><PatientSegments><PatientSegment><PatientSegment id="8285">Subjects with History of Human Papillomavirus(HPV) Infection/Related Conditions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01957878</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2013-003358-25</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Human Papillomavirus Vaccine" id="11110"><Endpoint>Assessments of Human Papillomavirus Infection</Endpoint><SubEndpoints><SubEndpoint disease="Human Papillomavirus Vaccine" id="11112">Assessment of frequency/incidence/persistence of human papillomavirus infection</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Papillomavirus infection" id="17892"><Endpoint>Resolution/Progression of HPV Infections/Lesions</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Human Papillomavirus Vaccine" id="11110"><Endpoint>Assessments of Human Papillomavirus Infection</Endpoint><SubEndpoints><SubEndpoint disease="Human Papillomavirus Vaccine" id="11112">Assessment of frequency/incidence/persistence of human papillomavirus infection</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Human Papillomavirus Vaccine" id="11119"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Human Papillomavirus Vaccine" id="11121">Assessment of local reactions</SubEndpoint><SubEndpoint disease="Human Papillomavirus Vaccine" id="11123">Assessment of serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Papillomavirus infection" id="17892"><Endpoint>Resolution/Progression of HPV Infections/Lesions</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Papillomavirus infection" id="17921"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Papillomavirus infection" id="17922">Adverse events/reactogenicity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Papillomavirus infection" id="17934"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Human Papillomavirus Vaccine" id="6893"><Criterion>Subjects with History of Human Papillomavirus(HPV) Infection/Related Conditions</Criterion></Inclusion><Inclusion disease="Human Papillomavirus Vaccine" id="6906"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Uterine cervix tumor" id="7722"><Criterion>Human Papilloma Virus (HPV) Positive Women</Criterion></Inclusion><Inclusion disease="Papillomavirus infection" id="16603"><Criterion>Subjects with High Risk Human Papillomavirus Infection</Criterion></Inclusion><Inclusion disease="Papillomavirus infection" id="16634"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Human Papillomavirus Vaccine" id="8437"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Human Papillomavirus Vaccine" id="8439">Subjects with history/scheduled to receive immunomodulators for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Human Papillomavirus Vaccine" id="8446"><Criterion>Subjects with Contraindication to Vaccine/Vaccine Ingredients</Criterion></Exclusion><Exclusion disease="Human Papillomavirus Vaccine" id="8450"><Criterion>Subjects with Human Papillomavirus(HPV) Infection/Related Conditions</Criterion><SubCriteria><SubCriterion disease="Human Papillomavirus Vaccine" id="8453">Subjects with cervical cancer/cervical dysplasia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Human Papillomavirus Vaccine" id="8455"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Human Papillomavirus Vaccine" id="8456">Subjects with history of human immunodeficiency virus (HIV) infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Human Papillomavirus Vaccine" id="8462"><Criterion>Subjects with Immune Disorders</Criterion></Exclusion><Exclusion disease="Human Papillomavirus Vaccine" id="8463"><Criterion>Subjects with Allergic Disorders</Criterion></Exclusion><Exclusion disease="Human Papillomavirus Vaccine" id="8476"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Human Papillomavirus Vaccine" id="8481"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Human Papillomavirus Vaccine" id="8501"><Criterion>Subjects with Sexually Transmitted Infection</Criterion></Exclusion><Exclusion disease="Uterine cervix tumor" id="9247"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Uterine cervix tumor" id="9283"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion><SubCriteria><SubCriterion disease="Uterine cervix tumor" id="9274">Subjects with history of prevention therapy for cervical cancer</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Papillomavirus infection" id="14609"><Criterion>Subjects with Pre-cancerous Lesions</Criterion><SubCriteria><SubCriterion disease="Papillomavirus infection" id="14610">Subjects with cervical intraepithelial neoplasia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Papillomavirus infection" id="14615"><Criterion>Subjects with HPV Related Cancers</Criterion><SubCriteria><SubCriterion disease="Papillomavirus infection" id="14616">Subjects with HPV related cervical cancer</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Papillomavirus infection" id="14623"><Criterion>Subjects with Other Malignancies</Criterion></Exclusion><Exclusion disease="Papillomavirus infection" id="14628"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Papillomavirus infection" id="14632"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Papillomavirus infection" id="14637"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Papillomavirus infection" id="14638">Subjects immunocompromized with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Papillomavirus infection" id="14639"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Papillomavirus infection" id="14644"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Papillomavirus infection" id="14645">Subjects with history of/scheduled to receive immunosuppressants for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Papillomavirus infection" id="14648"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Human Papillomavirus Vaccine" id="25882"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Human Papillomavirus Vaccine" id="8478">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Human Papillomavirus Vaccine" id="26532"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Human Papillomavirus Vaccine" id="8431">Subjects with prior preventive human papillomavirus(HPV) vaccination</SubCriterion><SubCriterion disease="Human Papillomavirus Vaccine" id="8433">Subjects with Prior Other Vaccination</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Papillomavirus infection" id="26552"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Papillomavirus infection" id="14640">Subjects with Prior HPV Vaccination</SubCriterion><SubCriterion disease="Papillomavirus infection" id="14641">Subjects with Prior Other Vaccination</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-10-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2014-11-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>11.03 Months</EnrollmentPeriod><EnrollmentRate>21.67 Patients/Month</EnrollmentRate><DateFirstReceived>2013-10-04T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-10-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2014-04-09T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2014-11-24T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-06-22T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="updated"><Date>2016-12-07T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="207411"><TitleDisplay>Phase I/II Study of KP-100IT in Acute Spinal Cord Injury</TitleDisplay><TitleOfficial>A Phase I/II Study to Evaluate the Safety and Efficacy of Intrathecal Injection of KP-100IT in Subjects With Acute Spinal Cord Injury</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02193334</Identifier><Identifier type="Organisational Study">KP-100-ND002</Identifier><Identifier type="Other">UMIN000014434</Identifier></Identifiers><Indications><Indication id="1258">Spinal cord injury</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>KP-100IT</Name><Drug id="76097">KP-100IT</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="76097">KP-100IT</Drug><IndicationsPioneer><Indication id="1258">Spinal cord injury</Indication></IndicationsPioneer><Companies><Company><Company id="1002521">Kringle Pharma Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1107695">Japan Agency for Medical Research and Development</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="24183">Keio University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1002521" type="Company"><TargetEntity id="4296240983" type="organizationId">Kringle Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1107695" type="Company"><TargetEntity id="5045823858" type="organizationId">Japan Agency for Medical Research and Development</TargetEntity></SourceEntity><SourceEntity id="24183" type="Company"><TargetEntity id="4296566429" type="organizationId">Keio University</TargetEntity></SourceEntity><SourceEntity id="1258" type="ciIndication"><TargetEntity id="10041552" type="MEDDRA"/><TargetEntity id="D013119" type="MeSH"/><TargetEntity id="90058" type="ORPHANET"/><TargetEntity id="-1980782964" type="omicsDisease"/><TargetEntity id="178" type="siCondition"/></SourceEntity><SourceEntity id="47112" type="Action"><TargetEntity id="6593" type="Mechanism">Drugs Targeting Hepatocyte Growth Factor (HGF)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>4</NumberOfSites><CompaniesSponsor><Company id="1002521">Kringle Pharma Inc</Company><Company id="24183">Keio University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1107695">Japan Agency for Medical Research and Development</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="47112">Hepatocyte growth factor ligand modulator</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="654">Intrathecal formulation</Technology><Technology id="80">Peptide</Technology><Technology id="85">Protein recombinant</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>45</PatientCountEnrollment><PatientCountEvaluable>45</PatientCountEvaluable><DateStart>2014-06-30T00:00:00Z</DateStart><DateEnd type="actual">2018-07-31T00:00:00Z</DateEnd><DateChangeLast>2019-06-06T02:04:54Z</DateChangeLast><DateAdded>2014-10-03T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Kringle Pharma, Inc.</Affiliation><Email>hashimura@kringle-pharma.com</Email><Name>Etsuro, Hashimura</Name><Phone>072-641-8739</Phone></Contact><Contact type="Public contact"><Affiliation>Kringle Pharma, Inc.</Affiliation><Email>hayata@kringle-pharma.com</Email><Name>Daichika, Hayata</Name><Phone>072-641-8739</Phone></Contact><Contact type="Scientific contact"><Affiliation>Kringle Pharma, Inc.</Affiliation><Name>Etsuro HASHIMURA</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age &gt;/= 18 and&amp;lt;/= 75 years&lt;/li&gt;&lt;li&gt;Cervical spinal cord injury, and Grade A, B1 or B2 in the modified Frankel Scale at 72 h since the injury&lt;/li&gt;&lt;li&gt;Patients able to provide written informed consent, which may require a relative to sign if arm/hand function of the patient is compromised&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Spinal cord injury at C1 to C2 or C2 to C3 level&lt;/li&gt;&lt;li&gt;Patients not  able to start rehabilitation within a week by setup of respirator or other reason&lt;/li&gt;&lt;li&gt;First dose of the study drug will not be given within 78 h since the injury&lt;/li&gt;&lt;li&gt;History of spinal cord injury or abnormality in spinal cavity. Or current considerable meningeal damage&lt;/li&gt;&lt;li&gt;Outcome assessment will not be conducted adequately through damage on injuries other than the injury&lt;/li&gt;&lt;li&gt;High-dose steroid therapy within 30 days before the entry&lt;/li&gt;&lt;li&gt;Patients who have diseases such as serious liver disorder, renal disorder, hear disease, blood dyscrasia, metabolism disorder and infections&lt;/li&gt;&lt;li&gt;History of malignant tumor&lt;/li&gt;&lt;li&gt;Patients who participated in other clinical study within 30 days before the entry&lt;/li&gt;&lt;li&gt;Patients who have allergies to drug scheduled to be used in the study&lt;/li&gt;&lt;li&gt;Administration of the study drug to the area of spinal cord injury is not appropriate for example by intrathecal infections or intrathecal tumor&lt;/li&gt;&lt;li&gt;Patients not able to understand 'informed consent' properly&lt;/li&gt;&lt;li&gt;Patients who are nursing or may be pregnant&lt;/li&gt;&lt;li&gt;Investigator considers that the patient is not appropriate for participating in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number and degree of adverse events: adverse events will be judged by general condition, vital sign, electrocardiogram, MRI, blood chemistry, hematology, urinalysis, cerebrospinal fluid examination, and antibody formation</Description><Timeframe>24 weeks</Timeframe></Measure><Measure><Description>Change of ASIA (American Spinal Injury Association) motor score from baseline</Description><Timeframe>24 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Lower limb motor score</Description><Timeframe>At weeks 20 and 24</Timeframe></Measure><Measure><Description>Change of ASIA motor score from baseline</Description><Timeframe>12 weeks</Timeframe></Measure><Measure><Description>Time-dependent change of ASIA motor score from baseline</Description><Timeframe>24 weeks</Timeframe></Measure><Measure><Description>Time-dependent change of ASIA sensory score from baseline</Description><Timeframe>24 weeks</Timeframe></Measure><Measure><Description>Time-dependent change of KP-100 concentration in plasma and cerebrospinal fluid</Description><Timeframe>6 weeks</Timeframe></Measure><Measure><Description>Time-dependent grade change of modified Frankel scale from baseline</Description><Timeframe>24 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In March 2019, results were presented. There were not any concerned adverse events and no significant difference of frequency on adverse events between KP-100IT and placebo. Safety and tolerance was confirmed for KP-100IT [&lt;ulink linkType="Reference" linkID="2132707"&gt;2132707&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study was a multicenter, randomized, double-blind, placebo-controlled, phase I/II study designed to      evaluate safety and efficacy of &lt;ulink linkType="Drug" linkID="76097"&gt;KP-100IT&lt;/ulink&gt;, code of Hepatocyte Growth Factor (HGF) formulation      for intrathecal injection, as a treatment for acute spinal cord injury [&lt;ulink linkType="Reference" linkID="2041168"&gt;2041168&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2132707"&gt;2132707&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2017, enrollment was completed  [&lt;ulink linkType="Reference" linkID="2041168"&gt;2041168&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In March 2019, results were presented. The primary endpoint, the change of ASIA motor score at week 24 from baseline, didn't show significant improvement of KP-100IT compared to placebo, however, it was indicated tendency of improvement. For the secondary endpoint, the change of ASIA motor score over time, KP-100IT showed difference compared to placebo and especially showed significant difference at week 20. The significant difference was shown for KP-100IT in lower limb motor score at week 20 and 24. The percentage of patients who were classified as Frankel grad A at the begning of the trial and improved to C1 at the end of observation was 26% (4/15) in KP-100IT and 6% (1/16) in placebo [&lt;ulink linkType="Reference" linkID="2132707"&gt;2132707&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would consists of two treatment groups:&lt;br/&gt;Group 1: patients would receive KP-100IT intrathecally at a dose of  0.6 mg    starting  at 72 h since the injury and the treatment will be repeated five times a week.&lt;br/&gt;Group 2:  patients would receive intrathecal injection of placebo starting  at 72 h since the injury and the treatment will be repeated five times a week.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received KP-100IT or placebo [&lt;ulink linkType="Reference" linkID="2132707"&gt;2132707&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="472795">KP-100IT</Intervention><Treatments><Treatment><Dose>0.6 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Comprehensive  Loss Center</Name><Address1>Fukuoka</Address1><Contacts/></Site><Site><Name>Murayama Medical Center</Name><Address1>Tokyo</Address1><Contacts/></Site><Site><Name>Hokkaido Chuo Rosai Hospital Sekison Center</Name><Address1>Bibai</Address1><Address2>Hokkaido</Address2><Address3>072-0015</Address3><CountrySubDivision>Hokkaido</CountrySubDivision><Contacts/></Site><Site><Name>Spinal Injuries Center</Name><Address1>Iizuka</Address1><Address2>Fukuoka</Address2><Address3>820-8508</Address3><CountrySubDivision>Fukuoka</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02193334</Identifier></Identifiers></Registry><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier>UMIN000014434</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2017-12-21T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2017-12-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>42.06 Months</EnrollmentPeriod><EnrollmentRate>1.07 Patients/Month</EnrollmentRate><DateFirstReceived>2014-06-27T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-10-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-12-28T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-03-28T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="308">Protocol &amp; Results section added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="308">Protocol &amp; Results section added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="308">Protocol &amp; Results section added</Reason></Change><Change type="updated"><Date>2019-03-28T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="311">Trial Treatment added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change></ChangeHistory></Trial><Trial id="257237"><TitleDisplay>Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures</TitleDisplay><TitleOfficial>Multicenter, Open-Label Trial, Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Patients With Partial Onset Seizures With or Without Secondary Generalized Seizures</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02726074</Identifier><Identifier type="Organisational Study">E2007-M065-412</Identifier></Identifiers><Indications><Indication id="119">Epilepsy</Indication><Indication id="3439">Partial seizure</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>perampanel</Name><Drug id="41705">perampanel</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="41705">perampanel</Drug><IndicationsPioneer/><Companies><Company><Company id="1070029">Eisai Korea Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="19620">Eisai Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="41705" type="Drug"><TargetEntity id="314603" type="siDrug">Perampanel</TargetEntity></SourceEntity><SourceEntity id="1070029" type="Company"><TargetEntity id="5000888197" type="organizationId">Eisai Korea Inc</TargetEntity></SourceEntity><SourceEntity id="19620" type="Company"><TargetEntity id="4297240541" type="organizationId">Eisai Inc</TargetEntity></SourceEntity><SourceEntity id="119" type="ciIndication"><TargetEntity id="G40" type="ICD10"/><TargetEntity id="345" type="ICD9"/><TargetEntity id="10015037" type="MEDDRA"/><TargetEntity id="D004827" type="MeSH"/><TargetEntity id="-2005570698" type="omicsDisease"/><TargetEntity id="115" type="siCondition"/></SourceEntity><SourceEntity id="3439" type="ciIndication"><TargetEntity id="10061334" type="MEDDRA"/><TargetEntity id="D004828" type="MeSH"/><TargetEntity id="-569935387" type="omicsDisease"/><TargetEntity id="120" type="siCondition"/></SourceEntity><SourceEntity id="53" type="Action"><TargetEntity id="151" type="Mechanism">AMPA Receptor Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>6</NumberOfSites><CompaniesSponsor><Company id="1070029">Eisai Korea Inc</Company></CompaniesSponsor><CompaniesCollaborator><Company id="19620">Eisai Inc</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="53">AMPA receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="70">Anticonvulsant agent</Class></Class><Technologies><Technology id="805">Daily dosing</Technology><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>106</PatientCountEnrollment><DateStart>2016-05-31T00:00:00Z</DateStart><DateEnd type="actual">2018-10-31T00:00:00Z</DateEnd><DateChangeLast>2018-12-18T05:40:49Z</DateChangeLast><DateAdded>2016-04-06T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Name>Eisai Korea Inc</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Have a diagnosis of epilepsy with partial onset seizures with or without secondarily generalized seizures according to the International League Against Epilepsy's Classification of Epileptic Seizures (1981)&lt;/li&gt;&lt;li&gt;Need an initial add-on therapy after failure to control seizures with the first or further monotherapy at the optimal dose and duration&lt;/li&gt;&lt;li&gt;Despite antiepileptic drug (AED) treatment within the last 8 weeks, participants must have had &gt;/= 2 partial onset seizures, and the interval between those seizures should be &gt; 24 h prior to visit 1 (week 0)&lt;/li&gt;&lt;li&gt;Are currently being treated with stable doses of monotherapy for 8 weeks prior to visit 1 (week 0) (standard AEDs)&lt;/li&gt;&lt;li&gt;If antidepressants or antianxiety drugs are used, participants must be receiving stable doses and administrations of antidepressants or antianxiety drugs for 8 weeks prior to visit 1 (week 0)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Females who are pregnant (positive beta-hCG test) or breastfeeding&lt;/li&gt;&lt;li&gt;Presence of previous history of Lennox-Gastaut syndrome&lt;/li&gt;&lt;li&gt;Presence of nonmotor simple partial seizures only&lt;/li&gt;&lt;li&gt;Presence of primary generalized epilepsies or seizures such as absences and/or myoclonic epilepsies&lt;/li&gt;&lt;li&gt;A history of status epilepticus within 12 weeks before visit 1 (week 0)&lt;/li&gt;&lt;li&gt;Participants on antipsychotics or who have psychotic disorder(s) or unstable recurrent affective disorder(s) with a history of attempted suicide within one year before visit 1 (week 0)&lt;/li&gt;&lt;li&gt;Presence of a progressive central nervous system (CNS) disease, including degenerative CNS diseases and progressive tumors&lt;/li&gt;&lt;li&gt;Concomitant use of barbiturates (except for seizure control indication and premedication for electroencephalogram [EEG]) and benzodiazepines (except for seizure control indication) within 8 weeks prior to visit 1 (week 0)&lt;/li&gt;&lt;li&gt;Use of intermittent rescue benzodiazepines (ie, 1 to 2 doses over a 24-hr period considered one-time rescue) 2 or more times in an 8-week period prior to visit 1 (week 0)&lt;/li&gt;&lt;li&gt;Participant who is participating in other intervention clinical trial&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The 50% responder rate in total seizures: the 50% responder rate is defined as the number of participants who have at least a 50% reduction in seizure frequency during the maintenance period relative to baseline</Description><Timeframe>36 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The 100% responder rate (seizure free rate) in secondarily generalized tonic clonic seizures: GTC seizures are defined as seizures involved with generalized stiffening and rhythmic jerking of the limbs, caused by bilateral malfunction of the brain. The 100% responder rate is defined as the number of participants who have at least a 100% reduction in seizure frequency during the maintenance period relative to baseline</Description><Timeframe>Baseline and 36 weeks</Timeframe></Measure><Measure><Description>The 100% responder rate (seizure free rate) in total seizures: the 100% responder rate is defined as the number of participants who have at least a 100% reduction in seizure frequency during the maintenance period relative to baseline</Description><Timeframe>Baseline and 36 weeks</Timeframe></Measure><Measure><Description>The 50% responder rate in secondarily generalized tonic clonic (GTC) seizures: GTC seizures are defined as seizures involved with generalized stiffening and rhythmic jerking of the limbs, caused by bilateral malfunction of the brain. The 50% responder rate is defined as the number of participants who have at least a 50% reduction in seizure frequency during the maintenance period relative to baseline</Description><Timeframe>Baseline and 36 weeks</Timeframe></Measure><Measure><Description>The 75% responder rate in secondarily generalized tonic clonic seizures: GTC seizures are defined as seizures involved with generalized stiffening and rhythmic jerking of the limbs, caused by bilateral malfunction of the brain. The 75% responder rate is defined as the number of participants who have at least a 75% reduction in seizure frequency during the maintenance period relative to baseline</Description><Timeframe>Baseline and 36 weeks</Timeframe></Measure><Measure><Description>The 75% responder rate in total seizures: the 75% responder rate is defined as the number of participants who have at least a 75% reduction in seizure frequency during the maintenance period relative to baseline</Description><Timeframe>Baseline and 36 weeks</Timeframe></Measure><Measure><Description>Number of participants with treatment emergent adverse events (AEs) and serious adverse events (SAEs): safety will be assessed by monitoring of AEs, withdrawal from treatment, clinical laboratory evaluations (hematology), and vital signs</Description><Timeframe>36 weeks</Timeframe></Measure><Measure><Description>Percent change in secondarily generalized tonic clonic seizure frequency in the titration and maintenance period relative to baseline: GTC seizures are defined as seizures involved with generalized stiffening and rhythmic jerking of the limbs, caused by bilateral malfunction of the brain. Percent change from baseline is calculated as: ([post-baseline value - the baseline value]/baseline value) x 100</Description><Timeframe>Baseline and week 36</Timeframe></Measure><Measure><Description>Percent change in total seizure frequency in the titration and maintenance periods relative to baseline: percent change from baseline is calculated as: ([post-Baseline value - the baseline value]/baseline value) x 100</Description><Timeframe>Baseline and week 36</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The  aim of this multicenter, open-label, single-arm, phase IV study was to evaluate the efficacy of      &lt;ulink linkType="Drug" linkID="41705"&gt;perampanel&lt;/ulink&gt; (E-2007) added to monotherapy for partial onset seizures with or without secondarily      generalized seizures (total seizures).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would consists of two periods: titration period (12 weeks)      and maintenance period (24 weeks). During the titration period, patients would begin      to receive perampanel 2 mg/day (mg/day) and be up-titrated in no less than 2-week      intervals in increments of 2 mg up to 12 mg according to the investigator's judgment. Upon      entering the maintenance period, patients would receive the last dose they achieved at      the end of the titration period and would continue receiving this dose, qd for the      remainder of the study.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="South Korea"><Sites><Site><Address1>Busan</Address1><Contacts/></Site><Site><Address1>Daegu</Address1><Contacts/></Site><Site><Address1>Daejeon</Address1><Contacts/></Site><Site><Address1>Gwangju</Address1><Contacts/></Site><Site><Address1>Seongnam</Address1><Contacts/></Site><Site><Address1>Seoul</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Epilepsy</Disease><PatientSegments><PatientSegment><PatientSegment id="10306">Subjects with Partial Seizures</PatientSegment><SubSegments><SubSegment id="10309">Subjects with partial seizures with secondary generalization</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02726074</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Epilepsy" id="17057"><Endpoint>Assessment of Seizure Activity</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17058">Assessment of seizure frequency</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Epilepsy" id="17166"><Endpoint>Assessment of Response Rates (RR)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Epilepsy" id="17057"><Endpoint>Assessment of Seizure Activity</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17058">Assessment of seizure frequency</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17070"><Endpoint>Assessment of Seizure Freedom</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17071">Assessment of rate of seizure freedom</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17077"><Endpoint>Assessment of Generalized Seizures</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17079">Assessment of tonic-clonic seizures</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17131"><Endpoint>Clinical Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17140">Assessment of hematological function</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17132"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17146"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17155"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17157">Assessment of serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17156"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17159"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17164">Assessment of drop-out rate/withdrawal rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Epilepsy" id="17166"><Endpoint>Assessment of Response Rates (RR)</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Epilepsy" id="15256"><Criterion>Subjects with Diagnosis of Epilepsy</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="15257">Subjects with partial onset epilepsy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Epilepsy" id="15271"><Criterion>Subjects with Epilepsy based on Seizure Type</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="15274">Subjects with partial seizures with secondary generalization</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Epilepsy" id="15318"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="15330">Subjects on stable drug regimen</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Epilepsy" id="15348"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Epilepsy" id="12677"><Criterion>Subjects with Diagnosis of Epilepsy</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12679">Subjects with generalized epilepsy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12681"><Criterion>Subjects with Epilepsy Based on Seizure Type</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12682">Subjects with simple partial seizures</SubCriterion><SubCriterion disease="Epilepsy" id="12685">Subjects with absence seizures</SubCriterion><SubCriterion disease="Epilepsy" id="12689">Subjects with myoclonic seizures</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12690"><Criterion>Subjects with Epileptic Syndromes</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12694">Subjects with Lennox-Gastaut Syndrome</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12701"><Criterion>Subjects with Status Epilepticus</Criterion></Exclusion><Exclusion disease="Epilepsy" id="12709"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12710">Subjects with other central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12748"><Criterion>Subjects with History/ Scheduled to receive Anti-epileptic Therapy</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12749">Subjects with history/ scheduled to receive GABA receptor agonists</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12764"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12766">Subjects with history/ scheduled to receive psychotropic medication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12784"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12787">Protocol specified exclusion criteria for females</SubCriterion><SubCriterion disease="Epilepsy" id="12789">Subjects with participation in investigational study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="25877"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12719">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-10-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2017-08-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>15.03 Months</EnrollmentPeriod><EnrollmentRate>7.05 Patients/Month</EnrollmentRate><DateFirstReceived>2016-03-24T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-04-06T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-06-08T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-08-25T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="270370"><TitleDisplay>A randomized, controlled trial of web-based weight-loss program combined with human support for male worker &lt; 40 years</TitleDisplay><TitleOfficial>A randomized, controlled trial of web-based weight-loss program combined with human support for male worker &lt; 40 years</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000023809</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="418" role="Therapeutic effect marker" type="Anthropomorphic">Waist circumference</BiomarkerName><BiomarkerName id="7586" role="Therapeutic effect marker" type="Anthropomorphic">Body fat percentage</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>web-based weight-loss program guidance and telephone support</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>standard web-based weight-loss program guidance</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1080970" type="Company"><TargetEntity id="5046656827" type="organizationId">Nagoya University Graduate School of Medicine</TargetEntity></SourceEntity><SourceEntity id="1081125" type="Company"><TargetEntity id="5044169924" type="organizationId">Grants-in-Aid for Scientific Research</TargetEntity></SourceEntity><SourceEntity id="1085187" type="Company"><TargetEntity id="5047108504" type="organizationId">Ehime University Graduate School of Medicine</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"/><TargetEntity id="10029883" type="MEDDRA"/><TargetEntity id="D009765" type="MeSH"/><TargetEntity id="-1640888899" type="omicsDisease"/><TargetEntity id="985" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1080970">Nagoya University Graduate School of Medicine</Company><Company id="1085187">Ehime University Graduate School of Medicine</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1081125">Grants-in-Aid for Scientific Research</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>140</PatientCountEnrollment><DateStart>2016-06-01T00:00:00Z</DateStart><DateChangeLast>2019-02-27T10:28:39Z</DateChangeLast><DateAdded>2016-09-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Nagoya City University, School of nursing</Affiliation><Email>itsuko@med.nagoya-cu.ac.jp</Email><Name>Itsuko Ozaki</Name><Phone>+81-52-853-8845</Phone></Contact><Contact type="Scientific contact"><Affiliation>Nagoya U0niversity, Graduate School of Medicine ; Department of Nursing</Affiliation><Email>izumiw@met.nagoya-u.ac.jp</Email><Name>Izumi Watai</Name><Phone>+81-52-719-3151</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Body mass index&amp;gt;/= 25&lt;/li&gt;&lt;li&gt;Subjects with life-style disease and orthopedic disorder obtained permission from the primary doctor&lt;/li&gt;&lt;li&gt;Subjects who can always access internet&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects who had surgery within 6 months&lt;/li&gt;&lt;li&gt;Subjects who have orthopedic disease&lt;/li&gt;&lt;li&gt;Subjects who have psychiatric problem&lt;/li&gt;&lt;li&gt;Subjects who participate other programs during this intervention&lt;/li&gt;&lt;li&gt;Subjects who succeeded in losing weight &gt;/= 5% in the past year&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Weight loss</Description><Timeframe>12, 24, 48 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Body mass index</Description></Measure><Measure><Description>Energy expenditure</Description></Measure><Measure><Description>Energy intake</Description></Measure><Measure><Description>Frequency of self-monitoring</Description></Measure><Measure><Description>Percent of body fat</Description></Measure><Measure><Description>Self-efficacy</Description></Measure><Measure><Description>Waist circumference</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study aimed to compare the effectiveness of a web-based weight-loss program combined with human support and a web-based weight-loss program.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would consists of three  arms.&lt;br/&gt;Arm 1: the participants of enhanced intervention group would be  provided group guidance regarding the weight loss strategy at the beginning and the end of 12-weeks program. And they would be  encouraged to log on the website and use self-monitoring tool. They would be  provided small-group session at the each group guidance to promote adherence to use the website. Additionally, participants would receive one telephone support and online advice a total of three  times during the program.&lt;br/&gt;Arm 2: the participants of standard intervention group would be  provided group guidance regarding the weight loss strategy at the beginning and the end of 12-weeks program. And they would be  encouraged to log on the website and use self-monitoring tool.&lt;br/&gt;Arm 3: the participants of delayed control group would  not be given specific instruction. They would be  provided the same program as control group after the 12-weeks program.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Nagoya University  Graduate School of Medicine</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Obesity</Disease><PatientSegments><PatientSegment><PatientSegment id="7733">Overweight (pre-obese) Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000023809</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20401">Assessment of weight loss</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Obesity" id="20392"><Endpoint>Assessment of fat</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20414"><Endpoint>Assessment of Metabolic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20416">Assessment of energy expenditure</SubEndpoint><SubEndpoint disease="Obesity" id="20421">Assessment of energy intake</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20715"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20402">Assessment of waist circumference</SubEndpoint><SubEndpoint disease="Obesity" id="20405">Assessment of BMI</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="29701"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="29761">Self efficacy</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19678"><Criterion>Subjects with Protocol Specified BMI</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19680">Subjects with BMI&gt;25</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19787"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22428">Overweight Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19790"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15295"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Obesity" id="15325"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Obesity" id="15364"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15368">Prior/Recent participating in clinical trial</SubCriterion><SubCriterion disease="Obesity" id="15392">Subjects with history of/planned surgery</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2017-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>8.00 Months</EnrollmentPeriod><EnrollmentRate>17.50 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-09-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-01-12T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-03-04T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-03-04T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-04T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="304736"><TitleDisplay>Efficacy and Safety of BGB-3111 in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</TitleDisplay><TitleOfficial>A Single-Arm, Open-Label, Multicenter, Phase II Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03206918</Identifier><Identifier type="Organisational Study">BGB-3111-205</Identifier></Identifiers><Indications><Indication id="1734">Chronic lymphocytic leukemia</Indication><Indication id="203">Lymphoma</Indication></Indications><BiomarkerNames><BiomarkerName id="1925" role="Toxic effect marker" type="Cellular">Neutrophils</BiomarkerName><BiomarkerName id="2054" role="Toxic effect marker" type="Cellular">Blood platelets</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>zanubrutinib</Name><Drug id="77343">zanubrutinib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="77343">zanubrutinib</Drug><IndicationsPioneer/><Companies><Company><Company id="1063251">BeiGene Co Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1063251" type="Company"><TargetEntity id="5036210022" type="organizationId">BeiGene Beijing Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1734" type="ciIndication"><TargetEntity id="10008958" type="MEDDRA"/><TargetEntity id="690" type="siCondition"/></SourceEntity><SourceEntity id="203" type="ciIndication"><TargetEntity id="10025310" type="MEDDRA"/><TargetEntity id="D008223" type="MeSH"/><TargetEntity id="-386134440" type="omicsDisease"/><TargetEntity id="698" type="siCondition"/></SourceEntity><SourceEntity id="3592" type="Action"><TargetEntity id="1668" type="Mechanism">Bruton's Tyrosine Kinase (BTK) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>13</NumberOfSites><CompaniesSponsor><Company id="1063251">BeiGene Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3592">Btk tyrosine kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="62255">Anticancer protein kinase inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>91</PatientCountEnrollment><PatientCountEvaluable>91</PatientCountEvaluable><DateStart>2017-03-09T00:00:00Z</DateStart><DateEnd type="estimated">2020-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-06-24T08:55:10Z</DateChangeLast><DateAdded>2017-07-14T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Confirmed diagnosis of CLL/SLL&lt;/li&gt;&lt;li&gt;Meeting at least one criterion for treatment according to IWCLL&lt;/li&gt;&lt;li&gt;Men and women&amp;gt; 18 years of age&lt;/li&gt;&lt;li&gt;Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&lt;/li&gt;&lt;li&gt;Measurable disease by contrast enhanced computerized tomography / magnetic resonance imaging (CT/MRI)&lt;/li&gt;&lt;li&gt;Previously treated with a minimum of 1 prior line of standard chemotherapy-containing regimen (with completion of &gt;/= 2 treatment cycles)&lt;/li&gt;&lt;li&gt;Documented failure to achieve at least partial response (PR) or documented disease progression after response to the most recent treatment regimen. Refractory disease is defined as treatment failure (stable disease, non-response, progressive disease [PD]) or disease progression within 6 months after the most recent prior therapy (Hallek et al, 2008)&lt;/li&gt;&lt;li&gt;Neutrophils &gt;/= 0.75 x 10(9)/l independent of growth factor support within 7 days of study entry&lt;/li&gt;&lt;li&gt;Platelets &gt;/= 50 x 10(9)/l, independent of growth factor support or transfusion within 7 days of study entry&lt;/li&gt;&lt;li&gt;Creatinine clearance of &gt;/= 30 ml/min (as estimated by the Cockcroft-Gault equation or estimated glomerular filtration rate [eGFR] from the Modification of Diet in Renal Disease [MDRD])&lt;/li&gt;&lt;li&gt;Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)&amp;lt;/=3 x ULN&lt;/li&gt;&lt;li&gt;Bilirubin&amp;lt;/=2 x ULN (unless documented Gilbert's syndrome)&lt;/li&gt;&lt;li&gt;International normalized ratio (INR)&amp;lt;/=1.5 and activated partial thromboplastin time (APTT) &amp;lt;/=1.5 x ULN&lt;/li&gt;&lt;li&gt;Subjects may be enrolled who relapse after autologous stem cell transplant if they are at least 6 months after transplant&lt;/li&gt;&lt;li&gt;Females of childbearing potential must agree to use highly effective forms of birth control throughout the course of the study and at least up to 90 days after last dose of study drug. Highly effective forms of birth control can be defined as abstinence, hysterectomy, bilateral oophorectomy with no menstrual bleeding for up to 6 months, intrauterine contraception, hormonal methods such as contraceptive injection, oral contraceptive, etc. Males must have undergone sterilization-vasectomy, or utilize a barrier method where the female partner utilizes the effective forms of birth control noted above&lt;/li&gt;&lt;li&gt;Life expectancy of &gt; 4 months&lt;/li&gt;&lt;li&gt;Able to provide written informed consent, can understand and comply with the requirements of the study&lt;/li&gt;&lt;li&gt;Echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) &gt;/= 50%; (AHA, 2016)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Current or history of central nervous system (CNS) lymphoma&lt;/li&gt;&lt;li&gt;Prior exposure to a BTK inhibitor&lt;/li&gt;&lt;li&gt;Prior corticosteroids given in excess of prednisone 10 mg/day or its equivalent with antineoplastic intent within 7 days&lt;/li&gt;&lt;li&gt;Major surgery within 4 weeks of screening&lt;/li&gt;&lt;li&gt;Not recovered from toxicity of any prior anti-cancer therapy to&amp;lt; Grade 1 (except for alopecia, absolute neutrophil count (ANC) and platelets&lt;/li&gt;&lt;li&gt;History of other active malignancies within two years of study entry, with exception of:&lt;ul&gt;&lt;li&gt;Adequately treated in-situ carcinoma of cervix&lt;/li&gt;&lt;li&gt;Localized basal cell or squamous cell carcinoma of skin&lt;/li&gt;&lt;li&gt;Previous malignancy confined and treated locally (surgery or other modality) with curative intent&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Currently active clinically significant cardiovascular disease&lt;/li&gt;&lt;li&gt;QTcF &gt;480 ms based on Fridericia's formula or other significant electrocardiogram abnormalities including second degree atrioventricular (AV) block Type II, or third degree AV block&lt;/li&gt;&lt;li&gt;Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction&lt;/li&gt;&lt;li&gt;Active infection including infections requiring oral or intravenous anti-microbials&lt;/li&gt;&lt;li&gt;Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C infection (detected positive by polymerase chain reaction [PCR])&lt;/li&gt;&lt;li&gt;Pregnant or lactating women&lt;/li&gt;&lt;li&gt;Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, or put the study at risk&lt;/li&gt;&lt;li&gt;Requires ongoing treatment with any medication which is a strong cytochrome P450, family 3, subfamily A (CYP3A) inhibitor or strong CYP3A inducer&lt;/li&gt;&lt;li&gt;Known or clinically suspected Richter's transformation at the time of study entry&lt;/li&gt;&lt;li&gt;History of stroke or intracranial hemorrhage within 6 months prior to enrollment&lt;/li&gt;&lt;li&gt;Has received allogenic hematopoietic stem cell transplantation prior to enrollment&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Objective response rate (ORR)</Description><Timeframe>Up to three years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Duration of response (DOR)</Description><Timeframe>Up to three years</Timeframe></Measure><Measure><Description>Progression-free survival (PFS)</Description><Timeframe>Up to three years</Timeframe></Measure><Measure><Description>The safety and tolerability of BGB-3111, measured by the incidence, timing, and severity of AEs</Description><Timeframe>Up to three years</Timeframe></Measure><Measure><Description>Time to response (TTR)</Description><Timeframe>Up to three years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In October 2018, results were presented. BGB-3111 safety profile was consistent with previously reported clinical data [&lt;ulink linkType="Reference" linkID="2086685"&gt;2086685&lt;/ulink&gt;]. In June 2019, similar  results were presented [&lt;ulink linkType="Reference" linkID="2166622"&gt;2166622&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2019, further   results were presented. The majority of treatment-emergent adverse events (TEAEs) were grade 1 or 2 in severity. Neutrophil count decrease (68.1%), upper respiratory tract infection (45.1%), purpura (34.1%), and platelet count decreased (33%) were the most frequently reported TEAEs. In 75.8% of patients, grade &gt;/= 3 TEAEs were observed, with the most frequently reported being neutrophil count decrease (44%), lung infection (9.9%), upper respiratory tract infection (9.9%), platelet count decrease (8.8%) and anemia (8.8%). TEAEs leading to death were observed in three patients  (one case each of lung infection/cardiac failure/respiratory, cardiopulmonary failure and multiple organ dysfunction syndrome in the setting of disease progression); these were determined unlikely or unrelated to BGB-3111 treatment       [&lt;ulink linkType="Reference" linkID="2166622"&gt;2166622&lt;/ulink&gt;]&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a single-arm, open-label, multicenter, phase II, pivotal study of &lt;ulink linkType="Drug" linkID="77343"&gt;BGB-3111&lt;/ulink&gt; in patients with histologically      documented chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had relapsed after &gt;/= 1 prior treatment regimen(s). The study was      composed of an initial screening phase, a single-arm treatment phase, and a follow-up phase [&lt;ulink linkType="Reference" linkID="2009310"&gt;2009310&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2056155"&gt;2056155&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2066744"&gt;2066744&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2166622"&gt;2166622&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;As of December 2017, enrollment was completed [&lt;ulink linkType="Reference" linkID="2009310"&gt;2009310&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2018, results of pooled analysis from four studies (&lt;ulink linkType="Protocol" linkID="304473"&gt;NCT03206970&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="301789"&gt;NCT03189524&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="220360"&gt;NCT02343120&lt;/ulink&gt; and NCT03206918) which evaluated the safety of BGB-3111 in patients with hematological malignancies (n = 476) were presented. A total of 35% of patients required dose modifications, 32% of patients had dose interruptions; 11% of patients had dose reductions; 23% patients had discontinued treatment due to progressive disease (14%), adverse events regardless of relation to treatment (5%), withdrawal by patient (2%), noncompliance (&amp;lt; 1%) and other (3%). In total, 94% of the patients experienced &gt;/= 1 adverse events (AEs); neutropenia/neutrophil count decreased (14%), anemia (7%), thrombocytopenia/platelet count reduced (7%).were the most commonly reported grade &gt;/= 3 AEs; other events were upper respiratory tract infection, rash, diarrhea, cough, constipation and fatigue. Serious AEs were reported in 116 patients, of these 8% were related to BGB-3111; the most common serious AEs were pneumonia/lung infection (6%), pleural effusion (1%) and febrile neutropenia (1%); treatment related serious AEs reported in &amp;gt; 1% patients was pneumonia/lung infection (2%); there were no cases of Pneumocystis jirovecii or cytomegalovirus reactivation. AEs of interest  such as infection, hemorrhage, major hemorrhage, neutropenia, thrombocytopenia, anemia, diarrhea, hypertension, second primary malignancies, atrial fibrillation/flutter and tumor lysis syndrome were reported in 396 of patients. Petechiae/purpura/contusion (27%) and hematuria (11%) were the most common bleeding events. Major hemorrhage (2%), included gastrointestinal hemorrhage, intra-parenchymal CNS hemorrhage grade 5, hematuria, purpura, hemorrhagic cystitis, renal hematoma, and hemathorax (each n = 1). It was observed that among these patients with major hemorrhage, only one had thrombocytopneia AEs or medical history of thrombocytopneia. The median time to first major hemorrhage was 1.2 months. Among the patients with emergent atrial fibrillation/flutter (n = 8), most of the patients had risk factor including hypertension, pre-existing cardiovascular disease (n = 2 each) and concurrent infection (n = 1). At months, 6, 12 and 18, the cumulative rates of grade &gt;/= 3 infections were 14, 19 and 21%, respectively; the exposure-adjusted incidence rate was 1.82 per 100 person-months. Vulvovaginal candidiasis, bronchopulmonary aspergilllosis and oral candidiasis (&amp;lt; 1%) were the most frequent fungal infection. Basal cell carcinoma (3%) and squamous cell carcinoma of skin (2%) were the most common reported second primary malignancies. Breast cancer, colon cancer, squamous cell carcinoma, invasive ductal breast carcinoma, lentigo, maligna, lung neoplasm malignant, malignant melanoma, metastases to central nervous system and prostate cancer were other  grade &gt;/= 3 second primary malignancies. BGB-3111 was well tolerated in patients with various B-cell malignancies [&lt;ulink linkType="Reference" linkID="2045673"&gt;2045673&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2018, results were presented.  An independent review of response data from this study, with a data cut-off of June 15, 2018 and a median follow-up of 9.1 months,   overall response rate (ORR)  was found to be 80% including complete response (2%), partial response (39%), and partial response with lymphocytosis (40%).  The median duration of response was not  reached as the majority of the responders remain in a response [&lt;ulink linkType="Reference" linkID="2086685"&gt;2086685&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2019, results were presented. As of the December 2018 data cutoff, 82.4% remained on study treatment. The median follow-up time  was 15.1 months. The ORR by IRC was 84.6%; the complete response (CR) rate was 3.3%; the partial response (PR) rate was 59.3% and the PR with lymphocytosis (PR-L) was 22%. Across different subgroups, ORRs per IRC were generally consistent. The  progression-free survival (PFS) was estimated at 87.2% 12 month and the median PFS had not been reached with median PFS follow-up at 12.9 months  [&lt;ulink linkType="Reference" linkID="2166622"&gt;2166622&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would  receive 160 mg  BGB-3111 (two  80 mg white opaque capsules) po bid.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received BGB-3111 [&lt;ulink linkType="Reference" linkID="2045673"&gt;2045673&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="2086685"&gt;2086685&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Patients received BGB-3111   160 mg po bid [&lt;ulink linkType="Reference" linkID="2166622"&gt;2166622&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>zanubrutinib</Name><Drug id="77343">zanubrutinib</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="1132">Purpura</Indication><CountPatientsAffectedPercentage>34.1</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="17">Anemia</Indication><CountPatientsAffectedPercentage>8.8</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="513">Lung infection</Indication><CountPatientsAffectedPercentage>9.9</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="516">Upper respiratory tract infection</Indication><CountPatientsAffectedPercentage>45.1</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="720869">zanubrutinib</Intervention><Treatments><Treatment><Dose>160 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Fujian Medical University Union Hospital</Name><Address1>Fuzhou</Address1><Address2>Fujian</Address2><Address3>350001</Address3><CountrySubDivision>Fujian</CountrySubDivision><Contacts/></Site><Site><Name>Guangdong General Hospital</Name><Address1>Guangzhou</Address1><Address2>Guangdong</Address2><Address3>510080</Address3><CountrySubDivision>Guangdong</CountrySubDivision><Contacts/></Site><Site><Name>Henan Cancer Hospital</Name><Address1>Zhengzhou</Address1><Address2>Henan</Address2><Address3>450008</Address3><CountrySubDivision>Henan</CountrySubDivision><Contacts/></Site><Site><Name>Jiangsu Province Hospital</Name><Address1>Nanjing</Address1><Address2>Jiangsu</Address2><Address3>210029</Address3><CountrySubDivision>Jiangsu</CountrySubDivision><Contacts/></Site><Site><Name>Nanfang Hospital</Name><Address1>Guangzhou</Address1><Address2>Guangdong</Address2><Address3>510515</Address3><CountrySubDivision>Guangdong</CountrySubDivision><Contacts/></Site><Site><Name>Peking Union Medical College Hospital</Name><Address1>Beijing</Address1><Address2>Beijing</Address2><Address3>100730</Address3><CountrySubDivision>Beijing</CountrySubDivision><Contacts/></Site><Site><Name>Peking University People's Hospital</Name><Address1>Beijing</Address1><Address2>Beijing</Address2><Address3>100082</Address3><CountrySubDivision>Beijing</CountrySubDivision><Contacts/></Site><Site><Name>Shanghai Ruijin Hospital</Name><Address1>Shanghai</Address1><Address2>Shanghai</Address2><Address3>200025</Address3><CountrySubDivision>Shanghai</CountrySubDivision><Contacts/></Site><Site><Name>The First Affiliated Hospital of Soochow University</Name><Address1>Suzhou</Address1><Address2>Jiangsu</Address2><Address3>215006</Address3><CountrySubDivision>Jiangsu</CountrySubDivision><Contacts/></Site><Site><Name>The First Affilliated Hospital of Jinlin University</Name><Address1>Changchun</Address1><Address2>Jinlin</Address2><Address3>130021</Address3><CountrySubDivision>Jinlin</CountrySubDivision><Contacts/></Site><Site><Name>Tianjin Hematonosis Hospital</Name><Address1>Tianjin</Address1><Address2>Tianjin</Address2><Address3>300020</Address3><CountrySubDivision>Tianjin</CountrySubDivision><Contacts/></Site><Site><Name>Tongji Hospital of Tongji Medical College of HUST</Name><Address1>Wuhan</Address1><Address2>Hubei</Address2><Address3>430030</Address3><CountrySubDivision>Hubei</CountrySubDivision><Contacts/></Site><Site><Name>West China Hospital of Sichuan University</Name><Address1>Chengdu</Address1><Address2>Sichuan</Address2><Address3>610041</Address3><CountrySubDivision>Sichuan</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lymphoma</Disease><PatientSegments><PatientSegment><PatientSegment id="3489">Subjects with B Cell Non Hodgkin's Lymphoma</PatientSegment><SubSegments><SubSegment id="3480">Subjects with small lymphocytic/prolymphocytic lymphoma</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3525">Subjects with Relapse/Recurrent Lymphoma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3530">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Leukemia</Disease><PatientSegments><PatientSegment><PatientSegment id="3980">Subjects with Chronic Lymphocytic Leukemia (CLL)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3999">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="4003">Subjects with Relapsed/Recurrent Leukemia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03206918</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lymphoma" id="7604"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7569">Assessment of Overall/Objective Response Rate (ORR)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="7906"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7909">Assessment of Overall/Objective Response Rate (ORR)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lymphoma" id="7547"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7604"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7605">Assessment of time to response</SubEndpoint><SubEndpoint disease="Lymphoma" id="7611">Assessment of tumor response rate (Duration of response)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7679"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7680"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7891"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7906"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7940">Assessment of time to resolution</SubEndpoint><SubEndpoint disease="Leukemia" id="9300">Assessment of tumor response rate (Duration of response)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8077"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8078"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lymphoma" id="3464"><Criterion>Subjects with B Cell Non Hodgkin's Lymphoma</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3455">Subjects with small lymphocytic/prolymphocytic lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3497"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3536"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3537">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Lymphoma" id="3538">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Lymphoma" id="3539">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3609"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3614"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3621"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3622">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Lymphoma" id="3633">Subjects with normal/acceptable cardiac function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3657"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Leukemia" id="4986"><Criterion>Subjects with Chronic Lymphocytic Leukemia (CLL)</Criterion></Inclusion><Inclusion disease="Leukemia" id="5071"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5073">Subjects with normal/adequate liver function</SubCriterion><SubCriterion disease="Leukemia" id="5077">Subjects with normal/adequate hematopoietic function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5085"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5086">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Leukemia" id="5087">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Leukemia" id="5088">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5164"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Leukemia" id="5173"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Leukemia" id="5187"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5206">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="34128"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3677">Subjects with adequate contraception</SubCriterion><SubCriterion disease="Lymphoma" id="3679">Non Pregnant/Non lactating women</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="34439"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3659">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34442"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5190">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="34915"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3660">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34918"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5189">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lymphoma" id="4692"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4702"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4761"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4763">Subject with history of surgery</SubCriterion><SubCriterion disease="Lymphoma" id="4775">Subject with history of targeted therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4804"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4810"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4825"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4831">Protocol specified exclusion criteria for females</SubCriterion><SubCriterion disease="Lymphoma" id="4833">Subjects with medical condition interfering with the study protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="6534"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Leukemia" id="6554"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Leukemia" id="6660"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Leukemia" id="6700"><Criterion>Subjects with Specific Grade of Toxicity</Criterion></Exclusion><Exclusion disease="Leukemia" id="6706"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6656">Subjects with history of surgery/procedure</SubCriterion><SubCriterion disease="Leukemia" id="6723">Protocol specified exclusion criteria for females</SubCriterion><SubCriterion disease="Leukemia" id="6725">Subjects not suitable to take part in study according to investigator's opinion</SubCriterion><SubCriterion disease="Leukemia" id="6931">Subjects with drugs/conditions affecting pharmacokinetics of study drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="8709"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6635">Subjects with history of targeted therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="24311"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Lymphoma" id="25574"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4839">Subjects not suitable to participate as per investigator's discretion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="25705"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Leukemia" id="27879"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6718">Subjects unwilling or unable to comply with the protocol/study requirements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="27884"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4828">Subjects with inability to comply with the protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-06-15T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2017-12-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>9.74 Months</EnrollmentPeriod><EnrollmentRate>9.34 Patients/Month</EnrollmentRate><DateFirstReceived>2017-06-29T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-07-14T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-03-02T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-08-06T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="added"><Date>2019-05-21T00:00:00Z</Date><Reason id="308">Protocol &amp; Results section added</Reason></Change><Change type="updated"><Date>2019-05-21T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-21T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-21T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="updated"><Date>2019-05-21T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="Added"><Date>2019-06-24T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-06-24T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-06-24T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-06-24T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="updated"><Date>2019-06-24T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-06-24T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-06-24T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-06-24T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="336073"><TitleDisplay>Prediction of WMH in Migraine Using a BOLD-CVR Map</TitleDisplay><TitleOfficial>Research of Brain White Matter Hyperintensity in Migraine Using a Cerebrovascular Reactivity Mapping Based on BOLD MRI</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03494673</Identifier><Identifier type="Organisational Study">2017-04-049</Identifier></Identifiers><Indications><Indication id="210">Migraine</Indication></Indications><BiomarkerNames><BiomarkerName id="2014" role="Disease marker" type="Physiological">End-tidal carbon dioxide</BiomarkerName><BiomarkerName id="10959" role="Disease marker" type="Structural (imaging)">White matter</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>BOLD MRI</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1004334" type="Company"><TargetEntity id="5035524568" type="organizationId">Samsung Medical Center</TargetEntity></SourceEntity><SourceEntity id="1074899" type="Company"><TargetEntity id="5037244024" type="organizationId">National Research Foundation of Korea</TargetEntity></SourceEntity><SourceEntity id="210" type="ciIndication"><TargetEntity id="G43" type="ICD10"/><TargetEntity id="10027599" type="MEDDRA"/><TargetEntity id="D008881" type="MeSH"/><TargetEntity id="-672899670" type="omicsDisease"/><TargetEntity id="27" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1004334">Samsung Medical Center (SMC)</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1074899">National Research Foundation of Korea</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical procedure</Category><Category>Diagnostic</Category></TrialCategories><TermsDesign><Term>Case Control</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>74</PatientCountEnrollment><DateStart>2018-07-13T00:00:00Z</DateStart><DateEnd type="estimated">2020-02-28T00:00:00Z</DateEnd><DateChangeLast>2019-04-11T04:53:34Z</DateChangeLast><DateAdded>2018-04-16T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine</Affiliation><Name>Mi Ji Lee, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Migraineurs(patients) :&lt;ul&gt;&lt;li&gt;Age 18 to 50 years&lt;/li&gt;&lt;li&gt;Migraine with or without aura as defined by the third edition of the International Classification of Headache Disorders (ICHD-3 beta)&lt;/li&gt;&lt;li&gt;Migraine duration&amp;gt; 6 months&lt;/li&gt;&lt;li&gt;Episodic migraine feature headache (&amp;lt; 15 attacks/m)&lt;/li&gt;&lt;li&gt;Not any preventive medications for migraine&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Control:&lt;ul&gt;&lt;li&gt;Age 18 to 50 years&lt;/li&gt;&lt;li&gt;No headache disorder requiring painkillers within the past year&lt;/li&gt;&lt;li&gt;No more than moderate intensity of headache within the past year&lt;/li&gt;&lt;li&gt;No headache disorder other than Infrequent episodic tension-type headache as defined by the ICHD-3 beta&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Chronic migraine within last month (&gt;/= 15 attacks/m)&lt;/li&gt;&lt;li&gt;Medication overuse headache as defined by ICHD-3 beta&lt;/li&gt;&lt;li&gt;Other comorbid disease that may affect vascular function (Hypertension, diabetes, hyperlipidemia, cerebral infarction, smoking etc)&lt;/li&gt;&lt;li&gt;Can not breath 20 l for 1 min because of basal cardiopulmonary disease (chronic obstructive pulmonary disease, heart failure etc)&lt;/li&gt;&lt;li&gt;A disease that can be exacerbated by elevated PCO2 in blood (Interstitial lung disease, amyotrophic lateral sclerosis etc)&lt;/li&gt;&lt;li&gt;Predicted to be unable to write the headache diary due to cognitive decline&lt;/li&gt;&lt;li&gt;Contraindications to MRI&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Refusal to informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>CVR association with WMH development: the investigators will obtain a CVR map using BOLD MR signal in the first year of study and also obtain changes in WMH during two years of follow-up period in patients and controls, respectively. Then the investigators will test whether CVR-map predicts consequent WMH development in patients and controls, respectively</Description><Timeframe>One-year follow-up ( second year)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Spatial pattern of CVR: the investigators will obtain a CVR map for each voxel using BOLD MR signal in response to % increase in EtCO2 respectively in patients and controls. Spatial pattern of CVR will be compared between patients and controls</Description><Timeframe>Baseline (first year)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The investigators aimed to test the spatial association between      areas with reduced cerebrovascular reactivity (CVR) to hypercapnic stimuli and consequent      development of white matter hyperintensities (WMHs).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A whole-brain map of CVR will be created in patients with migraine and normal controls.      Hypercapnic stimuli for CVR will be delivered by prospective end-tidal CO2 targeting device.      Hemodynamic responses will be determined by BOLD signal changes using fMRI. WMHs will be      determined by high-resolution 3D FLAIR imaging. Patients diagnosed with migraine based on the ICHD-3 beta and controls will undergo serial      BOLD MRIs with one year interval. Associations between areas of reduced CVR and consequent WMH      development will be tested in both patients and controls.&lt;br/&gt;Prospective End-tidal targeting RespirAct device (A specially designed gas blender and sequential rebreathing circuit) will be used to implement the gas targeting method which involves precise elevations in End-tidal PCO2 while maintaining a fixed End-tidal PO2. BOLD MR images will be obtained by using a T2*-weighted two-dimensional gradient-echo sequence with echoplanar readout.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="South Korea"><Sites><Site><Name>Samsung Medical Center, Sungkyunkwan University School of Medicine</Name><Contacts/></Site><Site><Name>Samsung Medical Center</Name><Address1>Seoul</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Migraine</Disease><PatientSegments><PatientSegment><PatientSegment id="15295">Others</PatientSegment><SubSegments><SubSegment id="18868">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03494673</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Migraine" id="44154"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Migraine" id="44154"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><ExclusionCriteria><Exclusion disease="Migraine" id="24279"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Migraine" id="24750"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Migraine" id="24954"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Migraine" id="24748">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Migraine" id="25588"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion><Exclusion disease="Migraine" id="27227"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Migraine" id="27895"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion><Exclusion disease="Migraine" id="28158"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-02-28T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2019-04-09T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>8.90 Months</EnrollmentPeriod><EnrollmentRate>8.31 Patients/Month</EnrollmentRate><DateFirstReceived>2018-03-28T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-04-16T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-10-15T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-04-11T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="83625"><TitleDisplay>Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin</TitleDisplay><TitleOfficial>A 6-Month, Multicenter, Randomized, Open-Label, Parallel-Group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Both Plus Mealtime Insulin in Patients With Type 2 Diabetes Mellitus With a 6-Month Safety Extension Period</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">EFC11628</Identifier><Identifier type="NCT">NCT01499082</Identifier><Identifier type="Secondary Organisational">2010-023769-23</Identifier><Identifier type="Other">U1111-1118-6903</Identifier><Identifier type="Other">NCT01434875</Identifier><Identifier type="Trial Acronym">EDITION I</Identifier></Identifiers><Indications><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker;Toxic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="7895" role="Therapeutic effect marker" type="Physiological">Estimated glomerular filtration rate</BiomarkerName><BiomarkerName id="12058" role="Toxic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>insulin glargine (new formulation), Sanofi</Name><Drug id="73334">insulin glargine (new formulation), Sanofi</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>insulin glargine</Name><Drug id="10252">insulin glargine</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="73334">insulin glargine (new formulation), Sanofi</Drug><IndicationsPioneer/><Companies><Company><Company id="1009547">Sanofi SA</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="73334" type="Drug"><TargetEntity id="472023" type="siDrug">Glarginamide insulin</TargetEntity></SourceEntity><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"/><TargetEntity id="10067585" type="MEDDRA"/><TargetEntity id="D003924" type="MeSH"/><TargetEntity id="-1888632793" type="omicsDisease"/><TargetEntity id="509" type="siCondition"/></SourceEntity><SourceEntity id="400" type="Action"><TargetEntity id="609" type="Mechanism">Insulin Secretagogues</TargetEntity><TargetEntity id="1034" type="Mechanism">Insulin Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3a Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>206</NumberOfSites><CompaniesSponsor><Company id="1009547">Sanofi SA</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="23014">Insulin ligand</Action><Action id="400">Insulin receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="38212">Human insulin intermediate acting product</Class><Class id="38215">Human insulin long acting product</Class><Class id="399">Hypoglycemic agent</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="805">Daily dosing</Technology><Technology id="85">Protein recombinant</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="589">Sustained release formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>807</PatientCountEnrollment><PatientCountEvaluable>807</PatientCountEvaluable><DateStart>2011-12-31T00:00:00Z</DateStart><DateEnd type="actual">2013-09-30T00:00:00Z</DateEnd><DateChangeLast>2019-03-18T12:05:11Z</DateChangeLast><DateAdded>2011-12-30T11:32:09Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Sanofi</Affiliation><Name>Clinical Sciences &amp; Operations</Name></Contact><Contact type="Public contact"><Name>Sanofi</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with type 2 diabetes mellitus&lt;/li&gt;&lt;li&gt;Substudy inclusion criteria&lt;ul&gt;&lt;li&gt;Completion of the 6-month study period in main study (visit 10)&lt;/li&gt;&lt;li&gt;Randomized and treated with&lt;ulink linkType="Drug" linkID="73334"&gt;insulin glargine (new formulation)&lt;/ulink&gt; during the 6-month treatment period (baseline to month 6)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Basal insulin &gt;/= 42 U/day&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;lt; 18 years&lt;/li&gt;&lt;li&gt;HbA1c&amp;lt; 7 or &amp;gt; 10% at screening&lt;/li&gt;&lt;li&gt;Diabetes other than type 2 diabetes mellitus&lt;/li&gt;&lt;li&gt;Has been&amp;lt; 1 year on basal plus mealtime insulin and self-monitoring of blood glucose&lt;/li&gt;&lt;li&gt;Any contraindication to use of&lt;ulink linkType="Drug" linkID="10252"&gt;Lantus&lt;/ulink&gt; as defined in the national product             label&lt;/li&gt;&lt;li&gt;Patients using human regular insulin as mealtime insulin in the last 3 months before             screening visit&lt;/li&gt;&lt;li&gt;Use of an insulin pump in the last 6 months before screening visit&lt;/li&gt;&lt;li&gt;Initiation of new glucose-lowering agents and/or weight loss drugs in the last 3             months before screening visit&lt;/li&gt;&lt;li&gt;History or presence of significant diabetic retinopathy or macular edema likely to             require laser or injectable drugs or surgical treatment during the study period&lt;/li&gt;&lt;li&gt;Pregnant or breast-feeding women or women who intend to become pregnant during the             study period&lt;/li&gt;&lt;li&gt;Substudy exclusion criteria:&lt;ul&gt;&lt;li&gt;Patient not willing to use the adaptable injection intervals on at least 2 days per week&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;The above information is not intended to contain all considerations relevant to a        patient's potential participation in a clinical trial&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in HbA1c from baseline to month 6 endpoint and percentage of patients achieving HbA1c targets (HbA1c &lt; 7, 7.5% or HbA1c reduction &gt;/= 0.5%)</Description><Timeframe>Baseline, month 6</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Observed variability in injection timings: time interval between two consecutive injections in the flexible and fixed dosing regimens in the last 7 days before the assessments</Description><Timeframe>At 7.5 and 9 months</Timeframe></Measure><Measure><Description>Change in HbA1c from month 6 to 9: substudy comparing fixed dosing regimen (every 24 h) versus adaptive dosing regimen (every 24 +/- 3 h) in a subset of participants randomized to HOE901-U300 and treated for 6 months</Description><Timeframe>Month 6 to 9</Timeframe></Measure><Measure><Description>Change in body weight was assessed using an ANCOVA model based on a meta-analysis with subgroup and subgroup-by-treatment as fixed effects</Description><Timeframe>Baseline to month 6</Timeframe></Measure><Measure><Description>Percentage of patients with at least one severe and/or confirmed nocturnal hypoglycemia from start of week 9 to month 6 endpoint: nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 h (clock time), regardless the participant was awake or woke up because of the event. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose &lt;/= 3.9 mmol/l (70 mg/dl)</Description><Timeframe>Week 9 up to month 6</Timeframe></Measure><Measure><Description>Change in variability of pre-injection SMPG: pre-injection SMPG was measured within 30 min prior to the injection of the study drug. Variability was assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit</Description><Timeframe>Baseline, month 6</Timeframe></Measure><Measure><Description>Change in 8-point SMPG profiles per time point from baseline to month 6 endpoint: change in each time-point of 8-point SMPG profile: 03:00 h (clock time) at night; before and 2 h after breakfast; before and 2 h after lunch; before and 2 h after dinner; and at bedtime</Description><Timeframe>Baseline, month 6</Timeframe></Measure><Measure><Description>Change in daily basal insulin dose and mealtime insulin dose from baseline to month 6 endpoint</Description><Timeframe>Baseline, month 6</Timeframe></Measure><Measure><Description>Safety and tolerability: adverse events</Description></Measure><Measure><Description>Change in average pre-injection self-monitored plasma glucose (SMPG) at month 6 endpoint: pre-injection SMPG was measured within 30 min prior to the injection of the study drug. Average was assessed by the mean of at least three SMPG calculated over the 7 days preceding the assessment visit</Description><Timeframe>Baseline, month 6</Timeframe></Measure><Measure><Description>Percentage of patients with HbA1c &lt; 7% at month 6 endpoint</Description><Timeframe>Month 6</Timeframe></Measure><Measure><Description>Change in fasting plasma glucose (FPG) from baseline to month 6 endpoint</Description><Timeframe>Baseline, month 6</Timeframe></Measure><Measure><Description>Percentage of patients with FPG &lt; 5.6 mmol/l (100 mg/dl) at month 6 endpoint</Description><Timeframe>Month 6</Timeframe></Measure><Measure><Description>Change in treatment satisfaction score using the Diabetes Treatment Satisfaction Questionnaire (DTSQs) from baseline to month 6 endpoint: DTSQ is a validated measure to assess how satisfied patients with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of eight questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4 to 8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction</Description><Timeframe>Baseline, month 6</Timeframe></Measure><Measure><Description>Percentage of patients with hypoglycemia (all and nocturnal) events from baseline up to month 12: hypoglycemia events were severe hypoglycemia; documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of &lt;/=3.9 mmol/l [70 mg/dl]); asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level &lt;,=3.9 mmol/l); probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level &lt;/=3.9 mmol/l, symptoms treated with oral carbohydrate without a test of plasma glucose); relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level &gt;3.9 mmol/l), severe and/or confirmed hypoglycemia (plasma glucose &lt;/=3.9 mmol/l)</Description><Timeframe>Baseline up to month 12</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In June 2013, results were published.  From 3 to 6 months, significant reduction in the percentage of modified intent-to-treat patients reporting at least one severe or confirmed nocturnal hypoglycemic event was 36.1% in arm 1  when compared with the 45.5% in arm 2 (p = 0.0070). Across the entire study group, the percentages of patients reporting severe or confirmed hypoglycemia at any time of the day at month 6 in arms 1 and 2 were 81.9 and 87.8%, respectively. Any hypoglycemia, any nocturnal hypoglycemia, any day time hypoglycemia and severe hypoglycemia were reported by 83.4, 45.3, 81.2 and 5.0% of patients, respectively, in arm 1 and 88.6, 59.7, 85.8 and 5.7% of patients, respectively, in arm 2. Safety results showed that treatment-emergent adverse events (AEs) and serious AEs were reported by 56.4 and 6.4% of patients, respectively, in arm 1 and 54.2 and 5.2% of patients, respectively, in arm 2. U300  was well-tolerated and  there were no differences in  adverse events were observed between treatments [&lt;ulink linkType="Reference" linkID="1442280"&gt;1442280&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1443529"&gt;1443529&lt;/ulink&gt;]. Similar results were presented in September 2013 [&lt;ulink linkType="Reference" linkID="1477862"&gt;1477862&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, results of the sub-study were presented. The aim of the sub-study were to compare the efficacy and safety of insulin glargine when administered in a flexible (24 +/- 3 h) versus fixed (24 h) dosing interval, in type 2 diabetes mellitus patients using basal and mealtime insulin. Between the two dosing regimens at any time (24 h) and during night, the number of patients who reported with &gt;/= 1 confirmed (&amp;lt;/= 70 mg/dl) or severe  were comparable and the number of patients with any hypoglycemic event with insulin glargine were similar. Insulin glargine was well tolerated with similar number of adverse events and serious adverse events in both regimens. Only one severe hypoglycemic event was reported in the fixed dosing regimen [&lt;ulink linkType="Reference" linkID="1569044"&gt;1569044&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, results were presented. A total of 85.9 and 91.5% of the patients reported &gt;/= 1 hypoglycemic events in the Gla-300 and Gla-100, groups, respectively. Severe hypoglycemia was seen in 6.7% patients in the Gla-300 group and 7.5% of patients in Gla-100 group. Both Gla-300 and Gla-100 were generally well tolerated and injection site reactions were seen in 12 and 6 patients, respectively [&lt;ulink linkType="Reference" linkID="1569940"&gt;1569940&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, results were presented. In the respective insulin glargine (new formulation) and Lantus groups, confirmed (&amp;lt;/= 3.9 mmol/l) or severe hypoglycemia was experienced by 85.9 and 91.5% of the patients at anytime and 54.5 and 64.7% of patients during night. In the respective insulin glargine (new formulation) and Lantus groups, documented symptomatic (&amp;lt;/= 3.9 mmol/l) hypoglycemia was experienced by 74.8 and 82.8% of the patients at anytime and 44.6 and 57.2% of patients during night. Significantly fewer patients in insulin glargine (new formulation) group experienced confirmed or severe or documented symptomatic hypoglycemic events during night when compared with those in Lantus group. In the respective insulin glargine (new formulation) and Lantus groups, the annualized rate of confirmed (&amp;lt;/= 3.9 mmol/l) or severe hypoglycemia was 22.3 and 21% at anytime and 2.9 and 3.2% during night. In the respective insulin glargine (new formulation) and Lantus groups, the annualized rate of documented symptomatic (&amp;lt;/= 3.9 mmol/l) hypoglycemia was 12.1 and 11.7% at anytime and 1.8 and 2.5% during night. Comparable rates of confirmed or severe hypoglycemia were observed for insulin glargine (new formulation) versus Lantus ay any time and during the night. Comparable rates of documented symptomatic hypoglycemia were observed between insulin glargine (new formulation) and Lantus at any time. Compared to Lantus, in the insulin glargine (new formulation) group, significantly fewer patients experienced documented symptomatic hypoglycemia during the night. Severe hypoglycemia was seen in 6.7% patients in insulin glargine (new formulation) group and 7.5% of patients in Lantus group. This corresponded with a rate per participant-year of 0.19 and 0.14, respectively over the 12-month treatment period. At month 12, overall weight change was comparable with insulin glargine (new formulation) and Lantus (LS mean was 1.17 and 1.4 kg, respectively). LS mean difference insulin glargine (new formulation) versus Lantus was -0.23 kg. Both insulin glargine (new formulation) and Lantus were generally well tolerated with similar rate of adverse events. Injection site reactions were observed in 12 and six patients in the insulin glargine (new formulation) and Lantus groups, respectively [&lt;ulink linkType="Reference" linkID="1592446"&gt;1592446&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, meta-analysis results were presented from  NCT01499082,  NCT01499095 and  NCT01676220. The annualized rates of hypoglycemia at anytime and nocturnal confirmed or severe hypoglycemia were significantly lower in the 300 U/ml group when compared with the 100 U/ml group (14 and 31% rate reduction over 6 months, respectively). Atleast one confirmed or severe hypoglycemic event was observed in fewer patients in the 300 U/ml group when compared with the 100 U/ml group during the 6-month treatment period.  Reduction in hypoglycemic events was more pronounced during the first 8 weeks. In the respective Gla-300 and Gla-100 groups, atleast one documented symptomatic hypoglycemic event was observed in 49.6 and 56.4% of patients, respectively, and severe hypoglycemia (atleast one event) in 2.3 and 2.6%, respectively. The mean change in body weight from baseline was 0.51 and 0.79 kg in 300 and 100 U/ml groups, respectively. Both treatments were well tolerated with a similar rate of adverse events [&lt;ulink linkType="Reference" linkID="1592459"&gt;1592459&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, patient-level meta-analysis results were presented from  NCT01499082,  NCT01499095 and  NCT01676220. Compared with Gla-100, few patients had &gt;/= 1 confirmed or severe hypoglycemic event during the night and at any time of day with Gla-300 and the rates of hypoglycemia were lower with Gla-300 during the night compared with Gla-100. In Gla-300 and Gla-100 groups, 40 and 45 patients respectively experienced &gt;/= 1 severe hypoglycemic events at any time of day and 11 and 18 patients, respectively, had nocturnal severe hypoglycemia. In Gla-300 group, less weight gain was observed with Gla-300 compared with Gla-100. In general, both treatments were well tolerated with similar rates of adverse events. Overall, Gla-300 exhibited more sustained glycemic control without risk of nocturnal and anytime hypoglycemia or weight gain compared with Gla-100 [&lt;ulink linkType="Reference" linkID="1667798"&gt;1667798&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, post hoc analysis were presented from NCT01499082,  NCT01499095 and  NCT01676220. Age or BMI did not affect the lower risk of confirmed or severe hypoglycemia with Gla-300 compared with Gla-100 at month 6, while the benefit of lower risk of confirmed or severe hypoglycemia at any time of day (24 h) was consistently in favor of Gla-300 in subgroup of diabetes duration. Body weight change was statistically comparable between subgroups, with consistently less weight gain with Gla-300 [&lt;ulink linkType="Reference" linkID="1668014"&gt;1668014&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, post-hoc patient-level meta-analysis were presented from NCT01499082,  NCT01499095 and  NCT01676220. In the Gla-300 group, annualized rates and percentages of patients experiencing &amp;gt; 1 nocturnal confirmed and documented or severe hypoglycemic event were lower compared with Gla-100 group, and numerically less hypoglycemia was observed at any time of the day. Low percentage of patients treated with Gla-300 versus Gla-100, experienced severe hypoglycemic nocturnal (1.5 versus 1.2%) and anytime (3.1 versus 4.2%) events, respectively. In the Gla-300 group, the percentage of patients who achieved HbA1c targets at month 6 without confirmed or severe hypoglycemia at night and any time of the day were higher compared with Gla-100 group. In Gla-300 (0.42) and Gla-100 (0.54 kg) treatment groups, the mean change in body weight from baseline to month 6 was small and comparable. In terms of adverse events, both treatments were generally well tolerated with similar rates of adverse events. Injection site reactions were observed in 10 and 7 patients treated with Gla-300 and Gla-100, respectively [&lt;ulink linkType="Reference" linkID="1668122"&gt;1668122&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, post-hoc analysis data were presented from multicenter, randomized, open-label, two-arm, parallel-group, phase IIIa study (EDITION I [NCT01499082]) which evaluated the efficacy when switched from bid basal insulin to qd new  insulin glargine (insulin glargine [new formulation]-300) in patients with type 2 diabetes mellitus, at the 75th ADA Scientific Sessions in Boston, MA. A lower risk of nocturnal confirmed or severe hypoglycemia was observed with qd insulin glargine (new formulation) in compared with qd Lantus. At baseline to month 6, hypoglycemia at any time of the day (24 h), percentage of patients &gt;/= 1 event was 85.7 and 90.8%, respectively, in insulin glargine-300 and Lantus (relative risk of 0.94). Nocturnal  hypoglycemia from baseline to month 6 was reported by 45.7 and 66.1% of patients  showing &gt;/= 1 event with relative risk of  0.69, respectively, in  insulin glargine (new formulation)  and Lantus [&lt;ulink linkType="Reference" linkID="1668155"&gt;1668155&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, results were published. At any time of day (24 h; 86 versus 92%) and during the night (54 versus 65%), lower percentages of patients had one confirmed (3.9 mmol/l [70 mg/dl]) or severe hypoglycemic event with insulin glargine (new formulation) than Lantus. But there was similarity in the annualized rates of such hypoglycemic events. Between-treatment differences in adverse events were not apparent [&lt;ulink linkType="Reference" linkID="1696280"&gt;1696280&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, results were published from a patient level meta-analysis from  EDITION I (NCT01499082), EDITION II (&lt;ulink linkType="Protocol" linkID="83626"&gt;NCT01499095&lt;/ulink&gt;)  and EDITION III (&lt;ulink linkType="Protocol" linkID="90581"&gt;NCT01676220&lt;/ulink&gt;) to  examine the endpoints over 6 months in a large type 2 dibetes population  treated with   insulin glargine (new formulation) (n = 1247) and Lantus (n = 1249). Severe hypoglycemia at any time (24-h) was rare: 2.3% with insulin glargine (new formulation) and   2.6% with Lantus. Both groups had only minor weight gain  (&amp;lt; 1 kg) and it was much lesser with with    insulin glargine (new formulation) (p = 0.039). Both drugs were well tolerated and had similar rates of adverse events [&lt;ulink linkType="Reference" linkID="1708998"&gt;1708998&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, results were presented from a patient-level meta-analysis of three multicenter, randomized, open-label, two-arm, parallel-group, phase IIIa studies (NCT01499082, EDITION I; NCT01499095, EDITION II; NCT01676220, EDITION III). The proportion of patients reporting &gt;/= 1 confirmed (&amp;lt;/= 3.9 mmol/l) or severe hypoglycemic event at night time (00:00 to 05:59 h; relative risk (RR) = 0.85) and at any time of the day (24 h; RR = 0.94) was less in the Gla-300 group when compared with the Gla-100 group. Only fewer patients receiving Gla-300 experienced &gt;/= 1 hypoglycemic event at any time of the day (RR = 0.86) at the stricter hypoglycemic threshold (&amp;lt; 3.0 mmol/l), and similar results were noted for documented symptomatic hypoglycemia (RR = 0.91). At the &amp;lt;/= 3.9 mmol/l threshold, annualized rates of hypoglycemia at night time were lesser with Gla-300 versus Gla-100. Gla-300 was associated with beneficial effects when compared with Gla-100 during the night time and beyond the prespecified nocturnal period with respect to the proportion of patients reporting &gt;/= 1 confirmed or severe hypoglycemic event and events per participant-year. The percentage of patients reporting &gt;/= 1 severe hypoglycemic event at any time of the day was 3.2 and 3.6% with Gla-300 and Gla-100, respectively (RR = 0.89) and 0.9 and 1.4% of patients reported nocturnal severe hypoglycemia, respectively (RR = 0.64). In the Gla-300 and Gla-100 groups, annualized rates of severe hypoglycemia were 0.08 and 0.07 events/participant-year at any time of the day (RR = 1.11) and 0.01 and 0.02 events/participant-year at night time (RR = 0.66), respectively. Weight gain was less in the Gla-300 group versus the Gla-100 group, with a LS mean change of 0.85 and 1.25 kg, respectively. Weight gain was less in the Gla-300 group versus the Gla-100 group, with a LS mean change of 0.85 and 1.25 kg, respectively. In general, both Gla-300 and Gla-100 exhibited good tolerability with similar incidence of adverse events [&lt;ulink linkType="Reference" linkID="1695134"&gt;1695134&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, safety results from 	post hoc analysis of three multicenter, randomized, open-label, two-arm, parallel-group, phase IIIa studies (NCT01499082, EDITION I; &lt;ulink linkType="Protocol" linkID="83626"&gt;NCT01499095&lt;/ulink&gt;, EDITION II; &lt;ulink linkType="Protocol" linkID="90581"&gt;NCT01676220&lt;/ulink&gt;, EDITION III) were presented. Despite the nocturnal window analyzed, Gla-300 was related to a lower percentage of patients experiencing &gt;/= 1 nocturnal confirmed (&amp;lt;/= 3.9 mmol/l) or severe hypoglycemia than the Gla-100 froup. Confirmed (&amp;lt;/= 3.9 mmol) or severe, confirmed  (&amp;lt; 3 mmol/l) or severe, documented symptomatic (&amp;lt;/= 3.9 mmol/l), and documented symptomatic (&amp;lt; 3.9 mmol/l) rates versus Gla-100 (protocol-defined nocturnal hypoglycemia) were found to be 31.8 and 44.9%, 9.8 and 13.9%, 24.8 and 31.6%, and 7.6 and 11.4%, respectively. Annualized rate of hypoglycemic events like confirmed (&amp;lt;/= 3.9 mmol/l) or severe, confirmed (&amp;lt; 3 mmol/l) or severe, documented symptomatic (&amp;lt;/= 3.9 mmol/l), and documented symptomatic (&amp;lt; 3 mmol/l) were found to be 2.2 and 3.6, 0.3 and 0.7, 1.4 and 2.6, and 0.2 and 0.6 events/patient year with Gla-300 and Gla-100, respectively. Clinically defined nocturnal hypoglycemia (22 h to pre-breakfast SMPG) events like confirmed (&amp;lt;/= 3.9 mmol/l) or severe, confirmed (&amp;lt; 3 mmol/l) or severe, documented symptomatic (&amp;lt;/= 3.9 mmol/l), and documented symptomatic (&amp;lt; 3 mmol/l) were found to be 58.4 and 72.0%, 19.6 and 25.9%, 40.1 and 47.3%, and 14.1 and 19.3% with Gla-300 and Gla-100, respectively.  Whereas clinically defined nocturnal hypoglycemia (22 h to pre-breakfast SMPG) events/patient-year like confirmed (&amp;lt;/= 3.9 mmol/l) or severe, confirmed (&amp;lt; 3 mmol/l) or severe, documented symptomatic (&amp;lt;/= 3.9 mmol/l), and documented symptomatic (&amp;lt; 3 mmol/l) were found to be 7.7 and 10.3, 0.9 and 1.5, 3.3 and 5.1, and 0.5 and 1.1 with Gla-300 and Gla-100, respectively. Similarly, numerically less hypoglycemia at any time of day (24 h) like confirmed (&amp;lt;/= 3.9 mmol/l) or severe, confirmed (&amp;lt; 3 mmol/l) or severe, documented symptomatic (&amp;lt;/= 3.9 mmol/l), and documented symptomatic (&amp;lt; 3 mmol/l) were found to be 71.6 and 77.4% (18 and 21.3 events/patient-year), 30 and 36.4% (2.1 and 2.5 events/patient-year), 51.4 and 57.5% (8.4 and 10.1 events/patient-year), and 23.9 and 26.8 (1.4 and 1.7 events/patient-year) with Gla-300 and Gla-100 , respectively  [&lt;ulink linkType="Reference" linkID="1695135"&gt;1695135&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Overall, 1.5 and 1.2% of patients reported severe hypoglycemic events at night time with Gla-300 and Gla-100, respectively (respective percentage of patients reporting severe hypoglycemia at any time was 3.1 and 4.2%). Gla-300 treatment was related to a consistently higher percentage of patients attaining HbA1c targets &amp;lt; 7.0%, &amp;lt; 7.5% and a &gt;/= 0.5% reduction in baseline level at month 6 without confirmed or severe hypoglycemia at night (absence of protocol defined nocturnal hypoglycemia) were found to be 25.5 (p = 0.003), 38.3 (p = 0.001), and 42.3% (p = 0.007) of Gla-300 patients versus 17.3, 27.1 and 31.9% of Gla-100 patients, respectively; absence of clinically defined nocturnal hypoglycemia (22 h to pre-breakfast SMPG) values were found to be 17.2, 24.5 and 25.5% of Gla-300 patients versus 10.6, (p = 0.006), 14.6 (p = 0.001), and 15.8% (p = 0.003) of Gla-100 patients, respectively) and at any time of day values were observed as 11.0, 15.0 and 16.6% of Gla-300 patients versus 7.9 (p = 0.127), 11.2 (p = 0.127), and 12.8% (p = 0.192) of Gla-100 patients, respectively) versus Gla-100 treatment. Mean change in baseline body weight at 6 months was less and comparable at 0.42 kg with Gla-300 and 0.54 kg with Gla-100 group, respectively. Both treatments were generally found to be well-tolerated with similar rates of adverse events. In the Gla-300 and Gla-100 groups, injection site reactions were experienced by 3.1 and 2.1% of patients, respectively  [&lt;ulink linkType="Reference" linkID="1695135"&gt;1695135&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2018, pooled results were published from NCT01499082, NCT01499095 and NCT01676220 which evaluate the efficacy and safety of insulin glargine 300 U/ml (Gla-300) versus insulin glargine 100 U/ml (Gla-100) over 12 months in a patient-level meta-analysis, in people with type 2 diabetes (T2DM). Severe hypoglycemia was rare. In both treatment groups the incidence of events at any time of day was &amp;lt;/= 3.6%, while rates were &amp;lt;/= 0.08 events per participant-year [&lt;ulink linkType="Reference" linkID="2021725"&gt;2021725&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2018, post hoc results of the EDITION I and II studies which evaluate the impact of duration of prior basal insulin therapy on study outcomes in people with type 2 diabetes mellitus receiving insulin glargine 300 or Lantus for 6-month were published. At night or any time (24 h), lower risk with insulin glargine 300 or Lantus of &gt;/= 1 confirmed (&amp;lt;/= 3.9 mmol/l [&amp;lt;/= 70 mg/dl]) or severe hypoglycemic event and weight change were unaffected by duration of prior basal insulin therapy [&lt;ulink linkType="Reference" linkID="2080016"&gt;2080016&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a comparison study of    &lt;ulink linkType="Drug" linkID="10252"&gt;Lantus&lt;/ulink&gt;  and &lt;ulink linkType="Drug" linkID="73334"&gt;insulin glargine (new formulation)&lt;/ulink&gt; in patients with type 2 diabetes mellitus (T2DM) on basal plus mealtime insulin. The primary objective wasto compare the efficacy of &lt;ulink linkType="Drug" linkID="73334"&gt;insulin glargine (new formulation)&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="10252"&gt;Lantus&lt;/ulink&gt; in terms of change      in HbA1c from baseline to endpoint (scheduled month 6) in adult patients with type 2 diabetes mellitus. Secondary objective was to compare the efficacy of  &lt;ulink linkType="Drug" linkID="73334"&gt;insulin glargine (new formulation)&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="10252"&gt;Lantus&lt;/ulink&gt; in terms of      occurrence of nocturnal hypoglycemia [&lt;ulink linkType="Reference" linkID="1795896"&gt;1795896&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2013, results were published. Reduction on HbA1c (glycated hemoglobin) was similar from baseline to 6 months between insulin glargine (new formulation) (Gla-300) and Lantus (Gla-100) (least squares mean change - 0.83% [0.06] in both groups; difference - 0.00%) in people with type 2 diabetes who had challenging treatment needs. In spite of receiving a combined therapy (oral antidiabetic agents plus basal and prandial insulins), approximately 40% of patients reached glycemic control (HbA1c &amp;lt; 7%) at month 6 both in the insulin glargine (new formulation) (39.6%) and in the Lantus arm (40.9%).  In both the arms, the reductions in fasting plasma glucose and glucose measurements of the 8-point profile were similar [&lt;ulink linkType="Reference" linkID="1442280"&gt;1442280&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1443529"&gt;1443529&lt;/ulink&gt;]. Similar results were presented in September 2013 [&lt;ulink linkType="Reference" linkID="1477862"&gt;1477862&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, results of  the sub-study were presented. The aim of the sub-study were to compare the efficacy and safety of iinsulin glargine (new formulation) (Gla-300) when administered in a flexible (24 +/- 3 h) versus fixed (24 h) dosing interval, in type 2 diabetes mellitus patients using basal and mealtime insulin. The mean and median dosing intervals were close to 24 h for both regimens. The changes in mean daily basal insulin dose levels were very minimal and did not differ between groups. The changes in HbA1c, fasting plasma glucose and 8-point SMPG profiles were similar between months 6 to 9. The results of EDITION I sub-study show that, the dosing interval for 87.5% of injections were in the range of 24 +/- 1 h in the fixed dosing group, whereas, in the flexible dosing group, patients were adapted to injection times in a way that 36.9% of the injection intervals remained outside the range of 24 +/- 1 h. Also, 13.9% of the injection intervals were &amp;gt; 3 h above or below the 24 h average in the flexible dosing group. The respective least square mean changes from months 6 to 9 for the various efficacy parameters in the flexible and fixed dosing groups were; 0.03, and 0.02 U/kg of mean daily basal insulin doses; 0.21, and 0.15% of HbA1c (least square mean intergroup difference of 0.05); and 25.9, and 21.1 mg/dl of fasting plasma glucose (least square mean intergroup difference of 4.9) [&lt;ulink linkType="Reference" linkID="1569044"&gt;1569044&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, results were presented from  EDITION I (NCT01499082), EDITION II (NCT01499095)  and EDITION III (NCT01676220). These studies met their primary endpoint by demonstrating similar blood sugar control with iinsulin glargine (new formulation) (Gla-300) as compared with Lantus (Gla-100). These trials demonstrated the rate ratio (per participant-year) of night-time low blood sugar events was reduced by 31% (significant) for insulin glargine (new formulation) (Gla-300)  compared with Lantus (Gla-100) over the 6-month study period (p = 0.0002) and the rate ratio was reduced (per participant-year) by 14% (significant) for low blood sugar events at any time of the day for insulin glargine (new formulation) (Gla-300)  versus Lantus (Gla-100) (p = 0.0116) [&lt;ulink linkType="Reference" linkID="1569340"&gt;1569340&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In June 2014, results were presented. Reduction in HbA1c was -0.86 and -0.69 mmol/mol for Gla-300 and Gla-100, respectively. At month 12, reduction in fasting plasma glucose was -29.6 and -26.0 mg/dl for Gla-300 and Gla-100, respectively [&lt;ulink linkType="Reference" linkID="1569940"&gt;1569940&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, results were presented. In insulin glargine (new formulation) and Lantus groups, least square mean reduction in HbA1c was -0.86 and -0.69 mmol/l, respectively and reduction in fasting plasma glucose (FPG) was -1.7 and -1.4 mmol/l, respectively, from baseline to month 12. LS mean difference in HbA1c and FPG between groups was -0.17 (p = 0.00074) and -0.3, respectively [&lt;ulink linkType="Reference" linkID="1592446"&gt;1592446&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, meta-analysis results were presented from  NCT01499082,  NCT01499095 and  NCT01676220. The mean change from baseline in HbA1c was comparable between  Gla-300 and Gla-100 groups at month 6. In Gla-300 and Gla-100 groups, reduction in fasting plasma group was similar; the mean change at month 6 was -2 and -2.3 mmol/l, respectively [&lt;ulink linkType="Reference" linkID="1592459"&gt;1592459&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, post hoc analysis were presented from NCT01499082,  NCT01499095 and  NCT01676220. HbA1c decrease remained comparable between Gla-300 and Gla-100 over 6 months. There was no evidence of heterogeneity of treatment effect noted regardless of age, BMI or diabetes duration [&lt;ulink linkType="Reference" linkID="1668014"&gt;1668014&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, the results were presented from a pooled analysis of three multicenter, randomized, open-label, two-arm, parallel group, 6-month, phase IIIa studies (EDITION I [NCT01499082], EDITION II [NCT01499095] and EDITION III [NCT01676220]) which evaluated the efficacy and safety of new insulin glargine (new formulation) (Gla-300) 300 U/ml compared with Lantus (Gla-100) 100 U/ml in patients with type 2 diabetes mellitus. The purpose of this sensitivity analysis was to assess the risk of observed nocturnal hypoglycemia with  insulin glargine (new formulation) (Gla-300) 300 U/ml compared with Lantus (Gla-100) 100 U/ml over 6 months using a different window to define nocturnal hypoglycemia. Timing of pre-breakfast SMPG and timing of pre-injection SMPG was comparable in all studies. Overall, more nocturnal confirmed (&amp;lt;/= 70 mg/dl) or severe hypoglycemic events were identified in the clinically defined window when compared with the protocol-defined window as a result of the extended nocturnal window. Nocturnal events were less with insulin glargine (new formulation) (Gla-300) 300 U/ml when compared with Lantus (Gla-100). Following new insulin glargine treatment, the absolute between-treatment difference in numbers of nocturnal events was more than two-fold greater in the clinically defined window (1145 fewer) when compared to protocol-defined window (556 fewer). The risk of experiencing &gt;/= 1 nocturnal confirmed or severe hypoglycemic event was lower for insulin glargine (new formulation) (Gla-300) 300 U/ml using protocol-defined (25% lower) and clinically defined (16% lower) windows when compared with Lantus (Gla-100). Over the 6-months, the annualized rates of nocturnal confirmed or severe hypoglycemic events were lower with insulin glargine (new formulation) (Gla-300) using protocol-defined (31% lower) and clinically defined (24% lower) windows when compared with Lantus (Gla-100) [&lt;ulink linkType="Reference" linkID="1668016"&gt;1668016&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, post-hoc patient-level meta-analysis were presented from NCT01499082,  NCT01499095 and  NCT01676220. In Gla-300 and Gla-100 groups, the mean daily average basal insulin dose was increased to 0.80 and 0.73 U/kg/day at month 6, respectively, and the increase occurred to a greater extent in Gla-300 compared with Gla-100 treatment group in the first 12 weeks. At month 6, mean HbA1c was 7.19% in both treatment groups and the proportion of patients who achieved HbA1c &amp;lt; 7.0, &amp;lt; 7.5, and HbA1c reduction from baseline &amp;gt; 0.5% were 33.7, 54.4, and 58.1 and 37.1, 56.7, and 62.9%, respectively [&lt;ulink linkType="Reference" linkID="1668122"&gt;1668122&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, post-hoc analysis data were presented from multicenter, randomized, open-label, two-arm, parallel-group, phase IIIa study (EDITION I [NCT01499082]) which evaluated the efficacy when switched from bid basal insulin to qd new insulin  glargine formulation (insulin glargine-300) in patients with type 2 diabetes mellitus at the 75th ADA Scientific Sessions in Boston, MA. When patients were switched from bid basal insulin to qd insulin glargine (new formulation)-300 or Lantus, reductions in HbA1c were observed with comparable decreases in both treatment groups and overall study population. In patients who switched from bid basal insulin, the weight gain was comparable between treatment groups and with a mean change of 1.39 kg for insulin glargine (new formulation) (Gla-300) -300 and 1.32 kg for Lantus (Gla-100) from baseline to 6 months [&lt;ulink linkType="Reference" linkID="1668155"&gt;1668155&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, patient-level meta-analysis results were presented from  NCT01499082,  NCT01499095 and  NCT01676220. During the first 12 weeks, the majority of the increase in insulin dose occurred. In both groups, glycemic control was sustained with a more sustained HbA1c reduction at 12 months for Gla-300 [&lt;ulink linkType="Reference" linkID="1667798"&gt;1667798&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, results were published. In both groups, glycemic control was sustained (mean HbA1c: insulin glargine [new formulation], 7.24%; Lantus, 7.42%), with more sustained HbA1c reduction for insulin glargine (new formulation) at 12 months. At 12 months, the mean daily basal insulin dose was 1.03 and 0.90 U/kg for insulin glargine (new formulation) and Lantus, respectively [&lt;ulink linkType="Reference" linkID="1696280"&gt;1696280&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2015, results were published from a patient level meta-analysis from  EDITION I (NCT01499082), EDITION II (NCT01499095)  and EDITION III (NCT01676220) to  examine the endpoints over 6 months in a large type 2 dibetes population  treated with   insulin glargine (new formulation) (n = 1247) and Lantus (n = 1249). The HbA1c mean change over 6 months was comparable for both the drugs (-1.02% for both). Over 6 months,    insulin glargine (new formulation) was associated with lesser annualized rates of confirmed (&amp;lt;/= 3.9 mmol/l) or severe hypoglycemia compared to Lantus with 31% difference during the night and 14% difference at any time. There were consistent reductions in percentage of patients with &gt;/= 1 hypoglycemic events [&lt;ulink linkType="Reference" linkID="1708998"&gt;1708998&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, results were presented from a patient-level meta-analysis of three multicenter, randomized, open-label, two-arm, parallel-group, phase IIIa studies (NCT01499082, EDITION I; NCT01499095, EDITION II; NCT01676220, EDITION III). Patients randomly received (1:1) Gla-300 or Gla-100, which was titrated to a fasting self-monitored plasma glucose target of 4.4 to 5.6 mmol/l. Overall, 81.4 and 78.9% of patients in the Gla-300 and Gla-100 groups, respectively, completed 12 months of treatment. In both treatment groups, a sustained glycemic control was observed, and Gla-300 was related to a more sustained HbA1c reduction: least squares (LS) mean change in baseline HbA1c at 12 months was -0.91 and -0.80% in the Gla-300 and Gla-100 groups, respectively (LS mean difference = -0.10) [&lt;ulink linkType="Reference" linkID="1695134"&gt;1695134&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, results were presented from 	post hoc analysis of three multicenter, randomized, open-label, two-arm, parallel-group, phase IIIa studies (NCT01499082, EDITION I; NCT01499095, EDITION II; NCT01676220, EDITION III) that compared the efficacy and safety of 6-month treatment with &lt;ulink linkType="Drug" linkID="73334"&gt;insulin glargine (new formulation)&lt;/ulink&gt; 300 U/ml (Gla-300) versus insulin glargine 100 U/ml (Gla-100) in a patient-level meta-analysis in older patients aged &gt;/= 65 years. In both treatment groups, the mean daily average basal insulin dose was found to be increased to 0.80 and 0.73 U/kg/day at month 6 for Gla-300 and Gla-100, respectively. Compared with Gla-100, greater increase was observed with Gla-300 in the first 12 weeks of treatment. At 6 months, mean HbA1c level was 7.19% in both Gla-300 (total n = 329) and Gla-100 (total n = 333) groups. HbA1c reductions at 6 months were found to be similar between both groups, with a least-squares (LS) mean change in baseline level at 6 months being -1.02% for both Gla-300 and Gla-100. The proportion of patients attaining HbA1c targets of HbA1c &amp;lt; 7.0%, &amp;lt; 7.5% and a &gt;/= 0.5% reduction in baseline levels at 6 months was 37.1, 56.7 and 62.9% in the Gla-300 group and was 33.7, 54.4 and 58.1% in the Gla-100 group, respectively [&lt;ulink linkType="Reference" linkID="1695135"&gt;1695135&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, results were presented from meta-analysis of the phase IIIa EDITION-1, -2 and -3 studies (NCT01499082; NCT01499095; NCT01676220) In the EDITION-1, -2 and -3 trials, Gla-300 demonstrated equivalent glycemic control compared with Gla-100. In total, 1005 and 1048 participants with available hypoglycemia and HbA1c data from the Gla-300 and Gla-100 groups, respectively, were included in the meta-analysis. Patients treated with Gla-300 experienced a lower rate of confirmed (&amp;lt;/=70 mg/dl (&amp;lt;/=3.9 mmmol/l)) or severe hypoglycemia at night and any time of day (24 h) compared with those treated with Gla-100 regardless of HbA1c level at 6 months. Data from the individual EDITION studies showed that the estimated rates of hypoglycemia were lower in the Gla-300 group compared with the Gla-100 group regardless of HbA1c level at 6 months [&lt;ulink linkType="Reference" linkID="1771913"&gt;1771913&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1771947"&gt;1771947&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2016, results from meta-analysis from the EDITION 1, 2 and 3 phase 3 clinical trials (n=2,103) were presented. Annualized rate of confirmed (&amp;lt;/= 3.9 mmol/l or &gt;/= 70.2 mg/dl) or severe hypoglycemia rate (events per participant-year) was correlated with HbA1c data at month 6 for each patient, using a negative binomial regression model. An overlap between the curves for Touje(insulin glargine 300 Units/ml) and Lantus (insulin glargine 100 Units/ml) was not seen, and showed that the hypoglycemia rate was lower with Toujeo than with Lantus at all levels of HbA1c. Patientstreated with Toujeo (insulin glargine 300 Units/ml) had a consistently lower rate of confirmed or severe hypoglycemia both at night and at any time of the day compared with those treated with Lantus (Gla-100; insulin glargine 100 Units/ml), at all levels of HbA1c (average blood glucose over the previous 3 months) achieved at month 6 [&lt;ulink linkType="Reference" linkID="1795896"&gt;1795896&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, meta-analysis pooled results from NCT01499082, EDITION I; &lt;ulink linkType="Protocol" linkID="83626"/&gt;NCT01499095, EDITION II; NCT01676220, EDITION III were presented at 76th ADA conference which evaluated glycemic control and hypoglycemia benefits with \Gla-300 (insulin glargine 300 U/ml) versus Gla-100 (insulin glargine 100 U/ml) in patients (n = 2476) with type-2 diabetes and mild-to-moderate renal impairment. In all renal function subgroups with estimated glomerular filtration rate of &gt;/= 30 to &gt;/= 90 ml/min/1.73 m2, the risk of confirmed &amp;lt;/= 70 mg/dl) or severe hypoglycemia was significantly lower for nocturnal (00:00 to 05:59 h) events and comparable or lower for anytime (24 h) events for Gla-300 when compared with those treated with Gla-100. For renal subgroup of patients with eGFR &gt;/= 30 to &amp;lt; 60, &gt;/= 60 to &amp;lt; 90 and &gt;/= 90, confirmed or severe hypoglycaemia was reported in 39.5, 32.1 and 20.1 versus 51.3, 40.0 and 32.7% of patients in nocturnal group and 79.5, 67.0, and 54.8 versus 80.4, 71.4, and 67.3% of patients in anytime (24 h), respectively, in Gla-300 versus Gla-100 arms. Consistent and comparable HbA1c reductions were observed for both the groups, regardless of renal function subgroups [&lt;ulink linkType="Reference" linkID="1772327"&gt;1772327&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2016, pooled results were presented from EDITION (NCT01499082, &lt;ulink linkType="Protocol" linkID="83626"&gt;NCT01499095&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="90581"&gt;NCT01676220&lt;/ulink&gt; and &lt;ulink linkType="Protocol" linkID="92089"&gt;NCT01689142&lt;/ulink&gt;) trials which evaluated the efficacy and safety of insulin glargine 100 and 300 U/ml in patients with type 2 diabetes mellitus. In EDITION meta-analysis, significantly better reduction in pre-breakfast SMPG was observed with Gla-100 compared with Gla-300 (p &amp;lt; 0.001), while reduction in FPG, HbA1c and average 24 h SMPG was comparable with both Gla-100 and Gla-300 (p = non-significant). ). The overall least square mean differences between insulin glargine 300 versus 100 U/ml in the EDITION trials were 0.09, 0.19, -0.35, and -0.01 for HbA1c (%), 24 h SMPG (mmol/l), FPG (mmol/l), and pre-breakfast SMPG (mmol/l), respectively. In EDITION trials, risk of &gt;/= 1 confirmed or severe hypoglycemic events was consistently lower with Gla-300 versus Gla-100 both at night (00:00 to 05:59 h; p = 0.007) and also at any time of day (24 h; p = 0.007). Risk of &gt;/= 1 documented symptomatic hypoglycemic events closely reflected that of confirmed or severe events for nocturnal and for anytime events with a relative risk of 0.74 (p &amp;lt; 0.001) and 0.89 (p &amp;lt; 0.001) in EDITON trials, respectively. In the EDITION trial, risk of experiencing &gt;/= 1 severe hypoglycemic events were comparable with Gla 300 versus Gla-100 and showed a relative risk of 0.87 (p = non-significant). Across individual trials, no significant heterogeneity of treatment effect for any glycemic control measure was observed (p = non-significant) [&lt;ulink linkType="Reference" linkID="1796461"&gt;1796461&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The estimated least square mean difference between insulin glargine 300 versus 100 U/ml in terms of HbA1c (%), 24 h SMPG (mmol/l), FPG (mmol/l), and pre-breakfast SMPG (mmol/l) were -0.03, 0.00, 0.05, and 0.38, respectively [&lt;ulink linkType="Reference" linkID="1796461"&gt;1796461&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, results from a post-hoc pooled analysis of three trials (NCT01499082; EDITION-1, NCT01499095; EDITION-2, NCT01676220, EDITION-3) aimed to evaluate whether baseline fasting plasma C-peptide was associated with hypoglycemia risk in patients with type 2 diabetes were presented (n = 2496). In insulin pre-treated patients, C-peptide levels &amp;lt; 0.4 nmol/l were more frequent in EDITION I and II trials, in comparison to insulin-naïve patients in EDITION III trial (54 and 11%, respectively). There were no difference in the mean change in HbA1c or insulin dose from baseline to month 6, between patients with &amp;lt; 0.4 and &gt;/= 0.4 nmol/l C-peptide levels. The mean changes from baseline to month-6 in HbA1c and fasting plasma glucose observed in EDITION-I study were -0.9% and-22mg/dl (insulin glargine 300 units/ml), -0.8% and -13mg/dl (insulin glargine 100 units/ml) in patients with C-peptide levels &amp;lt; 0.4 nmol/l, respectively, whereas those observed in patients with C-peptide levels &gt;/= 0.4 nmol/l were -0.9% and -36 mg/dl (insulin glargine 300 units/ml),  -0.9% and -51 mg/dl (insulin glargine 100 units/ml), respectively. In insulin glargine 300 and 100 units/ml dose, the change from baseline to month-6 in HbA1c observed was -0.8 and -0.7% (&amp;lt; 0.4 nmol/l), - 0.9 and -0.8% (&gt;/= 0.4 nmol/l) in EDITION-II study, -1.5 and -1.7% (&amp;lt; 0.4 nmol/l), -1.4 and -1.5 (&gt;/= 0.4 nmol/) in EDITION-III study, respectively. The change in fasting plasma glucose observed in insulin glargine 300 and 100 units/ml dose was -4 and -3 (&amp;lt; 0.4 nmol/l), - 41 and – 38 (&gt;/= 0.4 nmol/l) in EDITION-II study, -67 and -75 (&amp;lt; 0.4 nmol/l), -59 and -70 (&gt;/= 0.4 nmol/l) in EDITION-III study, respectively. Higher proportion of patients experienced &gt;/= 1 confirmed or severe hypoglycemic event in patients with fasting C-peptide levels &amp;lt; 0.4 nmol/l compared with patients with &gt;/= 0.4 nmol/l in all the EDITION studies, both at any time of day or at night. Even for the documented symptomatic hypoglycemia, higher risk of hypoglycemia was associated with lower C-peptide levels, across all three EDITION trials, at any time of day or at night, and for both &amp;lt;/= 70 and &amp;lt; 54 mg/dl glycemic thresholds. The annualized rates of confirmed or severe hypoglycemic events were found to be higher in patients with C-peptide levels &amp;lt; 0.4 nmol/l compared to patients with &gt;/= 0.4 nmol/ in all the three EDITION studies, for both glycemic thresholds Even for the documented symptomatic hypoglycemia, higher annualized rates were found in patients with lower, compared to higher C-peptide levels, at any time of day or at night, and for both &amp;lt;/= 70 and &amp;lt; 54 mg/dl glycemic thresholds. at any time of day or at night, a lower incidence and rate of hypoglycemia were observed with insulin glargine 300 units/ml compared to insulin glargine 100 units/ml, irrespective of C-peptide levels and glycemic thresholds [&lt;ulink linkType="Reference" linkID="1936399"&gt;1936399&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2018, results of post-hoc analysis were published to compare the glycaemic control and hypoglycaemia between insulin glargine 300 U/ml (Gla-300) and Lantus 100U/ml (Gla-100) administered once daily in people with type 2 diabetes (T2DM), who were previously receiving twice-daily insulin. Glycated hemoglobin change from baseline to Month 6 was similar over 6 months with Gla-300 or Gla-100 (least squares mean difference -0.01%). Patients previously receiving twice-daily insulin had a lower risk of confirmed (&amp;lt;/= 3.9 mmol/l [&amp;lt;/= 70 mg/dl]) or severe hypoglycaemia with Gla-300 versus Gla-100 at night, but not at any time (24 h) [&lt;ulink linkType="Reference" linkID="2018416"&gt;2018416&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2018, pooled results were published from NCT01499082, NCT01499095 and NCT01676220 which evaluate the efficacy and safety of insulin glargine 300 U/ml (Gla-300) versus insulin glargine 100 U/ml (Gla-100) over 12 months in a patient-level meta-analysis, in people with type 2 diabetes (T2DM). Compared to Lantus, reductions in glycated hemoglobin (HbA1c) were better sustained over 12 months with Gla-300 (least squares [LS] mean difference in change from baseline: -0.10% or -1.09 mmol/mol; p = 0.0174). Risk of confirmed (&amp;lt;/= 3.9 mmol/l) or severe hypoglycemia was 15% lower with Gla-300 compared to Gla-100 at night (relative risk 0.85) and 6% lower at any time of day (relative risk 0.94). At night, rates of hypoglycemia were 18% lower with Gla-300 versus Gla-100 (rate ratio 0.82 [95% CI 0.67-0.99]), but comparable at any time of day. HbA1c &amp;lt;7.0 % without nocturnal hypoglycemia was achieved by 24% more patients with Gla-300 than with Gla-100 (relative risk 1.24) [&lt;ulink linkType="Reference" linkID="2021725"&gt;2021725&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2018, post hoc results of the EDITION 1 and 2 studies which evaluate the impact of duration of prior basal insulin therapy on study outcomes in people with type 2 diabetes mellitus receiving insulin glargine 300 or Lantus for 6-month were published. Regardless of duration of prior basal insulin therapy, between insulin glargine 300 and Lantus groups, HbA1c change was comparable from baseline to month-6 [&lt;ulink linkType="Reference" linkID="2080016"&gt;2080016&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2018, pooled results of three studies (NCT01499082, NCT01499095, NCT01676220) which described in type 2 diabetes the 24-h distribution of hypoglycaemia and compared the frequency of nocturnal events based on a predefined nocturnal window or an expanded interval, using illustrative data for two insulin glargine formulations were published. There were confirmed (&amp;lt;/= 3.9 mmol/L [&amp;lt;/= 70 mg/dL]) or severe hypoglycaemic events most frequently between 06:00 and 10:00 h with both insulins. There were nearly threefold more events using the expanded nocturnal interval. Risk of &amp;gt; 1 nocturnal event was 25% lower with Gla-300 than Gla-100 with the predefined, and 16% lower with the expanded interval; annualized event rates were found to be 31 and 24% lower with the predefined and expanded window, respectively. The between-insulin difference in number of nocturnal events depended markedly on the chosen nocturnal interval (556 versus 1145 fewer events with Gla-300 using the predefined versus expanded interval) [&lt;ulink linkType="Reference" linkID="2097330"&gt;2097330&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2018, pooled results of three studies (EDITION I, II and III) which investigated the impact of renal function on the safety and efficacy of insulin glargine (new formulation) (Gla-300) and Lantus (Gla-100) were published. In the Gla-300 and Gla-100 groups, the decrease in HbA1c after 6 months and the proportion of patients with type 2 diabetes achieving HbA1c targets were found to be similar for both renal function subgroups. A reduced risk of nocturnal 12:00 to 5:59 AM) confirmed (&amp;lt;/= 3.9 mmol/L [&amp;lt;/= 70 mg/dL]) or severe hypoglycemia with Gla-300 was observed in both renal function subgroups (eGFR &amp;lt; 60 mL/min/1.73 m2: relative risk [RR] 0.76 and eGFR &gt;/= 60 mL/min/1.73 m2: RR 0.75). The hypoglycemia risk was lower with Gla-300 versus Gla-100 for confirmed (&amp;lt;/= 70 mg/ dL [&amp;lt;/= 3.9 mmol/L]) or severe hypoglycemia at any time of day (24 h) in both the lower (RR 0.94) and higher (RR 0.90) eGFR subgroups [&lt;ulink linkType="Reference" linkID="2104687"&gt;2104687&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, results of a pooled analysis of three trials (EDITOR I, II and III), aimed to evaluate the rates of confirmed (&amp;lt;/= 3.9 mmol/l [&amp;lt;/= 70 mg/dl]) or severe hypoglycemia over 6 months of treatment with insulin glargine (new formulation) or Lantus, as a function of HbA1c in patients with type 2 diabetes were published. In comparison to Lantus, patients  treated with insulin glargine (new formulation) reported a consistently lower rate of confirmed or severe hypoglycemia, regardless of HbA1c at month 6, analyzed using a negative binomial regression model [&lt;ulink linkType="Reference" linkID="2129417"&gt;2129417&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, pooled results of nine studies (&lt;ulink linkType="Protocol" linkID="219009"&gt;NCT02320721&lt;/ulink&gt;	, &lt;ulink linkType="Protocol" linkID="91189"&gt;NCT01683266&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="90581"&gt;NCT01676220&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="92089"&gt;NCT01689142&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="89933"&gt;NCT01658579&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="92080"&gt;NCT01689129&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="83626"&gt;NCT01499095&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="90582"&gt;NCT01676233&lt;/ulink&gt; and NCT01499082 were published to evaluate the effectiveness of insulin glargine 300 U/ml (Gla-300) compared to glargine 100 U/ml (Gla-100; Lantus) on reducing nocturnal hypoglycemia and improving glycemic control in type 1 and type 2 diabetes patients (n = 3977). Insulin glargine reduced the nocturnal hypoglycemia (rate ratio [RR] of 0.81] and clinically significant nocturnal hypoglycemia (RR of 0.75) compared to Lantus. There were no clinically significant reductions of nocturnal hypoglycemia events (RR of 0.64) in type 1 diabetes patients. Small decreases in HbA1c levels in favor of insulin glargine were found in the pooled sample [&lt;ulink linkType="Reference" linkID="2130519"&gt;2130519&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be randomized into two arms:&lt;br/&gt;Arm 1: patients would receive &lt;ulink linkType="Drug" linkID="73334"&gt;insulin glargine (new formulation)&lt;/ulink&gt;  (Gla-300; 300 U/ml)  sc  qd (evening) for 12 months on top of mealtime insulin analog. Dose titration would be done seeking fasting plasma glucose 4.4 to 5.6  mmol/l (80  to 100 mg/dl). After 6 months patients would be proposed to participate to the administration substudy and to receive either  &lt;ulink linkType="Drug" linkID="73334"&gt;insulin glargine (new formulation)&lt;/ulink&gt;  (300 U/ml)  qd at intervals of 24 +/- 3 h (adaptable dosing intervals) or to continue qd injections of  &lt;ulink linkType="Drug" linkID="73334"&gt;insulin glargine (new formulation)&lt;/ulink&gt;  (300 U/ml)  q24h (fixed dosing intervals) up to month 9.&lt;br/&gt;Arm 2: patients would receive &lt;ulink linkType="Drug" linkID="10252"&gt;Lantus&lt;/ulink&gt; (Gla-100; 100 U/ml) sc injection qd (evening) for 12 months on top of mealtime insulin analogue. Dose titration would be done seeking fasting plasma glucose 4.4 to 5.6 mmol/l (80 to 100 mg/dl).&lt;/para&gt;&lt;para&gt;The maximum study duration would be 58 weeks per patient, consisting of: up to 2 week screening period;6-month comparative efficacy and safety treatment period;6-month comparative safety extension period;4-week safety follow-up period in a subset of patients; a 3-month administration substudy period starting after completion of the 6-month study period for patients willing to in a subset of patients randomized to   &lt;ulink linkType="Drug" linkID="73334"&gt;insulin glargine (new formulation)&lt;/ulink&gt;.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients  were randomized (1 : 1) to evening &lt;ulink linkType="Drug" linkID="73334"&gt;insulin glargine (new formulation)&lt;/ulink&gt; (Gla-300; n = 404; 300 U, qd) or  &lt;ulink linkType="Drug" linkID="10252"&gt;Lantus&lt;/ulink&gt;  (Gla-100; n = 403; 100  U, qd) for 6 months while continuing mealtime insulin. The basal insulin was titrated to achieve fasting plasma glucose of 80 to 100 mg/dl followed by a 6-month extension period up to 12 months of treatment. After the 6 month extension treatment, patients using  &lt;ulink linkType="Drug" linkID="73334"&gt;insulin glargine (new formulation)&lt;/ulink&gt;  (300 U/ml) were again randomized (1 : 1) in a sub-study to continue &lt;ulink linkType="Drug" linkID="73334"&gt;insulin glargine (new formulation)&lt;/ulink&gt;  (300 U/ml qd) injections in the evening, either using flexible (24 +/- 3 h, n = 56) or fixed (24 h, n = 53) dosing intervals for another 3 months [&lt;ulink linkType="Reference" linkID="1442280"&gt;1442280&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1443529"&gt;1443529&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1477862"&gt;1477862&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1592446"&gt;1592446&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1569044"&gt;1569044&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1668016"&gt;1668016&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1668155"&gt;1668155&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1696280"&gt;1696280&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2018416"&gt;2018416&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>insulin glargine (new formulation), Sanofi</Name><Drug id="73334">insulin glargine (new formulation), Sanofi</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="445">Hypoglycemia</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionControl"><Name>insulin glargine</Name><Drug id="10252">insulin glargine</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="445">Hypoglycemia</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Investigational Site Number 124001</Name><Address1>Toronto</Address1><Address3>M4G 3E8</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124002</Name><Address1>Red Deer</Address1><Address3>T4N 6V7</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124004</Name><Address1>Montreal</Address1><Address3>H2W 1T8</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124005</Name><Address1>Oshawa</Address1><Address3>L1H 7K4</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124006</Name><Address1>Laval</Address1><Address3>H7T 2P5</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124007</Name><Address1>Thornhill</Address1><Address3>L4J 8L7</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124008</Name><Address1>Mississauga</Address1><Address3>L5M 2V8</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124009</Name><Address1>London</Address1><Address3>N6A 4V2</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124010</Name><Address1>Victoria</Address1><Address3>V8V 4A1</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124011</Name><Address1>Toronto</Address1><Address3>M5C 2T2</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124014</Name><Address1>Hamilton</Address1><Address3>L8N 3Z5</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124015</Name><Address1>Montreal</Address1><Address3>H2W 1R7</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124017</Name><Address1>Ville St-Laurent</Address1><Address3>H4T 1Z9</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124018</Name><Address1>Coquitlam</Address1><Address3>V3K 3P4</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124019</Name><Address1>Chatham</Address1><Address3>N7L 1C1</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124020</Name><Address1>Calgary</Address1><Address3>T2N 4L7</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124021</Name><Address1>Hamilton</Address1><Address3>L8L 5G8</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124022</Name><Address1>Winnipeg</Address1><Address3>R3E 3P4</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124023</Name><Address1>Calgary</Address1><Address3>T2H 2G4</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124024</Name><Address1>Beamsville</Address1><Address3>L0R 1B0</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124025</Name><Address1>Burlington</Address1><Address3>L7M 4Y1</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124026</Name><Address1>Quebec</Address1><Address3>G1V 4G5</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124003</Name><Address1>Brampton</Address1><Address3> L6R 3J5</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124012</Name><Address1>Montreal</Address1><Address3> H1S 3A9</Address3><Contacts/></Site><Site><Name>Investigational Site Number 124016</Name><Address1>Edmonton</Address1><Address3> T5C 0A3</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Czech Republic"><Sites><Site><Name>Investigational Site Number 203001</Name><Address1>Breclav</Address1><Address3>690 02</Address3><Contacts/></Site><Site><Name>Investigational Site Number 203002</Name><Address1>Hodonin</Address1><Address3>69501</Address3><Contacts/></Site><Site><Name>Investigational Site Number 203003</Name><Address1>Hradec Kralove</Address1><Address3>50005</Address3><Contacts/></Site><Site><Name>Investigational Site Number 203004</Name><Address1>Krnov</Address1><Address3>79401</Address3><Contacts/></Site><Site><Name>Investigational Site Number 203005</Name><Address1>Prostejov</Address1><Address3>79601</Address3><Contacts/></Site><Site><Name>Investigational Site Number 203006</Name><Address1>Beroun</Address1><Address3>26601</Address3><Contacts/></Site><Site><Name>Investigational Site Number 203007</Name><Address1>Hranice</Address1><Address3>75301</Address3><Contacts/></Site><Site><Name>Investigational Site Number 203008</Name><Address1>Praha 2</Address1><Address3>12808</Address3><Contacts/></Site><Site><Name>Investigational Site Number 203009</Name><Address1>Holesov</Address1><Address3>76901</Address3><Contacts/></Site><Site><Name>Investigational Site Number 203010</Name><Address1>Olomouc</Address1><Address3>77900</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><Name>Investigational Site Number 276002</Name><Address1>Riesa</Address1><Address3>01587</Address3><Contacts/></Site><Site><Name>Investigational Site Number 276003</Name><Address1>Schwabenheim</Address1><Address3>55270</Address3><Contacts/></Site><Site><Name>Investigational Site Number 276006</Name><Address1>Heidelberg</Address1><Address3>69115</Address3><Contacts/></Site><Site><Name>Investigational Site Number 276001</Name><Address1>Munich</Address1><Address3> 80804</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Estonia"><Sites><Site><Name>Investigational Site Number 233001</Name><Address1>Tallinn</Address1><Address3>13419</Address3><Contacts/></Site><Site><Name>Investigational Site Number 233002</Name><Address1>Pärnu</Address1><Address3>80018</Address3><Contacts/></Site><Site><Name>Investigational Site Number 233003</Name><Address1>Tallinn</Address1><Address3>13415</Address3><Contacts/></Site><Site><Name>Investigational Site Number 233004</Name><Address1>Tallinn</Address1><Address3>11313</Address3><Contacts/></Site><Site><Name>Investigational Site Number 233005</Name><Address1>Tartu</Address1><Address3>50410</Address3><Contacts/></Site><Site><Name>Investigational Site Number 233006</Name><Address1>Tallinn</Address1><Address3>11913</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Finland"><Sites><Site><Name>Investigational Site Number 246001</Name><Address1>Helsinki</Address1><Address3>00260</Address3><Contacts/></Site><Site><Name>Investigational Site Number 246002</Name><Address1>Oulu</Address1><Address3>90100</Address3><Contacts/></Site><Site><Name>Investigational Site Number 246005</Name><Address1>Kuopio</Address1><Address3>70210</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>Investigational Site Number 250002</Name><Address1>Strasbourg</Address1><Address3>67091</Address3><Contacts/></Site><Site><Name>Investigational Site Number 250004</Name><Address1>La Rochelle Cedex</Address1><Address3>17019</Address3><Contacts/></Site><Site><Name>Investigational Site Number 250001</Name><Address1>Montpellier Cedex 5</Address1><Address3> 34295</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Hungary"><Sites><Site><Name>Investigational Site Number 348001</Name><Address1>Zalaegerszeg</Address1><Address3>8900</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348002</Name><Address1>Budapest</Address1><Contacts/></Site><Site><Name>Investigational Site Number 348003</Name><Address1>Szeged</Address1><Address3>6722</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348004</Name><Address1>Balatonfüred</Address1><Address3>8230</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348005</Name><Address1>Debrecen</Address1><Address3>4043</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348006</Name><Address1>Szombathely</Address1><Address3>9700</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348007</Name><Address1>Nyiregyháza</Address1><Address3>4400</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348008</Name><Address1>Eger</Address1><Address3>3300</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348009</Name><Address1>Budapest</Address1><Address3>1139</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348010</Name><Address1>Baja</Address1><Address3>6500</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348011</Name><Address1>Sátorlaljaújhely</Address1><Address3>3980</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348012</Name><Address1>Mosonmagyaróvár</Address1><Address3>9200</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348013</Name><Address1>Budapest</Address1><Address3>1088</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348014</Name><Address1>Makó</Address1><Address3>6900</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348015</Name><Address1>Budapest</Address1><Address3>1083</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348017</Name><Address1>Budapest</Address1><Address3>1134</Address3><Contacts/></Site><Site><Name>Investigational Site Number 348018</Name><Address1>Gyula</Address1><Address3>5700</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Latvia"><Sites><Site><Name>Investigational Site Number 428001</Name><Address1>Riga</Address1><Address3>LV-1038</Address3><Contacts/></Site><Site><Name>Investigational Site Number 428002</Name><Address1>Riga</Address1><Address3>LV-1002</Address3><Contacts/></Site><Site><Name>Investigational Site Number 428003</Name><Address1>Sigulda</Address1><Address3>LV-2150</Address3><Contacts/></Site><Site><Name>Investigational Site Number 428004</Name><Address1>Riga</Address1><Address3>LV-1050</Address3><Contacts/></Site><Site><Name>Investigational Site Number 428005</Name><Address1>Ogre</Address1><Address3>LV-5001</Address3><Contacts/></Site><Site><Name>Investigational Site Number 428006</Name><Address1>Jekabpils</Address1><Address3>LV-5201</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Mexico"><Sites><Site><Name>Investigational Site Number 484001</Name><Address1>Cuernavaca</Address1><Address3>62250</Address3><Contacts/></Site><Site><Name>Investigational Site Number 484003</Name><Address1>Monterrey</Address1><Address3>64460</Address3><Contacts/></Site><Site><Name>Investigational Site Number 484004</Name><Address1>Pachuca</Address1><Address3>42060</Address3><Contacts/></Site><Site><Name>Investigational Site Number 484006</Name><Address1>Guadalajara</Address1><Address3>44670</Address3><Contacts/></Site><Site><Name>Investigational Site Number 484007</Name><Address1>Chihuahua</Address1><Address3>31000</Address3><Contacts/></Site><Site><Name>Investigational Site Number 484009</Name><Address1>Pachuca</Address1><Address3> 42090</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Netherlands"><Sites><Site><Name>Investigational Site Number 528001</Name><Address1>Hoorn</Address1><Address3>1064NP</Address3><Contacts/></Site><Site><Name>Investigational Site Number 528002</Name><Address1>Venlo</Address1><Address3>5912 BL</Address3><Contacts/></Site><Site><Name>Investigational Site Number 528004</Name><Address1>Eindhoven</Address1><Address3>5631 BM</Address3><Contacts/></Site><Site><Name>Investigational Site Number 528005</Name><Address1>Hoogeveen</Address1><Address3>7909 AA</Address3><Contacts/></Site><Site><Name>Investigational Site Number 528006</Name><Address1>Utrecht</Address1><Address3>3563 AZ</Address3><Contacts/></Site><Site><Name>Investigational Site Number 528007</Name><Address1>Groningen</Address1><Address3>9728 NT</Address3><Contacts/></Site><Site><Name>Investigational Site Number 528008</Name><Address1>Leeuwarden</Address1><Address3>8934 AD</Address3><Contacts/></Site><Site><Name>Investigational Site Number 528009</Name><Address1>Almelo</Address1><Address3>7609 PP</Address3><Contacts/></Site><Site><Name>Investigational Site Number 528003</Name><Address1>Gouda</Address1><Address3> 2805 AH</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Romania"><Sites><Site><Name>Investigational Site Number 642001</Name><Address1>Bacau</Address1><Address3>600114</Address3><Contacts/></Site><Site><Name>Investigational Site Number 642002</Name><Address1>Cluj Napoca</Address1><Address3>400006</Address3><Contacts/></Site><Site><Name>Investigational Site Number 642003</Name><Address1>Oradea</Address1><Address3>410169</Address3><Contacts/></Site><Site><Name>Investigational Site Number 642004</Name><Address1>Iasi</Address1><Address3>700547</Address3><Contacts/></Site><Site><Name>Investigational Site Number 642005</Name><Address1>Bucuresti</Address1><Address3>020475</Address3><Contacts/></Site><Site><Name>Investigational Site Number 642006</Name><Address1>Bucuresti</Address1><Address3>700164</Address3><Contacts/></Site><Site><Name>Investigational Site Number 642007</Name><Address1>Timisoara</Address1><Address3>300133</Address3><Contacts/></Site><Site><Name>Investigational Site Number 642008</Name><Address1>Iasi</Address1><Address3>700613</Address3><Contacts/></Site><Site><Name>Investigational Site Number 642009</Name><Address1>Targu Mures</Address1><Address3>540142</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Sweden"><Sites><Site><Name>Investigational Site Number 752001</Name><Address1>Stockholm</Address1><Address3> 14186</Address3><Contacts/></Site><Site><Name>Investigational Site Number 752002</Name><Address1>Angelholm</Address1><Address3> 262 81</Address3><Contacts/></Site><Site><Name>Investigational Site Number 752003</Name><Address1>Falun</Address1><Address3> 791 82</Address3><Contacts/></Site><Site><Name>Investigational Site Number 752004</Name><Address1>Lulea</Address1><Address3> 972 33</Address3><Contacts/></Site><Site><Name>Investigational Site Number 752005</Name><Address1>Lund</Address1><Address3> 22221</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Investigational Site Number 840001</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75230</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840002</Name><Address1>Walnut Creek</Address1><Address2>California</Address2><Address3>94598</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840003</Name><Address1>Wichita</Address1><Address2>Kansas</Address2><Address3>67211</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840004</Name><Address1>La Mesa</Address1><Address2>California</Address2><Address3>91942</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840005</Name><Address1>San Diego</Address1><Address2>California</Address2><Address3>92161</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840007</Name><Address1>Uniontown</Address1><Address2>Pennsylvania</Address2><Address3>15401</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840008</Name><Address1>Cincinnati</Address1><Address2>Ohio</Address2><Address3>45236</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840009</Name><Address1>Jacksonville</Address1><Address2>Florida</Address2><Address3>32258</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840010</Name><Address1>Draper</Address1><Address2>Utah</Address2><Address3>84020</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840011</Name><Address1>Jacksonville</Address1><Address2>Florida</Address2><Address3>32216</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840012</Name><Address1>Ocoee</Address1><Address2>Florida</Address2><Address3>34761</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840013</Name><Address1>Tustin</Address1><Address2>California</Address2><Address3>92780</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840015</Name><Address1>Little Rock</Address1><Address2>Arkansas</Address2><Address3>72205</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840016</Name><Address1>Hot Springs</Address1><Address2>Arkansas</Address2><Address3>71913</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840018</Name><Address1>Milwaukee</Address1><Address2>Wisconsin</Address2><Address3>53209-0996</Address3><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840019</Name><Address1>Springfield</Address1><Address2>Illinois</Address2><Address3>62704</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840020</Name><Address1>Mchenry</Address1><Address2>Illinois</Address2><Address3>60050</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840021</Name><Address1>Austin</Address1><Address2>Texas</Address2><Address3>78731</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840022</Name><Address1>Southfield</Address1><Address2>Michigan</Address2><Address3>48034</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840023</Name><Address1>New Port Richey</Address1><Address2>Florida</Address2><Address3>34652</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840032</Name><Address1>Searcy</Address1><Address2>Arkansas</Address2><Address3>72143</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840034</Name><Address1>Rockville</Address1><Address2>Maryland</Address2><Address3>20852</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840035</Name><Address1>Chesapeake</Address1><Address2>Virginia</Address2><Address3>23321</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840036</Name><Address1>Baltimore</Address1><Address2>Maryland</Address2><Address3>21237</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840039</Name><Address1>Chattanooga</Address1><Address2>Tennessee</Address2><Address3>37404</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840041</Name><Address1>Norfolk</Address1><Address2>Virginia</Address2><Address3>23510</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840042</Name><Address1>Paducah</Address1><Address2>Kentucky</Address2><Address3>42003</Address3><CountrySubDivision code="KY">Kentucky</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840043</Name><Address1>Brick</Address1><Address2>New Jersey</Address2><Address3>08274</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840045</Name><Address1>Wilmington</Address1><Address2>North Carolina</Address2><Address3>28401</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840047</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75246</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840048</Name><Address1>Rapid City</Address1><Address2>South Dakota</Address2><Address3>57701</Address3><CountrySubDivision code="SD">South Dakota</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840049</Name><Address1>Daytona Beach</Address1><Address2>Florida</Address2><Address3>32117</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840050</Name><Address1>Hollywood</Address1><Address2>Florida</Address2><Address3>33021</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840052</Name><Address1>Idaho Falls</Address1><Address2>Idaho</Address2><Address3>83404</Address3><CountrySubDivision code="ID">Idaho</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840053</Name><Address1>Kalispell</Address1><Address2>Montana</Address2><Address3>59901</Address3><CountrySubDivision code="MT">Montana</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840055</Name><Address1>Lawrenceville</Address1><Address2>Georgia</Address2><Address3>30045</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840057</Name><Address1>Huntington Beach</Address1><Address2>California</Address2><Address3>92648</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840058</Name><Address1>Las Vegas</Address1><Address2>Nevada</Address2><Address3>89148</Address3><CountrySubDivision code="NV">Nevada</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840059</Name><Address1>La Jolla</Address1><Address2>California</Address2><Address3>92037</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840060</Name><Address1>Ogden</Address1><Address2>Utah</Address2><Address3>84403</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840062</Name><Address1>Greenbrae</Address1><Address2>California</Address2><Address3>94904</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840065</Name><Address1>Ann Arbor</Address1><Address2>Michigan</Address2><Address3>48106</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840066</Name><Address1>Dearborn</Address1><Address2>Michigan</Address2><Address3>48124</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840067</Name><Address1>Fargo</Address1><Address2>North Dakota</Address2><Address3>58103</Address3><CountrySubDivision code="ND">North Dakota</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840068</Name><Address1>Eagan</Address1><Address2>Minnesota</Address2><Address3>55122</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840070</Name><Address1>Tempe</Address1><Address2>Arizona</Address2><Address3>85282</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840071</Name><Address1>Phoenix</Address1><Address2>Arizona</Address2><Address3>85028</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840074</Name><Address1>Norfolk</Address1><Address2>Virginia</Address2><Address3>23502</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840075</Name><Address1>Williamsburg</Address1><Address2>Virginia</Address2><Address3>23185</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840076</Name><Address1>Anaheim</Address1><Address2>California</Address2><Address3>92801</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840078</Name><Address1>Avon</Address1><Address2>Indiana</Address2><Address3>46123</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840079</Name><Address1>Greer</Address1><Address2>South Carolina</Address2><Address3>29651</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840080</Name><Address1>Lexington</Address1><Address2>Kentucky</Address2><Address3>40504</Address3><CountrySubDivision code="KY">Kentucky</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840081</Name><Address1>Austin</Address1><Address2>Texas</Address2><Address3>78758</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840082</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77096</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840083</Name><Address1>Medford</Address1><Address2>Oregon</Address2><Address3>97504</Address3><CountrySubDivision code="OR">Oregon</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840084</Name><Address1>Portland</Address1><Address2>Oregon</Address2><Address3>97239-3098</Address3><CountrySubDivision code="OR">Oregon</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840085</Name><Address1>Minneapolis</Address1><Address2>Minnesota</Address2><Address3>55416</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840086</Name><Address1>Jacksonville</Address1><Address2>Florida</Address2><Address3>32204</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840089</Name><Address1>Avon</Address1><Address2>Indiana</Address2><Address3>46123</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840090</Name><Address1>Fremont</Address1><Address2>Nebraska</Address2><Address3>68025</Address3><CountrySubDivision code="NE">Nebraska</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840091</Name><Address1>Omaha</Address1><Address2>Nebraska</Address2><Address3>68130</Address3><CountrySubDivision code="NE">Nebraska</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840092</Name><Address1>Longmont</Address1><Address2>Colorado</Address2><Address3>80501</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840097</Name><Address1>Avon</Address1><Address2>Indiana</Address2><Address3>46123</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840098</Name><Address1>Avon</Address1><Address2>Indiana</Address2><Address3>46123</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840099</Name><Address1>Mission Hills</Address1><Address2>California</Address2><Address3>91345</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840100</Name><Address1>Avon</Address1><Address2>Indiana</Address2><Address3>46123</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840102</Name><Address1>Glendale</Address1><Address2>Arizona</Address2><Address3>85306</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840103</Name><Address1>Flint</Address1><Address2>Michigan</Address2><Address3>48504</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840104</Name><Address1>Richmond</Address1><Address2>Virginia</Address2><Address3>23235</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840106</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><Address3>43213</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840107</Name><Address1>Palm Springs</Address1><Address2>California</Address2><Address3>92262</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840112</Name><Address1>Norfolk</Address1><Address2>Virginia</Address2><Address3>23507</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840114</Name><Address1>Colorado Springs</Address1><Address2>Colorado</Address2><Address3>80906</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840116</Name><Address1>Des Moines</Address1><Address2>Iowa</Address2><Address3>50314</Address3><CountrySubDivision code="IA">Iowa</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840117</Name><Address1>Nampa</Address1><Address2>Idaho</Address2><Address3>83686</Address3><CountrySubDivision code="ID">Idaho</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840119</Name><Address1>Maumee</Address1><Address2>Ohio</Address2><Address3>43537</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840120</Name><Address1>Hurst</Address1><Address2>Texas</Address2><Address3>76054</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840121</Name><Address1>Sun City</Address1><Address2>Arizona</Address2><Address3>85351</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840122</Name><Address1>Mentor</Address1><Address2>Ohio</Address2><Address3>44060</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840123</Name><Address1>Dayton</Address1><Address2>Ohio</Address2><Address3>45439</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840124</Name><Address1>Little Rock</Address1><Address2>Arkansas</Address2><Address3>72205</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840126</Name><Address1>Kalamazoo</Address1><Address2>Michigan</Address2><Address3>49048</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840127</Name><Address1>Vincennes</Address1><Address2>Indiana</Address2><Address3>47591</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840129</Name><Address1>Austin</Address1><Address2>Texas</Address2><Address3>78731</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840133</Name><Address1>Encino</Address1><Address2>California</Address2><Address3>91436</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840136</Name><Address1>Colorado Springs</Address1><Address2>Colorado</Address2><Address3>80910</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840143</Name><Address1>Chaska</Address1><Address2>Minnesota</Address2><Address3>55318</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840145</Name><Address1>Hickory</Address1><Address2>North Carolina</Address2><Address3>28601</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840146</Name><Address1>Asheville</Address1><Address2>North Carolina</Address2><Address3>28801</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840148</Name><Address1>Palm Harbor</Address1><Address2>Florida</Address2><Address3>34684</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840152</Name><Address1>Toms River</Address1><Address2>New Jersey</Address2><Address3>08721</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840155</Name><Address1>Baltimore</Address1><Address2>Maryland</Address2><Address3>21237</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840156</Name><Address1>Chandler</Address1><Address2>Arizona</Address2><Address3>85224</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840159</Name><Address1>Knoxville</Address1><Address2>Tennessee</Address2><Address3>37912</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840038</Name><Address1>Orem</Address1><Address2>Utah</Address2><Address3> 84058</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840044</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3> 90033</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840077</Name><Address1>Indianapolis</Address1><Address2>Indiana</Address2><Address3> 46202</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840095</Name><Address1>Toms River</Address1><Address2>New Jersey</Address2><Address3> 8753</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840130</Name><Address1>Walla Walla</Address1><Address2>Washington</Address2><Address3> 99362</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840132</Name><Address1>Santa Barbara</Address1><Address2>California</Address2><Address3> 93110</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840135</Name><Address1>Asheville</Address1><Address2>North Carolina</Address2><Address3> 28801</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840149</Name><Address1>Lafayette</Address1><Address2>Indiana</Address2><Address3> 47904</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840154</Name><Address1>Tipton</Address1><Address2>Pennsylvania</Address2><Address3> 16684</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>Investigational Site Number 840162</Name><Address1>Greensboro</Address1><Address2>North Carolina</Address2><Address3> 27401</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="South Africa"><Sites><Site><Name>Investigational Site Number 710001</Name><Address1>Paarl</Address1><Address3>7500</Address3><Contacts/></Site><Site><Name>Investigational Site Number 710002</Name><Address1>Observatory</Address1><Address3>7925</Address3><Contacts/></Site><Site><Name>Investigational Site Number 710003</Name><Address1>Johannesburg</Address1><Address3>2198</Address3><Contacts/></Site><Site><Name>Investigational Site Number 710004</Name><Address1>Somerset West</Address1><Address3>7130</Address3><Contacts/></Site><Site><Name>Investigational Site Number 710005</Name><Address1>Alberton</Address1><Address3>1450</Address3><Contacts/></Site><Site><Name>Investigational Site Number 710006</Name><Address1>Lenasia</Address1><Address3>1820</Address3><Contacts/></Site><Site><Name>Investigational Site Number 710008</Name><Address1>Pretoria</Address1><Address3>0167</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier>NCT01434875</Identifier><Identifier type="NCT">NCT01499082</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2010-023769-23</Identifier></Identifiers></Registry><Registry><Name id="1004">WHO ICTRP</Name><Identifiers><Identifier>U1111-1118-6903</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1358"><Endpoint>Assessment of Hemoglobin A1c (HbA1c) Levels</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1344"><Endpoint>Assessment of Blood Glucose Levels</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1350">Self monitoring of blood glucose (SMBG)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1514"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1345">Assessment of fasting blood glucose</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Non-insulin dependent diabetes" id="1514"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1521">Nocturnal hypoglycemia</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Non-insulin dependent diabetes" id="1624"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="855"><Criterion>Subjects with Diabetic Complications</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="857">Subjects with diabetic retinopathy</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="858">Diabetic macular edema</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="874"><Criterion>Subjects with Poor/Inadequate Control</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="928"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="946"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="957">Subjects on/treated with insulin</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="963"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="983"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="990">Hypersensitivity/contraindications to study medication/device</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5078"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-01-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2012-09-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>9.03 Months</EnrollmentPeriod><EnrollmentRate>89.37 Patients/Month</EnrollmentRate><DateFirstReceived>2011-12-16T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-12-30T11:32:09Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2013-10-18T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-03-16T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-16T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-19T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="89080"><TitleDisplay>A non-randomized, uncontrolled, open-label, phase II, multicenter, single arm trial to assess the safety and efficacy of BNC-105P in patients with progressive malignant pleural mesothelioma who had prior treatment with pemetrexed and a platinum</TitleDisplay><TitleOfficial>B2P2M2: Phase II, single arm trial to evaluate the response rate of BNC105P as 2nd line chemotherapy for advanced malignant pleural mesothelioma</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="Other">ACTRN12610000093088</Identifier><Identifier type="Trial Acronym">B2P2M2</Identifier></Identifiers><Indications><Indication id="1240">Mesothelioma</Indication></Indications><BiomarkerNames><BiomarkerName id="174" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-12</BiomarkerName><BiomarkerName id="175" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-10</BiomarkerName><BiomarkerName id="522" role="Therapeutic effect marker" type="Genomic;Proteomic">Mesothelin</BiomarkerName><BiomarkerName id="550" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-16</BiomarkerName><BiomarkerName id="554" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-8</BiomarkerName><BiomarkerName id="1051" role="Therapeutic effect marker" type="Genomic;Proteomic">Ferritin</BiomarkerName><BiomarkerName id="1912" role="Therapeutic effect marker" type="Physiological">Forced Vital Capacity</BiomarkerName><BiomarkerName id="2713" role="Therapeutic effect marker" type="Physiological">Forced expiratory volume</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>BNC-105P</Name><Drug id="74303">BNC-105P</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="74303">BNC-105P</Drug><IndicationsPioneer><Indication id="1240">Mesothelioma</Indication></IndicationsPioneer><Companies><Company><Company id="1059855">Australasian Lung Cancer Trials Group</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1064030">NHMRC Clinical Trials Centre</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20681">University of Sydney</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="29256">Bionomics Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="74303" type="Drug"><TargetEntity id="459076" type="siDrug">BNC-105P</TargetEntity></SourceEntity><SourceEntity id="1059855" type="Company"><TargetEntity id="5035555278" type="organizationId">Australasian Lung Cancer Trials Group</TargetEntity></SourceEntity><SourceEntity id="1064030" type="Company"><TargetEntity id="5036351948" type="organizationId">NHMRC Clinical Trials Centre</TargetEntity></SourceEntity><SourceEntity id="20681" type="Company"><TargetEntity id="4296634116" type="organizationId">University Of Sydney</TargetEntity></SourceEntity><SourceEntity id="29256" type="Company"><TargetEntity id="4295856352" type="organizationId">Bionomics Ltd</TargetEntity></SourceEntity><SourceEntity id="1240" type="ciIndication"><TargetEntity id="C45" type="ICD10"/><TargetEntity id="163" type="ICD9"/><TargetEntity id="10027406" type="MEDDRA"/><TargetEntity id="D008654" type="MeSH"/><TargetEntity id="50251" type="ORPHANET"/><TargetEntity id="-666440137" type="omicsDisease"/><TargetEntity id="2015" type="siCondition"/></SourceEntity><SourceEntity id="541" type="Action"><TargetEntity id="2493" type="Mechanism">Tubulin Polymerization Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20681">University of Sydney</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1059855">Australasian Lung Cancer Trials Group</Company><Company id="1064030">NHMRC Clinical Trials Centre</Company><Company id="29256">Bionomics Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="541">Tubulin receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2969">Vascular damaging agent</Class><Class id="61">Angiogenesis inhibitor</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><PatientCountEvaluable>30</PatientCountEvaluable><DateStart>2010-07-14T00:00:00Z</DateStart><DateChangeLast>2018-05-29T05:42:46Z</DateChangeLast><DateAdded>2012-07-13T10:14:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>NHMRC Clinical Trials Centre</Affiliation><Email>B2P2M2@ctc.usyd.edu.au</Email><Name>Helen Taylor</Name><Phone>+61 2 9562 5000</Phone></Contact><Contact type="Public contact"><Affiliation>NHMRC Clinical Trials Centre</Affiliation><Email>B2P2M2@ctc.usyd.edu.au</Email><Name>Prof Martin Stockler</Name><Phone>+61 2 9562 5000</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Confirmed diagnosis of malignant pleural mesothelioma&lt;/li&gt;&lt;li&gt;Progression after first line chemotherapy with pemetrexed and a platinum (cisplatin and/or carboplatin)&lt;/li&gt;&lt;li&gt;Evidence of measurable disease as per RECIST modified for mesothelioma&lt;/li&gt;&lt;li&gt;Performance status of ECOG 0 to 1&lt;/li&gt;&lt;li&gt;Adequate hepatic, renal and hematological function&lt;/li&gt;&lt;li&gt;Adequate cardiac function as assessed by Left ventricular ejection fraction (LVEF) and corrected QT interval (QTc)&amp;lt; 470 ms&lt;/li&gt;&lt;li&gt;Written informed consent&lt;/li&gt;&lt;li&gt;Patient is able and willing to complete the Quality of Life (QOL) questionnaires, or unable due to illiteracy or visual impairment. Inability to complete the questionnaires will not exclude the patient from the study&lt;/li&gt;&lt;li&gt;Patient is willing and able to comply with treatment and follow-up&lt;/li&gt;&lt;li&gt;Written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any prior chemotherapy other than pemetrexed and a platinum compound&lt;/li&gt;&lt;li&gt;Chemotherapy within 20 days, radiotherapy within 14 days, major surgery within 28 days or &gt; 25% of bone marrow&lt;/li&gt;&lt;li&gt;Known brain or leptomeningeal disease&lt;/li&gt;&lt;li&gt;History of another malignancy within five years prior to registration&lt;/li&gt;&lt;li&gt;Untreated and/or uncontrolled cardiovascular conditions or poorely controlled hypertension&lt;/li&gt;&lt;li&gt;Stroke, venous or arterial blood clots within 12 months prior to registration&lt;/li&gt;&lt;li&gt;Poorly controlled hypertension&lt;/li&gt;&lt;li&gt;Cerebrovascular accident, TIA or venous or arterial thromboembolic event within previous 12 months&lt;/li&gt;&lt;li&gt;Full dose anti-coagulation with warfarin, related oral anti-coagulants or heparin&lt;/li&gt;&lt;li&gt;Major surgery within 28 days prior to registration or minor surgery within 7 days prior to registration&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Patients would receive BNC-105P at a dose of 16 mg/m2 iv over 10 min on days 1 and 8 of a 21 day cycle, until progression or prohibitive toxicity</Description><Timeframe>Tumor assessments are performed at baseline, then at weeks 6, 12, 18, 24 and then 12 weekly until progression</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Progression-free survival (PFS, progression or death) as assessed by computed tomography (CT) scan using RECIST modified for mesothelioma</Description><Timeframe>Tumor assessments are performed at baseline, then at weeks 6, 12, 18, 24 and then 12 weekly until progression</Timeframe></Measure><Measure><Description>Treatment duration (TD, interval from first dose to last dose)</Description><Timeframe>Clinic visits are 3-weekly during treatment</Timeframe></Measure><Measure><Description>Adverse events eg, fatigue, nausea, lowering of blood counts. Adverse events will be assessed using physical examination, blood tests, and asking the patient about their health since the last assessment. Adverse Events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0)</Description><Timeframe>Adverse events are assessed at baseline, every 3 weeks during treatment, and 30 to 42 days after the last treatment dose</Timeframe></Measure><Measure><Description>Health-related quality of life (using the European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire - Cancer 30 questions [QLQ-C30], Quality of Life Module - Lung 13 questions [QLM-L13], and Patient Data Form [PDF])</Description><Timeframe>Quality of life questionaires are completed at baseline, every 3 weeks during treatment, and 30 to 42 days after the last treatment dose</Timeframe></Measure><Measure><Description>Changes in spirometric lung function tests (Forced expiratory volume in 1 s  [FEV1] and Forced vital capacity [FVC])</Description><Timeframe>Spirometric lung function tests are completed at baseline, every 3 weeks during treatment, and 30 to 42 days after the last treatment dose</Timeframe></Measure><Measure><Description>Overall survival (OS, death from any cause, as assessed by clinic visits and information available in the patient's medical record)</Description><Timeframe>Clinic visits are 3-weekly during treatment, then follow up visits are 12-weekly until 12 months after the last patient has entered the study</Timeframe></Measure><Measure><Description>Associations between serum mesothelin levels and clinical outcomes</Description></Measure><Measure><Description>Associations between serum and plasma biomarkers and clinical outcomes</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="74303"&gt;BNC-105P&lt;/ulink&gt; was safe and well-tolerated. Anorexia (n = 14), nausea (n = 12) and vomiting (n = 4) of grade 1/2 severity and fatigue (n = 3), venous thromboembolic events, febrile neutropenia, stroke; hypotension, confusion and colonic obstruction of grade 3/4 severity were some of the adverse events reported [&lt;ulink linkType="Reference" linkID="1295689"&gt;1295689&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this non-randomized, uncontrolled, open-label, phase II, multicenter, single arm trial was to assess the safety and efficacy of &lt;ulink linkType="Drug" linkID="74303"&gt;BNC-105P&lt;/ulink&gt; in patients with progressive malignant pleural mesothelioma who had prior treatment with &lt;ulink linkType="Drug" linkID="3536"&gt;pemetrexed&lt;/ulink&gt; and a platinum [&lt;ulink linkType="Reference" linkID="1295689"&gt;1295689&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1307995"&gt;1307995&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2012, results were presented. The objective tumor response (primary endpoint) was not met. As best response, partial response and stable disease were observed in 3 and 43% of patients, respectively. The median overall survival and progression-free survival were 8.7 and 1.5 months, respectively. At 3 h after the first dose of &lt;ulink linkType="Drug" linkID="74303"&gt;BNC-105P&lt;/ulink&gt;, macrophage-inflammatory protein, ferritin, IL-8, -10, -12, -16 and TNF-receptor2 were significantly increased [&lt;ulink linkType="Reference" linkID="1295689"&gt;1295689&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients  received &lt;ulink linkType="Drug" linkID="74303"&gt;BNC-105P&lt;/ulink&gt; at a dose of 16 mg/m2 iv over 10 min on days 1 and 8 of a 21 day cycle, until progression or prohibitive toxicity [&lt;ulink linkType="Reference" linkID="1295689"&gt;1295689&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1307995"&gt;1307995&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;The study was temporarily closed to accrual in order to complete central review of responses in the first 24 patients. The analysis of the first 24 patients triggered the study to terminate [&lt;ulink linkType="Reference" linkID="1295689"&gt;1295689&lt;/ulink&gt;].&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>BNC-105P</Name><Drug id="74303">BNC-105P</Drug><Dose unit="milligram/m2 dose">16.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="110">Emesis</Indication><CountPatientsTotal>30</CountPatientsTotal><CountPatientsAffected>4</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="1956">Confusion</Indication></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsTotal>30</CountPatientsTotal><CountPatientsAffected>12</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="3038">Appetite loss</Indication><CountPatientsTotal>30</CountPatientsTotal><CountPatientsAffected>14</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="3795">Febrile neutropenia</Indication></AdverseEvent><AdverseEvent><Indication id="408">Hypotension</Indication></AdverseEvent><AdverseEvent><Indication id="65">Stroke</Indication></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsTotal>30</CountPatientsTotal><CountPatientsAffected>3</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="222060">BNC-105P</Intervention><Treatments><Treatment><Dose>16 milligram/m2</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Australia"><Sites><Site><Address2>NSW,VIC,QLD,SA,WA</Address2><CountrySubDivision>NSW,VIC,QLD,SA,WA</CountrySubDivision><Contacts/></Site><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Mesothelioma</Disease><PatientSegments><PatientSegment><PatientSegment id="8132">Subjects with Malignant Pleural Mesothelioma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8145">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1011">Australian New Zealand Clinical Trials Registry (ANZCTR)</Name><Identifiers><Identifier type="Other">ACTRN12610000093088</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Mesothelioma" id="12491"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Mesothelioma" id="12492">Assessment of objective/overall response rate (ORR)</SubEndpoint><SubEndpoint disease="Mesothelioma" id="12493">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Mesothelioma" id="12494">Assessment of Complete Response</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Mesothelioma" id="12484"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Mesothelioma" id="12487"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Mesothelioma" id="12504"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Mesothelioma" id="12507">Assessment by EORTC QLQ-C30 questionnaire</SubEndpoint><SubEndpoint disease="Mesothelioma" id="27995">Assessment by EORTC QLQ-LC13</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Mesothelioma" id="12543"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Mesothelioma" id="12553"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Mesothelioma" id="12557"><Endpoint>Assessment of Systemic Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Mesothelioma" id="44926"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Mesothelioma" id="12491"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Mesothelioma" id="12495">Assessment of Stable Disease</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Mesothelioma" id="12550"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Mesothelioma" id="8531"><Criterion>Subjects with Malignant Pleural Mesothelioma</Criterion></Inclusion><Inclusion disease="Mesothelioma" id="8543"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Mesothelioma" id="8555"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8556">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Mesothelioma" id="8557">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mesothelioma" id="8564"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8565">Subjects with history of anti-cancer chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mesothelioma" id="8573"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Mesothelioma" id="8574"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8575">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Mesothelioma" id="8576">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Mesothelioma" id="8578">Subjects with normal/acceptable cardiac function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mesothelioma" id="34042"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8577">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mesothelioma" id="34357"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8584">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mesothelioma" id="34805"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8586">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Mesothelioma" id="10094"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Mesothelioma" id="10095"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Mesothelioma" id="10122"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="10123">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Mesothelioma" id="10130"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Mesothelioma" id="10134"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Mesothelioma" id="26346"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="10108">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2011-04-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>9.58 Months</EnrollmentPeriod><EnrollmentRate>6.26 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type><Type>Company</Type><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-07-13T10:14:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-04-09T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>